| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Award Winners
|
|
|
|
26 |
12S |
p. A6-A8
|
artikel
|
| 2 |
CO159 A Bayesian Network Meta-Analysis (NMA) for Evaluating the Relative Efficacy of Dual Therapy Combinations of Dapagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
|
Bao, H.
|
|
|
26 |
12S |
p. S43
|
artikel
|
| 3 |
CO139 Acalabrutinib (AKA) Versus Venetoclax With Obinutuzumab (VEN+OBI) in Patients With Untreated Chronic Lymphocytic Leukemia (CLL) and Unmutated IGHV Genes – Indirect Comparison
|
Kaczyński, Ł
|
|
|
26 |
12S |
p. S39
|
artikel
|
| 4 |
CO49 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Ixekizumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis
|
Thom, H.
|
|
|
26 |
12S |
p. S22-S23
|
artikel
|
| 5 |
CO10 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Psoriatic Arthritis
|
Mease, P.J.
|
|
|
26 |
12S |
p. S16
|
artikel
|
| 6 |
CO88 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis
|
Maksymowych, W.P.
|
|
|
26 |
12S |
p. S30
|
artikel
|
| 7 |
CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review
|
Pochopien, M.
|
|
|
26 |
12S |
p. S42-S43
|
artikel
|
| 8 |
CO57 A New Approach in Network Meta-Analysis Using Blended Survival Curves to Extrapolate Long-Term Survival from Immature Data
|
Che, Z.
|
|
|
26 |
12S |
p. S24
|
artikel
|
| 9 |
CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)
|
Hook, E.
|
|
|
26 |
12S |
p. S44
|
artikel
|
| 10 |
CO132 A Real-World Evidence Analysis of the Impact of Patient-Physician Sex Concordance on Cancer Treatment Practices and Outcomes
|
Cheung, W.Y.
|
|
|
26 |
12S |
p. S38
|
artikel
|
| 11 |
CO142 A Retrospective Study Characterizing Age at Key Clinical Disease Indicators Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States
|
Salvucci, A.
|
|
|
26 |
12S |
p. S40
|
artikel
|
| 12 |
CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States
|
Salvucci, A.
|
|
|
26 |
12S |
p. S33-S34
|
artikel
|
| 13 |
CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
|
Towle, K.
|
|
|
26 |
12S |
p. S23-S24
|
artikel
|
| 14 |
CO141 Assessing the Impact of Additional Follow-up Data on Disease-Free Survival (DFS) Projections of Nivolumab and Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Within the CheckMate-274 Trial
|
Chandler, T.
|
|
|
26 |
12S |
p. S40
|
artikel
|
| 15 |
CO91 Association Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)
|
Mastikhina, L.
|
|
|
26 |
12S |
p. S30-S31
|
artikel
|
| 16 |
CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus
|
Wang, J.
|
|
|
26 |
12S |
p. S41-S42
|
artikel
|
| 17 |
CO171 Associations of Sex and Race with Relative Efficacy in Clinical Trials
|
Zhao, P.
|
|
|
26 |
12S |
p. S45
|
artikel
|
| 18 |
CO106 A Structured Expert Elicitation Exercise Conducted With UK Clinicians to Inform and Validate Inputs for a Cost-Effectiveness Analysis of FILSUVEZ® Gel (Birch Bark Extract) in Epidermolysis Bullosa
|
Stainer, L.
|
|
|
26 |
12S |
p. S34
|
artikel
|
| 19 |
CO135 A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of Pharmaceutical Interventions for First-Line (1L) Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (MCRPC)
|
Castro, E.
|
|
|
26 |
12S |
p. S38-S39
|
artikel
|
| 20 |
CO25 A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated with Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
|
Papadakis-Sali, A.
|
|
|
26 |
12S |
p. S18-S19
|
artikel
|
| 21 |
CO48 A Systematic Review of Effectiveness and Safety of Acupuncture on Suicidal Behavior
|
Kwon, C.Y.
|
|
|
26 |
12S |
p. S22
|
artikel
|
| 22 |
CO45 A Systematic Review of Quality of Life and Gastroesophageal Reflux Disease
|
Goldsmith, M.
|
|
|
26 |
12S |
p. S22
|
artikel
|
| 23 |
CO109 A Targeted Review of Pharmacological Therapies for the Treatment of Chronic Spontaneous Urticaria
|
Lawrence, J.
|
|
|
26 |
12S |
p. S34
|
artikel
|
| 24 |
CO19 Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|
Domínguez, L.
|
|
|
26 |
12S |
p. S17
|
artikel
|
| 25 |
CO144 A Trial-Based Health Utility Analysis in Patients with Acanthamoeba Keratitis
|
Alves, A.
|
|
|
26 |
12S |
p. S40-S41
|
artikel
|
| 26 |
CO90 Augmenting Synthetic Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer
|
Strübing, A.
|
|
|
26 |
12S |
p. S30
|
artikel
|
| 27 |
CO160 Burden of Illness and Treatment Patterns of Adult Patients with Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer: A Systematic Literature Review
|
Chen, Z.
|
|
|
26 |
12S |
p. S43
|
artikel
|
| 28 |
CO190 Cannabis-Based Formulations: Clinical and Economic Results Promising Savings and Sustainability
|
Tanaka, E.
|
|
|
26 |
12S |
p. S48
|
artikel
|
| 29 |
CO64 Challenges Associated with Surrogate Endpoints for Healthcare Decision Making in Oncology
|
Ferguson, S.
|
|
|
26 |
12S |
p. S26
|
artikel
|
| 30 |
CO186 Characteristics of Psoriasis Patients According to Their Level of Severity Based on a Real-World Ambulatory Medical Database in France: Preliminary Results
|
Bertrand, S.
|
|
|
26 |
12S |
p. S47
|
artikel
|
| 31 |
CO84 Characterization of Long-COVID Phenotypes and Associated Clinical Phenotypes in Administrative Claims Data
|
Kirk, B.
|
|
|
26 |
12S |
p. S29
|
artikel
|
| 32 |
CO112 Clinical Characteristics and Quality of Life of Thai Moderate to Severe Psoriasis Patients Before Initiating Secukinumab: An Interim Analysis from Prompt Study
|
Wongpraparut, C.
|
|
|
26 |
12S |
p. S35
|
artikel
|
| 33 |
CO111 Clinical Efficacy and Safety of Interventions for Adult Patients With Moderately Severe to Severe Hemophilia B: A Systematic Review
|
Thakkar, S.
|
|
|
26 |
12S |
p. S35
|
artikel
|
| 34 |
CO35 Clinical Outcomes Associated with Sodium Zirconium Cyclosilicate for Treating Hyperkalaemia in Patients Receiving Haemodialysis
|
Ferraro, P.M.
|
|
|
26 |
12S |
p. S20
|
artikel
|
| 35 |
CO15 Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study
|
Fox, C.P.
|
|
|
26 |
12S |
p. S16-S17
|
artikel
|
| 36 |
CO92 Clinician-Reported Outcome Measure for Palonosetron Versus Standard of Care in Chemotherapy-Induced Nausea and Vomiting in Egypt
|
Elattar, M.
|
|
|
26 |
12S |
p. S31
|
artikel
|
| 37 |
CO36 Comparative Analysis of Coding Schemas for Assessing Major Bleeding Risk Between Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin
|
Chien, H.T.
|
|
|
26 |
12S |
p. S21
|
artikel
|
| 38 |
CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)
|
Brookhart, M.A.
|
|
|
26 |
12S |
p. S23
|
artikel
|
| 39 |
CO114 Comparative 30-Day Postoperative Outcomes between Robotic-Assisted Low Anterior Resection (RALAR) and Laparoscopic Low Anterior Resection (LLAR) Among Rectal Cancer Patients in Japan
|
Shim, H.
|
|
|
26 |
12S |
p. S35
|
artikel
|
| 40 |
CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
|
Krishnan, A.
|
|
|
26 |
12S |
p. S37
|
artikel
|
| 41 |
CO1 Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis
|
Burnett, H.
|
|
|
26 |
12S |
p. S15
|
artikel
|
| 42 |
CO189 Comparative Efficacy of Voclosporin in Combination With Mycophenolate Mofetil Versus Other Treatments in Active Lupus Nephritis: Systematic Review and Network Meta-Analysis
|
Lambton, M.
|
|
|
26 |
12S |
p. S47-S48
|
artikel
|
| 43 |
CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions
|
Huang, X.
|
|
|
26 |
12S |
p. S29
|
artikel
|
| 44 |
CO70 COPD Exacerbations Pre, During, and Post COVID-19 Pandemic in the US
|
Requena, G.
|
|
|
26 |
12S |
p. S27
|
artikel
|
| 45 |
CO24 Daratumumab in Combination with Lenalidomide and Dexamethasone Improves Survival in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: A Parametric Network Meta-Analysis in a United Kingdom Setting
|
van Beekhuizen, S.
|
|
|
26 |
12S |
p. S18
|
artikel
|
| 46 |
CO67 Development of an Investigator Global Assessment of Severity in Propionic Acidemia
|
Longo, N.
|
|
|
26 |
12S |
p. S26
|
artikel
|
| 47 |
CO156 Direct Oral Anticoagulants in Adults with Non-Valvular Atrial Fibrillation: Systematic Review and Network Meta-Analysis of Real-World Evidence
|
Subash, R.
|
|
|
26 |
12S |
p. S42
|
artikel
|
| 48 |
CO30 Disease Burden and Efficacy of Current Treatment for Non-Neuronopathic MPS II Patients: A Systematic Literature Review
|
Schmidt, E.
|
|
|
26 |
12S |
p. S19-S20
|
artikel
|
| 49 |
CO83 Disease Burden of Moderate to Severe Ulcerative Colitis in Chinese Patients Under Current Care: A Model Simulation Study
|
Tan, L.
|
|
|
26 |
12S |
p. S29
|
artikel
|
| 50 |
CO76 Does Next Generation Sequencing (NGS) Improve Outcome in Non-Small Cell Lung Cancer (NSCLC)? A Real-World Data (RWD) Example
|
Gendy, S.
|
|
|
26 |
12S |
p. S28
|
artikel
|
| 51 |
CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?
|
Lloyd, A.
|
|
|
26 |
12S |
p. S41
|
artikel
|
| 52 |
CO140 Drivers of Physicians’ Treatment Decision-Making and Future Treatment Expectations: Analysis of the Adelphi Real-World Ovarian Cancer II Disease Specific Programme (DSPTM)
|
Shukla, S.
|
|
|
26 |
12S |
p. S39-S40
|
artikel
|
| 53 |
CO126 Effectiveness of Cell-Based Treatment Compared to Current Standard of Care for Knee Osteoarthritis Patients in the Netherlands
|
Boot, I.
|
|
|
26 |
12S |
p. S37
|
artikel
|
| 54 |
CO191 Effectiveness of New Generation Heat and Moisture Exchangers and Adhesives for Laryngectomized Patients in Portugal
|
Boot, I.
|
|
|
26 |
12S |
p. S48
|
artikel
|
| 55 |
CO148 Effectiveness of Tocilizumab in Refractory Graves' Orbitopathy in a Real-World Setting
|
Sandoval-Fernandez-del-Castillo, S.
|
|
|
26 |
12S |
p. S41
|
artikel
|
| 56 |
CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data
|
Kim, Y.
|
|
|
26 |
12S |
p. S17
|
artikel
|
| 57 |
CO89 Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)
|
Pandey, P.
|
|
|
26 |
12S |
p. S30
|
artikel
|
| 58 |
CO166 Efficacy of Lecanemab in Patients With Early Alzheimer Disease: A Systematic Review and Meta-Analysis
|
Singh, B.
|
|
|
26 |
12S |
p. S44
|
artikel
|
| 59 |
CO26 Efficacy of the Dupilumab 200 Mg Dose Every 2 Weeks in Children with Moderate-to-Severe Asthma during Voyage and Excursion
|
Phipatanakul, W.
|
|
|
26 |
12S |
p. S19
|
artikel
|
| 60 |
CO182 Efficacy of Venetoclax+Obinutuzumab+Ibrutinib Compared to Alternative Therapeutic Options in the First-Line Treatment of Chronic Lymphocytic Leukemia (Fit Population): A Systematic Review and Network Meta-Analysis
|
Stożek-Tutro, A.
|
|
|
26 |
12S |
p. S46
|
artikel
|
| 61 |
CO134 Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model
|
Vidal, G.A.
|
|
|
26 |
12S |
p. S38
|
artikel
|
| 62 |
CO154 Evaluating Patients Perception of Generic Medicines in Greece
|
Yfantopoulos, I.
|
|
|
26 |
12S |
p. S42
|
artikel
|
| 63 |
CO69 Evidence Gap Analysis of the Burden of Illness and Treatment of Bullous Pemphigoid
|
Gildea, L.
|
|
|
26 |
12S |
p. S27
|
artikel
|
| 64 |
CO153 Exploring the Impact of Healthcare Provider Stress on Patient Outcomes: A Review Protocol
|
Hargreaves, J.
|
|
|
26 |
12S |
p. S42
|
artikel
|
| 65 |
CO184 Exploring the Relationship Between Surrogate and Long-Term Outcomes in Lysosomal Storage Diseases: A Targeted Literature Review
|
Palli, J.M.
|
|
|
26 |
12S |
p. S47
|
artikel
|
| 66 |
CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data
|
Lanzetta, P.
|
|
|
26 |
12S |
p. S27
|
artikel
|
| 67 |
CO68 Gastrointestinal Manifestations and Incontinence Products in the Real World Among Patients with Rett Syndrome in the United States
|
May, D.
|
|
|
26 |
12S |
p. S27
|
artikel
|
| 68 |
CO22 Healthcare Resource Utilization (HCRU), Effectiveness and Safety of Trifluridine/Tipiracil in Treatment of Refractory Metastatic Colorectal Cancer in a Portuguese Comprehensive Cancer Center (PCCC)
|
Redondo, P.
|
|
|
26 |
12S |
p. S18
|
artikel
|
| 69 |
CO98 Health Outcomes and Cost-Effectiveness of Atezolizumab in Small Cell Lung Cancer
|
Marin Pozo, J.F.
|
|
|
26 |
12S |
p. S32
|
artikel
|
| 70 |
CO137 Health Outcomes of ALK-Inhibitors in Non-Small Cell Lung Cancer in Real Clinical Practice
|
Marin Pozo, J.F.
|
|
|
26 |
12S |
p. S39
|
artikel
|
| 71 |
CO128 Health-Related Quality of Life in Generalized Myasthenia Gravis- the Relationship between MG-ADL and EQ-5D-5L in the Raise Study
|
Grimson, F.
|
|
|
26 |
12S |
p. S37
|
artikel
|
| 72 |
CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives
|
Borges, S.
|
|
|
26 |
12S |
p. S18
|
artikel
|
| 73 |
CO17 How to Assess Nationwide Population-Based Clinical Benefit of Treatments Using Public Information? Immunotherapies Case Study
|
Grumberg, V.
|
|
|
26 |
12S |
p. S17
|
artikel
|
| 74 |
CO104 Identification and Selection of Biomarkers in Patient-Centric Treatment Management of Rare/Orphan Kidney Diseases: An Ongoing Research Project Aiming to Develop Personalized Treatment Algorithms
|
Merante, D.
|
|
|
26 |
12S |
p. S33
|
artikel
|
| 75 |
CO14 Identification & Use of Prognostic Variables (PVs)/Treatment Effect Modifiers (TEMs) in Indirect Treatment Comparisons (ITCs) By Systematic Literature Review (SLR): Case Study of Chimeric Antigen Receptor (CAR) T-Cell Therapies
|
Igbelina, C.D.
|
|
|
26 |
12S |
p. S16
|
artikel
|
| 76 |
CO143 Identifying Evidence Gaps for Hemophilia B by Developing a Factsheet Using Targeted Review of Literature: Shaping the Future Real-World Evidence Studies
|
Kaushik, P.
|
|
|
26 |
12S |
p. S40
|
artikel
|
| 77 |
CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea
|
Kim, M.
|
|
|
26 |
12S |
p. S23
|
artikel
|
| 78 |
CO113 Impact of Clinical Pharmacist-Led Intervention on Somatic Cell Therapy Medicinal Product Circuit in Portugal
|
Fonseca, A.
|
|
|
26 |
12S |
p. S35
|
artikel
|
| 79 |
CO147 Impact of COVID-19 on Patients With Asthma in US Routine Care
|
Noorduyn, S.G.
|
|
|
26 |
12S |
p. S41
|
artikel
|
| 80 |
CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial
|
Sekeres, M.
|
|
|
26 |
12S |
p. S28-S29
|
artikel
|
| 81 |
CO66 Improvements in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and Correlation With Bayley-III Scores and Motor Milestones in Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd)
|
Hwu, W.L.
|
|
|
26 |
12S |
p. S26
|
artikel
|
| 82 |
CO194 Integration of Clinical Outcome Assessments (COA) in Drug Approval Process to Foster Patient-Centric Clinical Trials: A Review of 3 Regulatory Guidelines for Drug Development in the APAC
|
Pawar, D.
|
|
|
26 |
12S |
p. S48
|
artikel
|
| 83 |
CO37 Inventory-Facilitated Goal Setting Interview Conducted by Disease Experts Yields a Broader Range of Goal Areas
|
Cheema, K.
|
|
|
26 |
12S |
p. S21
|
artikel
|
| 84 |
CO61 Isatuximab in Multiple Myeloma: Safety and Effectiveness
|
Domínguez, L.
|
|
|
26 |
12S |
p. S25
|
artikel
|
| 85 |
CO146 Language Model-Based Approach for Extracting Comorbidities and Complications in Fabry Disease Clinical Notes
|
Cossio, M.
|
|
|
26 |
12S |
p. S41
|
artikel
|
| 86 |
CO87 Lifetime Cumulative Risk of Bone Fracture in Chinese Male Patients with Osteoporosis: A Model Simulation Study
|
Huang, H.
|
|
|
26 |
12S |
p. S29-S30
|
artikel
|
| 87 |
CO123 Long COVID Symptom Diary: Development of a PRO Instrument to Support Drug Development and Regulatory Submissions in Europe
|
Rudell, K.
|
|
|
26 |
12S |
p. S36
|
artikel
|
| 88 |
CO41 Long-Term Clinical Outcomes in People with Heart Failure with Preserved Ejection Fraction (HFpEF) Treated with Standard Care
|
Sun, L.
|
|
|
26 |
12S |
p. S21-S22
|
artikel
|
| 89 |
CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib
|
Bouwmeester, W.
|
|
|
26 |
12S |
p. S31
|
artikel
|
| 90 |
CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)
|
Ejzykowicz, F.
|
|
|
26 |
12S |
p. S24-S25
|
artikel
|
| 91 |
CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)
|
Jen, M.H.
|
|
|
26 |
12S |
p. S18
|
artikel
|
| 92 |
CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
|
Moreau, P.
|
|
|
26 |
12S |
p. S31
|
artikel
|
| 93 |
CO11 Medication Adherence in Osteoporosis Treatments and the Impact in Patients' Quality of Life
|
Tsaousis, P.
|
|
|
26 |
12S |
p. S16
|
artikel
|
| 94 |
CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System
|
Falavigna, M.
|
|
|
26 |
12S |
p. S33
|
artikel
|
| 95 |
CO65 Modelled Impact of Nirsevimab for All Infants in the Prevention of Respiratory Syncytial Virus (RSV): Related Hospitalizations and Its Predicted Cost to the Brazilian Public Healthcare System
|
Falavigna, M.
|
|
|
26 |
12S |
p. S26
|
artikel
|
| 96 |
CO162 More Serbia: Molnupiravir Real World Utilization Among COVID-19 Patients in Serbia
|
Nađvinski, N.
|
|
|
26 |
12S |
p. S43
|
artikel
|
| 97 |
CO188 Mortality and Clinical Complications Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France
|
Baldwin, J.
|
|
|
26 |
12S |
p. S47
|
artikel
|
| 98 |
CO34 Mortality and Clinical Complications Among Patients with Transfusion-Dependent Beta-Thalassemia in France
|
Baldwin, J.
|
|
|
26 |
12S |
p. S20
|
artikel
|
| 99 |
CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)
|
McNamara, S.
|
|
|
26 |
12S |
p. S33
|
artikel
|
| 100 |
CO96 Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS) v4.0: Measurement Properties from the Momentum Phase 3 Study
|
Daskalopoulou, C.
|
|
|
26 |
12S |
p. S31-S32
|
artikel
|
| 101 |
CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic Melanoma
|
Thosar, M.
|
|
|
26 |
12S |
p. S25
|
artikel
|
| 102 |
CO40 Non-Communicable Diseases Prevention in India: A Review of Suitable Instruments for Surveillance and a General Overview of Cultural, Behavioral Practices and Risk Factors for the Adult Population
|
Jarodia, K.
|
|
|
26 |
12S |
p. S21
|
artikel
|
| 103 |
CO75 Non-Pharmacological Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Comprehensive Review
|
Jangid, S.
|
|
|
26 |
12S |
p. S28
|
artikel
|
| 104 |
CO175 OCTOPUS: Ambispective Observational Study Describing Diagnosis and Treatment Patterns in Adults with Metastatic NSCLC with BRAF V600E Mutation in Clinical Practice, to Assess Treatment Effectiveness and Quality of Life (TIP)
|
Planchard, D.
|
|
|
26 |
12S |
p. S45-S46
|
artikel
|
| 105 |
CO138 Outcomes and Health-Related Costs of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Public Health System
|
Dias, C.
|
|
|
26 |
12S |
p. S39
|
artikel
|
| 106 |
CO173 Outcomes, Treatment Pattern, and Related Cost of Late-Stage Non-Small Cell Lung (NSCLC) Cancer in Taiwan
|
Yang, Y.H.
|
|
|
26 |
12S |
p. S45
|
artikel
|
| 107 |
CO73 Overview of COA Measures in SLE Clinical Trials and Label Claims
|
Suminski, N.
|
|
|
26 |
12S |
p. S28
|
artikel
|
| 108 |
CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity
|
Smoyer, K.E.
|
|
|
26 |
12S |
p. S15
|
artikel
|
| 109 |
CO169 Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies in the Framework of the EU Project, Harmony: the Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology
|
Lang, K.
|
|
|
26 |
12S |
p. S44
|
artikel
|
| 110 |
CO58 Patient Characteristics and Treatment Patterns in Patients with Mantle Cell Lymphoma in Spain: A Real-World, Cross-Sectional Study
|
Esteban-Burgos, L.
|
|
|
26 |
12S |
p. S24
|
artikel
|
| 111 |
CO42 4P Care and Adjusting Therapy for Hypothyroidism – A Potential to Reduce Costs of Healthcare and Loss of Productivity
|
Högqvist Tabor, V.
|
|
|
26 |
12S |
p. S22
|
artikel
|
| 112 |
CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
|
Jensen, C.
|
|
|
26 |
12S |
p. S33
|
artikel
|
| 113 |
CO9 Post-Discharge Mortality in Patients with Mental Illness Hospitalized Compulsorily in Accordance with the Provisions of Article 29 of the Japanese Mental Health and Welfare Law
|
Inagaki, A.
|
|
|
26 |
12S |
p. S15-S16
|
artikel
|
| 114 |
CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)
|
Samjoo, I.
|
|
|
26 |
12S |
p. S25
|
artikel
|
| 115 |
CO121 Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis B Undergoing Antiviral Treatments in a Real-World Setting
|
Lee, H.
|
|
|
26 |
12S |
p. S36
|
artikel
|
| 116 |
CO117 Prognostic Factors and Surrogate Endpoints in Obstructive Hypertrophic Cardiomyopathy: A Systematic Literature Review
|
Krause, T.
|
|
|
26 |
12S |
p. S36
|
artikel
|
| 117 |
CO31 Progressive Pulmonary Fibrosis: A Modelling Analysis of Long-Term Progression Based on Inbuild
|
Raspin, C.
|
|
|
26 |
12S |
p. S20
|
artikel
|
| 118 |
CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in France: A Simulation Study
|
Osumili, B.
|
|
|
26 |
12S |
p. S22
|
artikel
|
| 119 |
CO130 Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend
|
Mohseninejad, L.
|
|
|
26 |
12S |
p. S37
|
artikel
|
| 120 |
CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer
|
Maheshwari, V.K.
|
|
|
26 |
12S |
p. S24
|
artikel
|
| 121 |
CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia
|
Domínguez, L.
|
|
|
26 |
12S |
p. S32
|
artikel
|
| 122 |
CO29 Real-World Benefit of Ataluren Treatment in Milestones Not Related to Ambulatory Function in Nonsense Duchenne Muscular Dystrophy Versus Standard of Care
|
Machado, D.
|
|
|
26 |
12S |
p. S19
|
artikel
|
| 123 |
CO38 Real-World Comparative COVID-19 Vaccine Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 Among Immunocompromised Adults in the US
|
Beck, E.
|
|
|
26 |
12S |
p. S21
|
artikel
|
| 124 |
CO174 Real World Data of Daratumumab Treatment in Patient with Multiple Myeloma: A Portuguese Study
|
Gomes, A.
|
|
|
26 |
12S |
p. S45
|
artikel
|
| 125 |
CO97 Real-World Outcomes in Third-Line and Beyond (3L+) Small-Cell Lung Cancer (SCLC): A Systematic Literature Review (SLR)
|
Dirnberger, F.
|
|
|
26 |
12S |
p. S32
|
artikel
|
| 126 |
CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
|
Leung, L.
|
|
|
26 |
12S |
p. S24
|
artikel
|
| 127 |
CO100 Regular Laboratory Checks for Ileostomy Patients After Surgery Are Not Performed Comprehensively, but Could Result in Better Health Outcomes
|
Surendranathan, N.
|
|
|
26 |
12S |
p. S32
|
artikel
|
| 128 |
CO187 Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg after Loading Phase in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
|
Bührer, C.
|
|
|
26 |
12S |
p. S47
|
artikel
|
| 129 |
CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach
|
Petrica, N.
|
|
|
26 |
12S |
p. S34
|
artikel
|
| 130 |
CO51 Safety Profile of Approved Alzheimer's Medication By USFDA
|
Almutairi, R.
|
|
|
26 |
12S |
p. S23
|
artikel
|
| 131 |
CO183 Simulated Treatment Comparison and Matching-Adjusted Indirect Comparison of the Efficacy of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
|
Karam, C.
|
|
|
26 |
12S |
p. S46-S47
|
artikel
|
| 132 |
CO110 Systematic Literature Review and Network Meta-Analysis to Assess the Comparative Efficacy of Topical Fixed-Dose Combinations for Moderate to Severe Acne Vulgaris as Measured By Lesion Counts
|
Harper, J.
|
|
|
26 |
12S |
p. S34
|
artikel
|
| 133 |
CO63 Systematic Literature Review of Health-Related Quality of Life in Advanced or Metastatic Esophageal Cancer
|
Pandey, A.
|
|
|
26 |
12S |
p. S25-S26
|
artikel
|
| 134 |
CO133 Systematic Literature Review (SLR) of Clinical Data from First-Line Treatment or First-Line Maintenance Therapy for Advanced or Metastatic Ovarian Cancer (2010–2023)
|
Kiss, Z.
|
|
|
26 |
12S |
p. S38
|
artikel
|
| 135 |
CO136 Systematic Literature Review (SLR) of Clinical Data in Third-Line and Beyond (3L+) Small Cell Lung Cancer (SCLC) Patients
|
Dirnberger, F.
|
|
|
26 |
12S |
p. S39
|
artikel
|
| 136 |
CO6 Teduglutide for Treating Short-Bowel Syndrome in Adults: A Meta-Analysis of Real-World Evidence Compared to Clinical Trial Data
|
Eaton, J.
|
|
|
26 |
12S |
p. S15
|
artikel
|
| 137 |
CO27 The Feasibility of Systematic Goal Quality Assurance During Goal Attainment Scaling in a Rare Disease
|
Chapman, C.A.
|
|
|
26 |
12S |
p. S19
|
artikel
|
| 138 |
CO115 The Interpretation and Grading of Evidence Derived From Interim Analyses for the Assessment of the Pharmacotherapeutic Efficacy of Medicines
|
al Dulaimi, R.
|
|
|
26 |
12S |
p. S35-S36
|
artikel
|
| 139 |
CO116 The Significance of Serum Transaminases As Predictors of Mortality in Paraquat Poisoning: A Systematic Review and Meta-Analysis
|
Kaur, H.
|
|
|
26 |
12S |
p. S36
|
artikel
|
| 140 |
CO78 Time to Diagnosis in Hypertrophic Cardiomyopathies and the Association With Adverse Outcomes Post-Diagnosis
|
Lim, V.G.
|
|
|
26 |
12S |
p. S29
|
artikel
|
| 141 |
CO176 Treatment Approvals in Oncology and Relationship with Improvement in 5-Year Relative Survival for Cancer Patients in Europe
|
Gulotta, G.
|
|
|
26 |
12S |
p. S46
|
artikel
|
| 142 |
CO170 Treatment Exposure-Adjusted Event Rates (EAERs) for Grade 3/4 AEs Associated with Emerging and Existing Systemic Therapies for mCRC with at Least 2 Prior Lines of Therapy: Informing Payer and Pathway Formulary Decision Making
|
Howe, A.
|
|
|
26 |
12S |
p. S44-S45
|
artikel
|
| 143 |
CO155 Trial-Level Endpoint Surrogacy Analysis: Feasibility Assessment and Comparison of Different Methodological Approaches
|
Petersohn, S.
|
|
|
26 |
12S |
p. S42
|
artikel
|
| 144 |
CO178 Understanding Physicians’ Decision-Making Practices Related to Biomarker Testing: Analysis of the Adelphi Real-World Ovarian Cancer II Disease Specific Programme (DSPTM)
|
Glasspool, R.
|
|
|
26 |
12S |
p. S46
|
artikel
|
| 145 |
CO20 Use of Inpatient Systemic Chemotherapy and/or Radiotherapy and Related Predictive Factors for Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Study in a Clinical Practice Setting in Italy
|
Kearney, M.
|
|
|
26 |
12S |
p. S17-S18
|
artikel
|
| 146 |
CO131 Using Non-Randomized Trials to Assess the Clinical Benefit of Systemic Anti-Cancer Treatments: Viable or Not?
|
Xander, N.
|
|
|
26 |
12S |
p. S37-S38
|
artikel
|
| 147 |
CO32 Validation of a Scoring Algorithm for the Clinician-Reported Outcome ”Prurigo Activity and Severity (PAS)’’ Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis
|
Zeidler, C.
|
|
|
26 |
12S |
p. S20
|
artikel
|
| 148 |
CO165 Validation of High Risk Criteria in Medication Reconciliation in Major Orthopedic Surgery: A Delphi Study
|
Luque, J.
|
|
|
26 |
12S |
p. S43-S44
|
artikel
|
| 149 |
Cover
|
|
|
|
26 |
12S |
p. OFC
|
artikel
|
| 150 |
CO72 Vitamin D as an Adjunct Therapy in the Treatment of Atopic Dermatitis: A Targeted Review
|
Borecka, O.
|
|
|
26 |
12S |
p. S27-S28
|
artikel
|
| 151 |
CO12 5 Years of Real-World Data on the Use of Cladribine Tablets for the Treatments of Multiple Sclerosis in Portugal
|
Ribeiro, M.
|
|
|
26 |
12S |
p. S16
|
artikel
|
| 152 |
Disclaimer
|
|
|
|
26 |
12S |
p. A1
|
artikel
|
| 153 |
EE352 A Budget Impact Analysis of Cladribine in England and Wales for Patients With Highly Active Relapsing-Remitting Multiple Sclerosis (HA-RRMS)
|
Herbert, A.
|
|
|
26 |
12S |
p. S119
|
artikel
|
| 154 |
EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective
|
Antonazzo, I.C.
|
|
|
26 |
12S |
p. S121
|
artikel
|
| 155 |
EE186 A Comparative Cost Analysis between Dalbavancin, Oritavancin and Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Spain
|
Rios, M.
|
|
|
26 |
12S |
p. S86
|
artikel
|
| 156 |
EE401 A Comparison of Health State Occupancy Between Cipaglucosidase Alfa/Miglustat and Alglucosidase Alfa Within a Cost-Effectiveness Modelling Analysis of Late-Onset Pompe Disease
|
Raza, S.
|
|
|
26 |
12S |
p. S128
|
artikel
|
| 157 |
EE560 A Comparison of Time-Driven Activity-Based Costs for Patients and Caregivers Receiving Intravitreal Treatments for Neovascular Age-Related Macular Degeneration
|
Hurley, B.
|
|
|
26 |
12S |
p. S160
|
artikel
|
| 158 |
EE532 A Conceptual Model for the Cost Effectiveness of Artificial Intelligence-Assisted Chest Computed Tomography (CT) to Detect Lung Nodules and Improve Decision Making
|
Gregory, L.
|
|
|
26 |
12S |
p. S154
|
artikel
|
| 159 |
EE322 A Cost Analysis for Macrovascular Events, Comparison of Glargine 300U/Ml (GLA-300) and Degludec 100U/Ml (IDeg-100) in the Treatment of Type 2 Diabetes Mellitus in Older Population or Renal Impairment Individuals in Latin America
|
Londono, S.
|
|
|
26 |
12S |
p. S113
|
artikel
|
| 160 |
EE72 A Cost-Effectiveness Analysis of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer in Portugal
|
Andrade, A.
|
|
|
26 |
12S |
p. S64
|
artikel
|
| 161 |
EE78 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment Following Complete Resection and Platinum-Based Chemotherapy in Adult Patients With Early-Stage Non-Small Cell Lung Cancer With a High Risk of Recurrence
|
Silva Miguel, L.
|
|
|
26 |
12S |
p. S65
|
artikel
|
| 162 |
EE689 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment (Monotherapy) for Adult Patients With Non-Small Cell Lung Cancer Following Resection and Platinum-Based Chemotherapy in Greece
|
Nomikos, N.
|
|
|
26 |
12S |
p. S186-S187
|
artikel
|
| 163 |
EE615 A Cost-Effectiveness Analysis of the CNIC-Polypill Strategy, Compared to Usual Care, in Secondary Cardiovascular Prevention from a Spanish Perspective Using Data from the Secure Trial
|
Hopmans, M.
|
|
|
26 |
12S |
p. S171
|
artikel
|
| 164 |
EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting
|
Ota, R.
|
|
|
26 |
12S |
p. S83
|
artikel
|
| 165 |
EE483 A Cost-Impact Analysis of a Novel Diagnostic Test to Assess Community-Acquired Pneumonia Etiology in the Emergency Departments: A French Perspective
|
Porta, C.
|
|
|
26 |
12S |
p. S144
|
artikel
|
| 166 |
EE266 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Iron Deficiency Anemia in China
|
Zhang, F.
|
|
|
26 |
12S |
p. S102-S103
|
artikel
|
| 167 |
EE619 A Cost-Utility Analysis of Low-Dose vs Standard-Dose Intravenous Alteplase in the Management of Acute Non-Lacunar Ischaemic Strokes: A Perspective From the NHS
|
Okechukwu, H.
|
|
|
26 |
12S |
p. S172
|
artikel
|
| 168 |
EE82 A Cost-Utility Analysis of the MyPal eHealth Application, an ePro Intervention Aiming to Foster Palliative Care of Cancer Patients: Results From a Randomized Clinical Trial in 4 European Countries
|
Naoum, P.
|
|
|
26 |
12S |
p. S66
|
artikel
|
| 169 |
EE582 Actuarial Value Chain Modelling of Valoctocogene Roxaparvovec (VALROX) Therapy for Hemophilia A: An Adaptation from ICER Final Evidence Report*
|
Garg, M.
|
|
|
26 |
12S |
p. S165
|
artikel
|
| 170 |
EE714 A De Novo Cost-Effectiveness Model to Evaluate the Real-World Value of Pegcetacoplan in the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration in the United States
|
Cummings Joyner, A.K.
|
|
|
26 |
12S |
p. S192
|
artikel
|
| 171 |
EE653 A Health Economic Model to Assess the Effects of Introducing Home Polysomnography for the Diagnosis of Sleep Apnea in Germany
|
Braun, M.
|
|
|
26 |
12S |
p. S179
|
artikel
|
| 172 |
EE233 Alternatives to Bayesian Network Meta-Analysis in Case of Proportional Hazards Invalidity: Review of HAS Cost-Utility Studies Opinions in France
|
Kirion, J.
|
|
|
26 |
12S |
p. S96
|
artikel
|
| 173 |
EE168 A Markov Model to Determine the Cost-Effectiveness of a Multi-Targeting Bacterial Gene Therapy (AUP-16) at Healing a Diabetic Foot Ulcer When Compared to the Current Standard of Care
|
Basskin, L.
|
|
|
26 |
12S |
p. S82-S83
|
artikel
|
| 174 |
EE490 Analysis of Access and Avalibility of Low Molecular Heparins for the Treatment of COVID-19 during Wartime in Ukraine
|
Zaliska, O.
|
|
|
26 |
12S |
p. S146
|
artikel
|
| 175 |
EE633 Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease
|
Harper, S.
|
|
|
26 |
12S |
p. S175
|
artikel
|
| 176 |
EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain
|
Calleja, T.
|
|
|
26 |
12S |
p. S153
|
artikel
|
| 177 |
EE434 Analysis of the Clinical and Economic Impact of High Protein Concentration Ons in a Spanish Hospital Setting
|
Kvasz, M.
|
|
|
26 |
12S |
p. S134
|
artikel
|
| 178 |
EE124 Analysis of the Use of the Haute Autorité De Santé (HAS) Opinions by Hospital Pharmacists in France
|
Moutier, H.
|
|
|
26 |
12S |
p. S74
|
artikel
|
| 179 |
EE172 An Early Economic Analysis of the Costs and Benefits of Medical Alert Assistance Dogs (MAADS) in the Management of Emergency Episodes for People with Postural Tachycardia Syndrome (POTS) Using Real-World Evidence (RWE)
|
Ryczek, E.
|
|
|
26 |
12S |
p. S83
|
artikel
|
| 180 |
EE442 An Economic Evaluation of Universal Childhood Varicella Vaccination in Ireland
|
Ahern, S.
|
|
|
26 |
12S |
p. S136
|
artikel
|
| 181 |
EE12 An Economic Model Comparing Fever Management to Fever Prevention With Advanced Targeted Temperature Management (ATTM) in Out-of-Hospital Cardiac Arrest (OHCA) Patients
|
Kelly, T.
|
|
|
26 |
12S |
p. S52
|
artikel
|
| 182 |
EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa
|
Snell, T.
|
|
|
26 |
12S |
p. S159
|
artikel
|
| 183 |
EE53 An Investigation of Value for Money of Oncology Drugs in Canada
|
Jackson, A.
|
|
|
26 |
12S |
p. S60
|
artikel
|
| 184 |
EE461 An Italian Real-World Analysis of Economic Impact in Patients with Hypercholesterolemia Treated with Rosuvastatin/Ezetimibe as Free Vs Single-Pill Combination
|
Degli Esposti, L.
|
|
|
26 |
12S |
p. S140
|
artikel
|
| 185 |
EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia
|
Sanogo, V.
|
|
|
26 |
12S |
p. S147
|
artikel
|
| 186 |
EE60 An Overview of Systematic Reviews of Economic Evaluations on Cancer Screening: Landscape, Quality, and Recommendations
|
Tickell, L.A.
|
|
|
26 |
12S |
p. S61
|
artikel
|
| 187 |
EE105 anti-VEGFs Use in Neovascular Age-Related Macular Degeneration: An Analysis of the National Report on Medicines Use in Italy
|
Ghetti, G.
|
|
|
26 |
12S |
p. S70-S71
|
artikel
|
| 188 |
EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States
|
Oluwole, O.
|
|
|
26 |
12S |
p. S151
|
artikel
|
| 189 |
EE284 A Qualitative Primary Market Research Study on the Economic Investment of Scaling up Bariatric Surgery Capacity Within the NHS
|
Baker-Knight, J.
|
|
|
26 |
12S |
p. S105
|
artikel
|
| 190 |
EE700 Are Acute Therapies and Curative Drugs More Affordable Than Chronic Treatments in Rare Diseases? An Analysis of the Top 10 Most Expensive Drugs in the US Compared with Germany
|
Craddy, P.
|
|
|
26 |
12S |
p. S189
|
artikel
|
| 191 |
EE148 Are General Population Utilities Appropriate to Use as Baselines for Age-Adjustment of Utility Values?
|
Chang-Douglass, S.
|
|
|
26 |
12S |
p. S78-S79
|
artikel
|
| 192 |
EE188 A Retrospective Cohort Comparing the Tuberculosis Diagnosis Related Costs and Health Resource Use (HRU) Using a Rapid Nucleic Acid Amplification (NAA) Test Vs. Conventional Tests in China, Followed By a Budget Impact Model
|
Li, R.
|
|
|
26 |
12S |
p. S87
|
artikel
|
| 193 |
EE106 Artificial Intelligence (AI) Based Telemedicine for Cost-Effective Cataract Surgery Follow-up at NHS: An Economic Evaluation
|
Bajre, M.
|
|
|
26 |
12S |
p. S71
|
artikel
|
| 194 |
EE590 Assessing Health Outcomes and Cost-Effectiveness of Adult HPV Vaccination in Italy
|
Cherif, A.
|
|
|
26 |
12S |
p. S166
|
artikel
|
| 195 |
EE601 Assessing the Barriers to Healthcare Resource Use (HRU) Data Collection and Offering Solutions to Support the Evidence Generation Process in LMICs
|
Kodabuckus, S.
|
|
|
26 |
12S |
p. S169
|
artikel
|
| 196 |
EE101 Assessing the Cost-Effectiveness of Introducing Benralizumab in the Treatment of Severe Uncontrolled Eosinophilic Asthma Patients in Prince Sultan Military Medical City (PSMMC) - Kingdom of Saudi Arabia (KSA)
|
Idrees, M.
|
|
|
26 |
12S |
p. S70
|
artikel
|
| 197 |
EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal
|
Borges, M.
|
|
|
26 |
12S |
p. S104
|
artikel
|
| 198 |
EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)
|
Chandler, T.
|
|
|
26 |
12S |
p. S187
|
artikel
|
| 199 |
EE535 Assessing the Impact of Adverse Events on Cost-Effectiveness Results for NICE Single Technology Appraisals of Oncology Medicines
|
Zein, M.
|
|
|
26 |
12S |
p. S155
|
artikel
|
| 200 |
EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations
|
Gomez Montero, M.
|
|
|
26 |
12S |
p. S187
|
artikel
|
| 201 |
EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation
|
Muehlbacher, A.
|
|
|
26 |
12S |
p. S179
|
artikel
|
| 202 |
EE739 Assessing the Value of Next Generation Sequencing in NSCLC
|
Mathews, C.
|
|
|
26 |
12S |
p. S197
|
artikel
|
| 203 |
EE156 Assessing Treatment Costs and Economic Burden of Major Cardiovascular Conditions in Turkiye
|
Öztürk, F.
|
|
|
26 |
12S |
p. S80
|
artikel
|
| 204 |
EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
|
Rodriguez-Martinez, C.E.
|
|
|
26 |
12S |
p. S156
|
artikel
|
| 205 |
EE570 A Swedish Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease
|
Lindgren, S.
|
|
|
26 |
12S |
p. S162
|
artikel
|
| 206 |
EE698 A Systematic Literature Review of Economic Evaluations in Primary Biliary Cholangitis
|
Pashley, A.
|
|
|
26 |
12S |
p. S188
|
artikel
|
| 207 |
EE199 A Systematic Literature Review of Economic Evaluations of Community-Based Interventions to Improve Mobility, Continence, and Psychological Wellbeing in Individuals with Neuro-Physical Disabilities
|
Gorman, A.
|
|
|
26 |
12S |
p. S89
|
artikel
|
| 208 |
EE91 A Systematic Literature Review of Health-Related Quality of Life, Costs, and Healthcare Resource Use in Primary Biliary Cholangitis
|
Pashley, A.
|
|
|
26 |
12S |
p. S68
|
artikel
|
| 209 |
EE358 A Systematic Literature Review of Reviews Related to the Impacts of Catastrophic Health Expenditures Related to Cancer Care
|
Sutherland, C.S.
|
|
|
26 |
12S |
p. S120
|
artikel
|
| 210 |
EE617 A Systematic Review of Economic Evaluations of Balloons and Stents for Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
|
Ma, Y.
|
|
|
26 |
12S |
p. S171-S172
|
artikel
|
| 211 |
EE587 A Systematic Scoping Review to Identify Challenges in the Economic Evaluation of Prognostic and Predictive Companion Diagnostics in Personalized Medicine: The Radioval Study
|
Hakkarainen, T.
|
|
|
26 |
12S |
p. S166
|
artikel
|
| 212 |
EE178 A Targeted Literature Review of Cost-Utility Analyses for Ulcerative Colitis/Crohn’s Disease Treatment
|
Bisen, R.
|
|
|
26 |
12S |
p. S85
|
artikel
|
| 213 |
EE198 A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis
|
Kloska, T.
|
|
|
26 |
12S |
p. S89
|
artikel
|
| 214 |
EE208 A Total Cost of Care Analysis of Immune-Oncology (IO) Treatments for Unresectable Hepatocellular Carcinoma (uHCC): A Canadian Payer Perspective
|
Sah, J.
|
|
|
26 |
12S |
p. S91
|
artikel
|
| 215 |
EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
|
Ortiz-Maldonado, V.
|
|
|
26 |
12S |
p. S184-S185
|
artikel
|
| 216 |
EE556 Beclometasone/Formoterol/Glycopyrronium Vs. Fixed and Open Combinations of Inhaled Corticosteroids, Long-Acting B2-Agonist, and Long-Acting Muscarinic Antagonist in Adults with Uncontrolled Asthma: A Network Meta-Analysis
|
Orlovic, M.
|
|
|
26 |
12S |
p. S159-S160
|
artikel
|
| 217 |
EE458 Benefits, Costs and Cost Effectiveness of a Chronic Heart Failure Disease Management Program for Austria – a Decision-Analytic Modeling Study
|
Jahn, B.
|
|
|
26 |
12S |
p. S139
|
artikel
|
| 218 |
EE46 BoNT-As for Cervical Dystonia: Cost of Treatment and Response to Therapy in Canadian Patients
|
Johnston, K.
|
|
|
26 |
12S |
p. S58
|
artikel
|
| 219 |
EE496 Botulinum Toxin Type a for the Treatment of Focal Spasticity in Children with Cerebral Palsy in Thailand: A Cost-Utility Analysis
|
Prawjaeng, J.
|
|
|
26 |
12S |
p. S147
|
artikel
|
| 220 |
EE310 Botulinum Toxin Type a for the Treatment of Patients with Post-Stroke Focal Spasticity in Thailand: A Cost-Utility Analysis
|
Hadnorntun, P.
|
|
|
26 |
12S |
p. S110-S111
|
artikel
|
| 221 |
EE626 Budget Impact Analysis (BIA) of Adopting Real-Time Continuous Glucose Monitoring (rt-CGM) vs Intermittent-Scanning Continuous Glucose Monitoring (is-CGM) in Patients With Type 1 Diabetes on Insulin Therapy (PWT1D) in Italy
|
Ilham, S.
|
|
|
26 |
12S |
p. S173
|
artikel
|
| 222 |
EE750 Budget Impact Analysis (BIA) of Increased COVID-19 Booster Vaccinations in Austria
|
Traunfellner, M.
|
|
|
26 |
12S |
p. S199
|
artikel
|
| 223 |
EE329 Budget Impact Analysis of Adding Risankizumab and Upadacitinib for the Treatment of Inflammatory Bowel Disease in the Kingdom of Saudi Arabia
|
Mosli, M.
|
|
|
26 |
12S |
p. S114
|
artikel
|
| 224 |
EE406 Budget Impact Analysis of Dupilumab 200 Mg for Treatment of Adolescent and Adult With Severe Asthma in Algerian Setting
|
Gharnaout, M.
|
|
|
26 |
12S |
p. S129
|
artikel
|
| 225 |
EE380 Budget-Impact Analysis of Encorafenib with Binimetinib for Unresectable or Metastatic Melanoma in BRAFV600-Mutated Patients in an Argentinian Social Security Payer Setting
|
Vega, C.
|
|
|
26 |
12S |
p. S123-S124
|
artikel
|
| 226 |
EE712 Budget Impact Analysis of Faricimab for Treating Patients With Diabetes Macular Edema or Neovascular Age-Related Macular Degeneration in El Salvador, Honduras, and Dominican Republic
|
Hidalgo, J.
|
|
|
26 |
12S |
p. S191
|
artikel
|
| 227 |
EE173 Budget Impact Analysis of IDegAsp for the Management of Type 2 Diabetes in Saudi Arabia
|
Alharbi, B.
|
|
|
26 |
12S |
p. S83-S84
|
artikel
|
| 228 |
EE377 Budget Impact Analysis of Implementing a Breast Cancer Screening Program in Bulgaria
|
Dacheva, A.
|
|
|
26 |
12S |
p. S123
|
artikel
|
| 229 |
EE291 Budget Impact Analysis of Mrna-1273 (Spikevax) in Patients with COVID-19 in Bulgaria
|
Dacheva, A.
|
|
|
26 |
12S |
p. S106-S107
|
artikel
|
| 230 |
EE488 Budget Impact Analysis of Oral Treatment With Nirmaltrevir+Ritonavir for COVID-19 in Argentina
|
Rey-Ares, L.
|
|
|
26 |
12S |
p. S145
|
artikel
|
| 231 |
EE167 Budget Impact Analysis of Sensor Augmented Pump Therapy for Type 1 Diabetes (T1D) in Bulgaria
|
Yu, J.
|
|
|
26 |
12S |
p. S82
|
artikel
|
| 232 |
EE16 Budget Impact Analysis of the Introduction of Dexcom ONE for the Treatment of Patients With T2 Diabetes on an Intensive Insulin Schedule From the Perspective of the Italian Healthcare Payer
|
Genugten, M.
|
|
|
26 |
12S |
p. S53
|
artikel
|
| 233 |
EE572 Budget Impact Analysis of the Introduction of Endo Arteriovenous Fistula System (WAVELINQ) for Hemodialysis Access Creation in Patients with End-Stage Kidney Disease
|
Rathi, H.
|
|
|
26 |
12S |
p. S163
|
artikel
|
| 234 |
EE502 Budget Impact Analysis of Transanal Irrigation for the Treatment of Low Anterior Resection Syndrome in Spain
|
Marinello, F.
|
|
|
26 |
12S |
p. S148
|
artikel
|
| 235 |
EE97 Budget Impact Analysis with and without Performance-Based Managed Entry Agreement (PBMEA) of Different Treatments for Spinal Muscular Atrophy (SMA) in the Kingdom of Saudi Arabia
|
Al Jedai, A.
|
|
|
26 |
12S |
p. S69
|
artikel
|
| 236 |
EE218 Budget Impact and Cost Minimization Analysis of Phesgo ® (Trastuzumab + Pertuzumab SC) for the Treatment of HER2+ Breast Cancer in the Chilean Public Health System
|
Rojas, R.
|
|
|
26 |
12S |
p. S93
|
artikel
|
| 237 |
EE141 Budget Impact Model for the Swiss Healthcare System: Assessing Potential Budget Savings of an Adapted Fall-2023-COVID-19 Vaccination Strategy
|
Certejan, T.
|
|
|
26 |
12S |
p. S77
|
artikel
|
| 238 |
EE386 Budget Impact of Durvalumab for the Treatment of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Private Healthcare System
|
Meirelles, I.
|
|
|
26 |
12S |
p. S125
|
artikel
|
| 239 |
EE417 Budget Impact of Efmoroctocog Alfa in Treatment of Severe Haemophilia a Patients in Turkey
|
Tatar, M.
|
|
|
26 |
12S |
p. S131
|
artikel
|
| 240 |
EE241 Budget Impact of Making Emicizumab Available at the Community Pharmacy in Addition to the Hospital Pharmacy
|
Leleu, H.
|
|
|
26 |
12S |
p. S97
|
artikel
|
| 241 |
EE350 Budget Impact of Memantine for Alzheimer's Patient in the United States
|
Almutairi, R.
|
|
|
26 |
12S |
p. S118
|
artikel
|
| 242 |
EE723 Budget Impact of New Potassium-Lowering Therapies in the Treatment of Chronic Hyperkalemia: A Saudi Experience
|
Alshahrani, A.
|
|
|
26 |
12S |
p. S193-S194
|
artikel
|
| 243 |
EE644 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the US
|
Sandin, R.
|
|
|
26 |
12S |
p. S177
|
artikel
|
| 244 |
EE11 Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital
|
Tatar, M.
|
|
|
26 |
12S |
p. S51-S52
|
artikel
|
| 245 |
EE720 Budget Impact of Preoperative Anemia Management, the First Pillar of Patient Blood Management, on the Romanian Healthcare System
|
Lorenzovici, L.
|
|
|
26 |
12S |
p. S193
|
artikel
|
| 246 |
EE24 Budget Impact of Stepping Off Patients from Long-Term Inappropriate Proton Pump Inhibitors (PPIs) Use to Episodic Alginate Treatment
|
Wray, J.
|
|
|
26 |
12S |
p. S54
|
artikel
|
| 247 |
EE254 Budget Impact of Telemonitoring (TM)-Enabled Care of Obstructive Sleep Apnea Hypoanpnea Syndrome (OSAH) in the UK
|
Deger, M.
|
|
|
26 |
12S |
p. S100
|
artikel
|
| 248 |
EE128 Budget Impact of the Jada System for the Treatment of Patients with Abnormal Post-Partum Bleeding or Hemorrhage in the United States
|
Yong, C.
|
|
|
26 |
12S |
p. S75
|
artikel
|
| 249 |
EE504 Buprenorphine–Naloxone Film Yields Cost Savings in Administration Time Compared With Sublingual Tablets in Sweden
|
Macnair, P.
|
|
|
26 |
12S |
p. S148
|
artikel
|
| 250 |
EE382 Burden and Economic Impact of Vaccine-Preventable Cancer Mortality in Europe
|
Bencina, G.
|
|
|
26 |
12S |
p. S124
|
artikel
|
| 251 |
EE335 Burden of COVID-19 Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany—A Retrospective Claims Data Analysis
|
Schnaidt, S.
|
|
|
26 |
12S |
p. S115-S116
|
artikel
|
| 252 |
EE443 Burden of Hospitalization Related to Adult Herpes Zoster Infection in Portugal
|
Silva, F.
|
|
|
26 |
12S |
p. S136
|
artikel
|
| 253 |
EE217 Cancer-Related Mortality in Turkiye: Years of Life Lost and Productivity Costs
|
Akyol Ersoy, B.
|
|
|
26 |
12S |
p. S93
|
artikel
|
| 254 |
EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma
|
Kurte, M.S.
|
|
|
26 |
12S |
p. S91
|
artikel
|
| 255 |
EE616 Cardiometabolic Disease Prevention Policy Models: A Systematic Review
|
Putri, S.
|
|
|
26 |
12S |
p. S171
|
artikel
|
| 256 |
EE127 CAR-T Cell Therapies' Pathway: Evolution of Management and of Costing Methodology in the French Cost-Effectiveness Analyses (CEA) Landscape
|
Sellami, R.
|
|
|
26 |
12S |
p. S74-S75
|
artikel
|
| 257 |
EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology
|
Zannat, N.E.
|
|
|
26 |
12S |
p. S186
|
artikel
|
| 258 |
EE64 Change in Healthcare Resource Use and Associated Costs of Patients with Metastatic Lung Cancer between 2013 and 2019: An Observational Study from the French National Claims Database
|
Chouaid, C.
|
|
|
26 |
12S |
p. S62
|
artikel
|
| 259 |
EE1 Characterising the Economic Burden Associated With Obstructive Hypertrophic Cardiomyopathy: Healthcare Resource Use and Costs in England
|
Osman, F.
|
|
|
26 |
12S |
p. S50
|
artikel
|
| 260 |
EE201 Clinical and Economic Consequences of Epilepsy Treatment across Incremental Treatment Lines in Spain: A Real Life Database Analysis
|
Toledano, R.
|
|
|
26 |
12S |
p. S90
|
artikel
|
| 261 |
EE206 Clinical and Economic Evaluation of Atezolizumab + Vemurafenib + Cobimetinib Combination in Treatment of Adult Patients with Metastatic Braf-Positive Melanoma
|
Makarova, E.
|
|
|
26 |
12S |
p. S91
|
artikel
|
| 262 |
EE360 Clinical and Economic Evaluation of Atezolizumab Versus Durvalumab Administration in Adult Patients with Extensive Stage Small Cell Lung Cancer
|
Makarova, E.
|
|
|
26 |
12S |
p. S120
|
artikel
|
| 263 |
EE324 Clinical and Economic Evaluation of the Potential Implementation of P4P for Type 2 Diabetes in Bulgaria
|
Slavchev, G.
|
|
|
26 |
12S |
p. S113
|
artikel
|
| 264 |
EE345 Clinical and Economic Impact Analysis of Viscosupplementation With Hylan G-F 20 Versus Hyaluronic Acid for the Treatment of Knee Osteoarthrosis in Colombia
|
Vásquez, E.
|
|
|
26 |
12S |
p. S117
|
artikel
|
| 265 |
EE29 Clinical and Economic Impact of Pre-Exposure Prophylaxis With Tixagevimab+Cilgavimab in 2022 in Switzerland to Protect Immunocompromised Individuals
|
Rivolo, S.
|
|
|
26 |
12S |
p. S55
|
artikel
|
| 266 |
EE90 Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Show Substantial Healthcare Resource Utilization
|
Sirimanne, M.
|
|
|
26 |
12S |
p. S67-S68
|
artikel
|
| 267 |
EE389 Collective vs Health Insurance Perspective in a French Efficiency Model: A Diversity of Cost Measurement Sources
|
Alaoui, E.
|
|
|
26 |
12S |
p. S125
|
artikel
|
| 268 |
EE189 Combining Causal Inference and Within-Trial Economic Evaluation Methods to Assess the Cost-Effectiveness of a Mental Health Service Using Real-World Data: The Quasi-Experimental Adapt Study
|
Franklin, M.
|
|
|
26 |
12S |
p. S87
|
artikel
|
| 269 |
EE253 Comparative Efficacy of Beclomethasone/Formoterol/Glycopyrronium (BDP/FOR/GLY) Vs Budesonide/Glycopyrrolate/Formoterol (BUD/GLY/FOR): Indirect Comparison in Chinese Patients with Chronic Obstructive Pulmonary Disease
|
Orlovic, M.
|
|
|
26 |
12S |
p. S100
|
artikel
|
| 270 |
EE180 Comparing the Environmental Costs of Differentiated Service Delivery of Antiretroviral Therapy for People Living with HIV in Rural South Africa
|
Tseng, A.S.
|
|
|
26 |
12S |
p. S85
|
artikel
|
| 271 |
EE470 Comparing Three Indirect Cost Approaches in the IQVIA Core Diabetes Model
|
Martins, L.
|
|
|
26 |
12S |
p. S142
|
artikel
|
| 272 |
EE42 Comparison of Cost of Incident Rheumatoid Arthritis Patients in Turkey with Selected European Countries
|
Baser, O.
|
|
|
26 |
12S |
p. S57-S58
|
artikel
|
| 273 |
EE452 Comparison of Disease Agnostic Healthcare Resource Utilization and Costs Across the US and EU5 Population
|
Silber, A.
|
|
|
26 |
12S |
p. S138
|
artikel
|
| 274 |
EE586 Comparison of Enteral Nutritional Therapy to Induce and Maintain Remission in Paediatric Patients with Mild-to-Moderate Crohn’S Disease: A Cost-Effectiveness Analysis in the UK
|
Wooller, S.A.
|
|
|
26 |
12S |
p. S165-S166
|
artikel
|
| 275 |
EE289 Comparison of the Clinical and Economic Impact of Two COVID-19 mRNA Vaccines in High Risk Individuals in the Tokyo Prefecture
|
Kohli, M.
|
|
|
26 |
12S |
p. S106
|
artikel
|
| 276 |
EE594 Comparison of the Clinical and Economic Impact of Two COVID-19 Vaccines in Immunocompromised Patients in France
|
Uhart, M.
|
|
|
26 |
12S |
p. S167
|
artikel
|
| 277 |
EE140 Comparison of the Clinical and Economic Impact of Two MRNA COVID-19 Vaccines in High Risk Individuals in Japan
|
Kohli, M.
|
|
|
26 |
12S |
p. S77
|
artikel
|
| 278 |
EE8 Еconomic Evaluation of Intravascular Ultrasound (IVUS) for Imaging in Patients with Coronary Artery Disease in Bulgaria
|
Dacheva, A.
|
|
|
26 |
12S |
p. S51
|
artikel
|
| 279 |
EE301 Consumption Value of a Quality-Adjusted Life Year: A Time Trade-Off for Income Analysis of Hungarian Cross-Sectional Data
|
Valay, V.
|
|
|
26 |
12S |
p. S108
|
artikel
|
| 280 |
EE435 Cost-Analysis of a Machine Learning-Based Clinical Decision Support System to Guide Resilience-Strengthening Intervention Decisions in Breast Cancer Treatment: The Bounce Study
|
Hakkarainen, T.
|
|
|
26 |
12S |
p. S134-S135
|
artikel
|
| 281 |
EE75 Cost Analysis of Managing Brain Metastases in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in Greece
|
Zisimopoulou, O.
|
|
|
26 |
12S |
p. S64
|
artikel
|
| 282 |
EE476 Cost Analysis of Patiromer Versus Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia in the UK, Italy and Spain
|
Ramirez de Arellano Serna, A.
|
|
|
26 |
12S |
p. S142-S143
|
artikel
|
| 283 |
EE687 Cost Analysis of Prostav®: A New Telomere-Based Biomarker for the Early Detection of Prostate Cancer Available in Europe
|
Parramon, M.
|
|
|
26 |
12S |
p. S186
|
artikel
|
| 284 |
EE433 Cost and Duration of Hospital Stays for Complex Patients Receiving a Micra or a Conventional Pacemaker With Epicardial Leads in France
|
Boveda, S.
|
|
|
26 |
12S |
p. S134
|
artikel
|
| 285 |
EE543 Cost and Opportunity in Hemophilia: The Economic Impact of Drug Treatment
|
Mata, V.
|
|
|
26 |
12S |
p. S156-S157
|
artikel
|
| 286 |
EE249 Cost and Outcomes of Teduglutide in Adult Patients With Short Bowel Syndrome—Is the Combination With BSC Cost-Effective for the Society?
|
Walter, E.
|
|
|
26 |
12S |
p. S99
|
artikel
|
| 287 |
EE323 Cost Comparison Analysis of Patiromer Versus Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia in Saudi Arabia
|
Ramirez de Arellano Serna, A.
|
|
|
26 |
12S |
p. S113
|
artikel
|
| 288 |
EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK
|
Miller, B.
|
|
|
26 |
12S |
p. S180
|
artikel
|
| 289 |
EE677 Cost-Consequence of Using NGS vs Single-Testing in NSCLC Patients at Diagnosis – Real-World Data From a Portuguese Hospital
|
Teixeira, M.
|
|
|
26 |
12S |
p. S184
|
artikel
|
| 290 |
EE125 Cost Consequences of Using Clevidipine in Acute Hypertension from the Perspective of a US Hospital
|
Gutierrez, M.
|
|
|
26 |
12S |
p. S74
|
artikel
|
| 291 |
EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital
|
Gutierrez, M.
|
|
|
26 |
12S |
p. S196
|
artikel
|
| 292 |
EE579 Cost Consequences of Using Clevidipine in Neurological Emergencies from the Perspective of a US Hospital
|
Gutierrez, M.
|
|
|
26 |
12S |
p. S164
|
artikel
|
| 293 |
EE676 Cost Considerations: Exploring the Economic Implications of Choosing SC or IV Administration
|
Gherardi, A.
|
|
|
26 |
12S |
p. S184
|
artikel
|
| 294 |
EE318 Cost-Effectiveness Analysis for Soliqua in the Treatment of T2DM in Turkiye
|
Atikeler, K.
|
|
|
26 |
12S |
p. S112
|
artikel
|
| 295 |
EE108 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab for Treatment of Moderate-to-Severe Atopic Dermatitis in Chinese Adults
|
Jiang, Y.
|
|
|
26 |
12S |
p. S71
|
artikel
|
| 296 |
EE363 Cost-Effectiveness Analysis of Adding Tumor Treating Fields Therapy to Temozolomide Versus Temozolomide Only in Patients with Glioblastoma in France
|
Nino de Rivera Guzman, J.
|
|
|
26 |
12S |
p. S121
|
artikel
|
| 297 |
EE159 Cost-Effectiveness Analysis of an Adjusted Polygenic Risk Score in Cardiovascular Disease Prevention
|
Hatziandreou, E.
|
|
|
26 |
12S |
p. S81
|
artikel
|
| 298 |
EE480 Cost-Effectiveness Analysis of an Implantable Device for Chronic Gastro-Oesophageal Reflux Disease in Sweden
|
Lundell, L.
|
|
|
26 |
12S |
p. S143-S144
|
artikel
|
| 299 |
EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy
|
Bao, X.
|
|
|
26 |
12S |
p. S56
|
artikel
|
| 300 |
EE675 Cost-Effectiveness Analysis of Cancer Susceptibility Gene-Specific Prevention and Surveillance Strategies for Ovarian and Breast Cancer
|
Wei, X.
|
|
|
26 |
12S |
p. S183-S184
|
artikel
|
| 301 |
EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective
|
Elsisi, G.
|
|
|
26 |
12S |
p. S101
|
artikel
|
| 302 |
EE574 Cost-Effectiveness Analysis of Difelikefalin for Patients with Chronic Kidney Disease-Associated Pruritus (CKD AP) Undergoing Haemodialysis in Italy
|
Cicchetti, A.
|
|
|
26 |
12S |
p. S163
|
artikel
|
| 303 |
EE276 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Prurigo Nodularis in Adult Patients in Italy
|
Prada, M.
|
|
|
26 |
12S |
p. S104
|
artikel
|
| 304 |
EE753 Cost-Effectiveness Analysis of Fracture Prevention with 25-Hydroxyvitamin D (25(OH)D) Screening Among the Population over 65 Years Old in China
|
Liu, Y.
|
|
|
26 |
12S |
p. S199
|
artikel
|
| 305 |
EE305 Cost-Effectiveness Analysis of Genetic Screening in First-Degree Relative of Hypertrophic Cardiomyopathy Patients From the Perspective of the Brazilian United Health System
|
Braga, A.
|
|
|
26 |
12S |
p. S109
|
artikel
|
| 306 |
EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America
|
Londono, S.
|
|
|
26 |
12S |
p. S172
|
artikel
|
| 307 |
EE487 Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in Jordan
|
Naser, A.
|
|
|
26 |
12S |
p. S145
|
artikel
|
| 308 |
EE336 Cost-Effectiveness Analysis of Isavuconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Jordan
|
Naser, A.
|
|
|
26 |
12S |
p. S116
|
artikel
|
| 309 |
EE402 Cost Effectiveness Analysis of Levonorgestrel Vs Etonorgestrel in Contraception from the Mexican Context
|
Monroy Cruz, B.
|
|
|
26 |
12S |
p. S128
|
artikel
|
| 310 |
EE74 Cost-Effectiveness Analysis of LUNGFLAGTM Risk Prediction Model in the Selection of Individuals for Lung Cancer Screening in Spain
|
Pajares, V.
|
|
|
26 |
12S |
p. S64
|
artikel
|
| 311 |
EE340 Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore.
|
Junyang, Z.
|
|
|
26 |
12S |
p. S116-S117
|
artikel
|
| 312 |
EE220 Cost-Effectiveness Analysis of Netupitant/Palonosetron for Chemotherapy Induced Nausea and Vomiting in Brazilian Private Healthcare System Perspective
|
Araujo, G.
|
|
|
26 |
12S |
p. S93
|
artikel
|
| 313 |
EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
|
Libanore, A.
|
|
|
26 |
12S |
p. S90
|
artikel
|
| 314 |
EE383 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Nivolumab Monotherapy (NIVO) for Patients With Advanced Melanoma in the Netherlands
|
Foo, J.
|
|
|
26 |
12S |
p. S124
|
artikel
|
| 315 |
EE554 Cost-Effectiveness Analysis of Novoseven® Treatment for Postpartum Hemorrhage in Turkiye
|
Öztürk, F.
|
|
|
26 |
12S |
p. S159
|
artikel
|
| 316 |
EE446 Cost-Effectiveness Analysis of Nuvaxovid Vaccination for Japanese Elderly Population
|
Kato, M.
|
|
|
26 |
12S |
p. S137
|
artikel
|
| 317 |
EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario
|
Meijer, A.
|
|
|
26 |
12S |
p. S67
|
artikel
|
| 318 |
EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient
|
Tan, E.C.H.
|
|
|
26 |
12S |
p. S52-S53
|
artikel
|
| 319 |
EE457 Cost-Effectiveness Analysis of Patiromer in Heart Failure Patients with Reduced Ejection Fraction for the Treatment of Hyperkalemia: Analysis of the Diamond Clinical Trial
|
Stawowczyk, E.
|
|
|
26 |
12S |
p. S139
|
artikel
|
| 320 |
EE370 Cost-Effectiveness Analysis of Pembrolizumab as Adjuvant Treatment for Resected Stage IIB/IIC Melanoma in Greece
|
Yfantopoulos, N.
|
|
|
26 |
12S |
p. S122
|
artikel
|
| 321 |
EE369 Cost-Effectiveness Analysis of Pembrolizumab as a Second-Line Therapy for Advanced Urothelial Carcinoma in the United States
|
Chen, N.C.
|
|
|
26 |
12S |
p. S122
|
artikel
|
| 322 |
EE66 Cost Effectiveness Analysis of Pembrolizumab as First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer in Greece
|
Yfantopoulos, N.
|
|
|
26 |
12S |
p. S62
|
artikel
|
| 323 |
EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
|
Swami, S.
|
|
|
26 |
12S |
p. S183
|
artikel
|
| 324 |
EE672 Cost-Effectiveness Analysis of Pembrolizumab for the Adjuvant Treatment of Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy in Greece
|
Yfantopoulos, N.
|
|
|
26 |
12S |
p. S183
|
artikel
|
| 325 |
EE210 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as Neoadjuvant Therapy and Continued as a Single Agent as Adjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer in Greece
|
Yfantopoulos, N.
|
|
|
26 |
12S |
p. S91
|
artikel
|
| 326 |
EE95 Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
|
Tzanetakos, C.
|
|
|
26 |
12S |
p. S69
|
artikel
|
| 327 |
EE701 Cost-Effectiveness Analysis of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in China
|
Bai, X.
|
|
|
26 |
12S |
p. S189
|
artikel
|
| 328 |
EE292 Cost Effectiveness Analysis of Recombinant Zoster Vaccine Among 50 Years Old and Older in Sweden
|
Zarkadoulas, E.
|
|
|
26 |
12S |
p. S107
|
artikel
|
| 329 |
EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece
|
Gountas, I.
|
|
|
26 |
12S |
p. S136-S137
|
artikel
|
| 330 |
EE25 Cost-Effectiveness Analysis of S-Adenosylmethionine for the Treatment of Intrahepatic Cholestasis in China
|
Kim, H.
|
|
|
26 |
12S |
p. S54
|
artikel
|
| 331 |
EE103 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Fulfil Trial: China Medical Insurance System Perspective
|
Noorduyn, S.G.
|
|
|
26 |
12S |
p. S70
|
artikel
|
| 332 |
EE604 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Impact Trial: China Medical Insurance System Perspective
|
Wang, X.
|
|
|
26 |
12S |
p. S169
|
artikel
|
| 333 |
EE197 Cost-Effectiveness Analysis of Spinal Cord Stimulation in Sweden
|
Goates, S.
|
|
|
26 |
12S |
p. S89
|
artikel
|
| 334 |
EE732 Cost-Effectiveness Analysis of Strategies of Autologous Stem-Cell Transplantation and Maintenance Therapy for Transplant-Eligible Multiple Myeloma in China
|
Wu, W.
|
|
|
26 |
12S |
p. S195
|
artikel
|
| 335 |
EE517 Cost-Effectiveness Analysis of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Greece
|
Karaiskou, M.
|
|
|
26 |
12S |
p. S151
|
artikel
|
| 336 |
EE38 Cost-Effectiveness Analysis of the NEON Intervention for People With Psychosis and Non-Psychosis Mental Health Problems
|
Gavan, S.
|
|
|
26 |
12S |
p. S57
|
artikel
|
| 337 |
EE749 Cost-Effectiveness Analysis of the Pediatric 20-Valent Pneumococcal Conjugate Vaccine Compared to Lower-Valent Alternatives in Argentina
|
Ta, A.
|
|
|
26 |
12S |
p. S199
|
artikel
|
| 338 |
EE40 Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
|
Gourzoulidis, G.
|
|
|
26 |
12S |
p. S57
|
artikel
|
| 339 |
EE264 Cost-Effectiveness Analysis of Upadacitinib in Patients with Active Non-Radiographic Axial Spondyloarthritis in Greece
|
Tzanetakos, C.
|
|
|
26 |
12S |
p. S102
|
artikel
|
| 340 |
EE481 Cost-Effectiveness Analysis of Upadacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in Greece
|
Tzanetakos, C.
|
|
|
26 |
12S |
p. S144
|
artikel
|
| 341 |
EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible
|
Isla, D.
|
|
|
26 |
12S |
p. S63-S64
|
artikel
|
| 342 |
EE115 Cost-Effectiveness Analysis of Using Ketoanalogues of Essential Aminoacids in Patients With Chronic Kidney Disease in Kazakhstan
|
Avdeyev, A.
|
|
|
26 |
12S |
p. S73
|
artikel
|
| 343 |
EE499 Cost-Effectiveness Analysis of Using the Fixed-Dose Combination of Levodopa/Carbidopa/Entacapone in Patients With Parkinson’s Disease in Kazakhstan
|
Avdeyev, A.
|
|
|
26 |
12S |
p. S147
|
artikel
|
| 344 |
EE467 Cost-Effectiveness and Budget Impact Analyses Using Real World Data from Brazilian Health Care Insurance Companies in the Treatment of Iron Deficiency in Patients with Heart Failure
|
Campagnaro, M.
|
|
|
26 |
12S |
p. S141
|
artikel
|
| 345 |
EE158 Cost Effectiveness and Budget Impact of Patient Blood Management in a Turkish State Hospital
|
Sanal, L.
|
|
|
26 |
12S |
p. S80-S81
|
artikel
|
| 346 |
EE596 Cost-Effectiveness and Public Health Impact of a Nine-Valent Human Papillomavirus Vaccination Program in Ukraine
|
Ugrekhelidze, D.
|
|
|
26 |
12S |
p. S168
|
artikel
|
| 347 |
EE286 Cost Effectiveness and Public Health Impact of Implementing Gender-Neutral Vaccination with the 9-Valent Human Papillomavirus Vaccine in Turkiye
|
Akyol Ersoy, B.
|
|
|
26 |
12S |
p. S106
|
artikel
|
| 348 |
EE748 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine in Hong Kong
|
Huang, L.
|
|
|
26 |
12S |
p. S198-S199
|
artikel
|
| 349 |
EE28 Cost-Effectiveness Formulation of PCR-Test Screening for COVID-19 Regarding Multiple Factors in Epidemic
|
Kamae, I.
|
|
|
26 |
12S |
p. S55
|
artikel
|
| 350 |
EE541 Cost-Effectiveness, Health-State Utility Values (HSUVs) and Cost and Resource Use (CRU) Associated with Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS): An Economic Systematic Literature Review (SLR)
|
Papadakis-Sali, A.
|
|
|
26 |
12S |
p. S156
|
artikel
|
| 351 |
EE177 Cost-Effectiveness Modelling in Moderate to Severe Ulcerative Colitis: Novel Approaches to Capture Variable Induction Periods, Treatment Sequences, and Variable Treatment Cycle Lengths
|
Smith-Tilley, J.
|
|
|
26 |
12S |
p. S84-S85
|
artikel
|
| 352 |
EE593 Cost-Effectiveness Model of COVID-19 Vaccination: The United Kingdom Perspective
|
Gojović, MŽ
|
|
|
26 |
12S |
p. S167
|
artikel
|
| 353 |
EE737 Cost-Effectiveness Models of Continuous Glucose Monitoring in Individuals With Type 1 Diabetes: A Systematic Review on Methodology and Quality
|
de Jong, L.
|
|
|
26 |
12S |
p. S196
|
artikel
|
| 354 |
EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial
|
Hejblum, G.
|
|
|
26 |
12S |
p. S144-S145
|
artikel
|
| 355 |
EE232 Cost-Effectiveness of a Genomic Profiling Test for HRD Determination in Ovarian Cancer Into the Current Clinical Practice for Platinum-Sensitive Patients With Advanced Ovarian Cancer in Greece
|
Zisis, K.
|
|
|
26 |
12S |
p. S95-S96
|
artikel
|
| 356 |
EE4 Cost-Effectiveness of Andexanet Alfa Versus Prothrombin Complex Concentrate Is Likely for the Treatment of Factor Xa Inhibitor–Related Major Bleeds in the Netherlands
|
Lewis, M.
|
|
|
26 |
12S |
p. S50
|
artikel
|
| 357 |
EE695 Cost-Effectiveness of a New Multi-Lumen Infusion Device to Reduce Central Venous Line-Related Infections in a Neonatal Intensive Care Unit
|
Martelin, A.
|
|
|
26 |
12S |
p. S188
|
artikel
|
| 358 |
EE267 Cost-Effectiveness of a Web-Based Interactive Therapeutic Education Platform: Evidence From a Randomized Clinical Trial for Patients With End-Stage Renal Disease
|
Pillebout, E.
|
|
|
26 |
12S |
p. S103
|
artikel
|
| 359 |
EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements
|
Pennings, E.R.A.
|
|
|
26 |
12S |
p. S150
|
artikel
|
| 360 |
EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel in 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States Utilizing Real-World Evidence of Chimeric Antigen Receptor T-Cell Therapies
|
Locke, F.L.
|
|
|
26 |
12S |
p. S95
|
artikel
|
| 361 |
EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden
|
Eklund, O.
|
|
|
26 |
12S |
p. S155
|
artikel
|
| 362 |
EE540 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in the United Kingdom
|
Spousta, T.
|
|
|
26 |
12S |
p. S156
|
artikel
|
| 363 |
EE400 Cost-Effectiveness of Cannabidiol (CBD) for the Treatment of Seizures in Patients with Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands
|
Siddiqui, J.
|
|
|
26 |
12S |
p. S127-S128
|
artikel
|
| 364 |
EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama
|
Castillo-Fernandez, O.
|
|
|
26 |
12S |
p. S66
|
artikel
|
| 365 |
EE120 Cost-Effectiveness of Difelikefalin for the Treatment of Moderate to Severe Chronic Kidney Disease-Associated Pruritus (CKD-AP) in Adult Patients Receiving in-Centre Haemodialysis
|
Collins, C.
|
|
|
26 |
12S |
p. S74
|
artikel
|
| 366 |
EE522 Cost-Effectiveness of Direct Oral Anticoagulants (DOACS) Versus Low-Molecular-Weight Heparins (LMWH) in Patients with Cancer-Associated Venous Thromboembolism (CAT) in Hong Kong
|
Kang, W.
|
|
|
26 |
12S |
p. S152
|
artikel
|
| 367 |
EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China
|
Chen, L.
|
|
|
26 |
12S |
p. S181-S182
|
artikel
|
| 368 |
EE265 Cost-Effectiveness of Efmoroctocog Alfa in Treatment of Severe Hemophilia A Patients in Turkey
|
Tatar, M.
|
|
|
26 |
12S |
p. S102
|
artikel
|
| 369 |
EE569 Cost-Effectiveness of Eftrenonacog Alfa in Treatment of Severe Haemophilia B Patients in Turkey
|
Tatar, M.
|
|
|
26 |
12S |
p. S162
|
artikel
|
| 370 |
EE421 Cost-Effectiveness of Empagliflozin in Adult Patients with Chronic Kidney Disease in the Netherlands
|
Fens, T.
|
|
|
26 |
12S |
p. S132
|
artikel
|
| 371 |
EE420 Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease (CKD) Management in the UK
|
Ramos, M.
|
|
|
26 |
12S |
p. S131-S132
|
artikel
|
| 372 |
EE117 Cost-Effectiveness of Empagliflozin in Patients Affected By Chronic Kidney Disease in Italy
|
Di Costanzo, A.
|
|
|
26 |
12S |
p. S73
|
artikel
|
| 373 |
EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations
|
Chueh, C.H.
|
|
|
26 |
12S |
p. S60
|
artikel
|
| 374 |
EE271 Cost-Effectiveness of Finerenone in Addition to Standard-of-Care in Treating Type 2 Diabetes and Chronic Kidney Disease in China
|
He, Y.
|
|
|
26 |
12S |
p. S103
|
artikel
|
| 375 |
EE595 Cost-Effectiveness of HPV Catch-up Vaccination Program in Women Aged 13-24 Years in Low-and Middle- Income Country
|
Tantitamit, T.
|
|
|
26 |
12S |
p. S167-S168
|
artikel
|
| 376 |
EE9 Cost-Effectiveness of Icosapent Ethyl for Patients at High Cardiovascular Risk with Elevated Triglycerides in Greece
|
Stratopoulos, A.
|
|
|
26 |
12S |
p. S51
|
artikel
|
| 377 |
EE163 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for Primary Prevention in China
|
Sun, H.
|
|
|
26 |
12S |
p. S82
|
artikel
|
| 378 |
EE10 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for 1.5 Primary Prevention in China: An Analysis Using the Improve SCA Study
|
Sun, H.
|
|
|
26 |
12S |
p. S51
|
artikel
|
| 379 |
EE164 Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol
|
Wong, M.
|
|
|
26 |
12S |
p. S82
|
artikel
|
| 380 |
EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands
|
Buisman, L.
|
|
|
26 |
12S |
p. S110
|
artikel
|
| 381 |
EE718 Cost-Effectiveness of Medical Cannabis for Treatment of Chronic Pain: A Longitudinal Cohort Study of a Large German Hybrid Telemedicine Platform
|
Keller, M.
|
|
|
26 |
12S |
p. S192-S193
|
artikel
|
| 382 |
EE509 Cost-Effectiveness of Multicancer Early Detection (MCED) With Preferential Detection of Clinically Aggressive Cancers
|
Kansal, A.
|
|
|
26 |
12S |
p. S149
|
artikel
|
| 383 |
EE326 Cost-Effectiveness of Multiparametric MRI (mpMRI) Compared to No Test for Monitoring of NASH Treatment in the UK
|
Rezaeihemami, M.
|
|
|
26 |
12S |
p. S114
|
artikel
|
| 384 |
EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France
|
Cagnan, L.
|
|
|
26 |
12S |
p. S61
|
artikel
|
| 385 |
EE524 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in Costa Rica
|
Rendon, A.M.
|
|
|
26 |
12S |
p. S152
|
artikel
|
| 386 |
EE337 Cost-Effectiveness of Nirmatrelvir/Ritonavir in High-Risk Swedish Adults Including Post-Acute COVID Syndrome (PACS) From a Societal Perspective
|
Aldvén, M.
|
|
|
26 |
12S |
p. S116
|
artikel
|
| 387 |
EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort
|
Kieffer, A.
|
|
|
26 |
12S |
p. S135
|
artikel
|
| 388 |
EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067
|
Kendall, R.
|
|
|
26 |
12S |
p. S187
|
artikel
|
| 389 |
EE505 Cost-Effectiveness of Ofatumumab in Treatment of Relapsing Multiple Sclerosis in Turkey
|
Tatar, M.
|
|
|
26 |
12S |
p. S148
|
artikel
|
| 390 |
EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial
|
Perrier, L.
|
|
|
26 |
12S |
p. S61-S62
|
artikel
|
| 391 |
EE333 Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK
|
Muszbek, N.
|
|
|
26 |
12S |
p. S115
|
artikel
|
| 392 |
EE238 Cost-Effectiveness of Online Cognitive Behavioral Therapy for Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Compared to Online Activity Management: FITNET-NHS Trial Findings
|
Cochrane, M.
|
|
|
26 |
12S |
p. S97
|
artikel
|
| 393 |
EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France
|
Saiag, P.
|
|
|
26 |
12S |
p. S182
|
artikel
|
| 394 |
EE671 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Renal Cell Carcinoma Post-Nephrectomy in France
|
Apert, M.
|
|
|
26 |
12S |
p. S183
|
artikel
|
| 395 |
EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy
|
Ivanyi, P.
|
|
|
26 |
12S |
p. S120
|
artikel
|
| 396 |
EE745 Cost- Effectiveness of Pneumococcal Vaccination for Adults Aged 60 Years and Older in Peru
|
Figueroa, J.
|
|
|
26 |
12S |
p. S198
|
artikel
|
| 397 |
EE183 Cost-Effectiveness of Raltegravir Oral Granules Prophylaxis in Neonates to Prevent HIV Mother-to-Child Transmission in Brazil
|
Castro, R.
|
|
|
26 |
12S |
p. S86
|
artikel
|
| 398 |
EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence
|
Kahan, T.
|
|
|
26 |
12S |
p. S196-S197
|
artikel
|
| 399 |
EE143 Cost-Effectiveness of Replacing the Sequence PCV13→PPV23 with PCV20 in the French Adult Pneumococcal Vaccination Program
|
Fiévez, S.
|
|
|
26 |
12S |
p. S78
|
artikel
|
| 400 |
EE80 Cost-Effectiveness of Ribociclib Plus a Non-Steroidal Aromatase Inhibitor for the Treatment of Pre- and Peri-Menopausal Women with HR+/HER2 Advanced Breast Cancer in Turkey
|
Tatar, M.
|
|
|
26 |
12S |
p. S65-S66
|
artikel
|
| 401 |
EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece
|
Golnas, P.
|
|
|
26 |
12S |
p. S57
|
artikel
|
| 402 |
EE686 Cost Effectiveness of Ruxolitinib for Treatment of Steroid Refractory Acute Graft Versus Host Disease in Patients >12 Years of Age from a Singapore Healthcare System Perspective
|
Ong, M.
|
|
|
26 |
12S |
p. S186
|
artikel
|
| 403 |
EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin
|
Chiang, S.T.
|
|
|
26 |
12S |
p. S63
|
artikel
|
| 404 |
EE14 Cost Effectiveness of Sensor Augmented Pump Therapy with Automated Insulin Suspension in the Management of Type 1 Diabetes (T1D) in Bulgaria
|
Ozdemir Saltik, A.Z.
|
|
|
26 |
12S |
p. S52
|
artikel
|
| 405 |
EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada
|
Fischer, A.
|
|
|
26 |
12S |
p. S84
|
artikel
|
| 406 |
EE405 Cost-Effectiveness of Single-Inhaler Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium vs Other Open or Single-Inhaler Triple Therapies in Adult Patients with Uncontrolled Asthma in England
|
Orlovic, M.
|
|
|
26 |
12S |
p. S128-S129
|
artikel
|
| 407 |
EE327 Cost-Effectiveness of Teduglutide in Adult and Pediatric Patients with Short Bowel Syndrome in Argentina: A Markov Model Analysis
|
Boissonnet, C.
|
|
|
26 |
12S |
p. S114
|
artikel
|
| 408 |
EE525 Cost Effectiveness of the Chimeric Antigen Receptor (CAR) T Cell Treatment Lisocabtagene Maraleucel (Liso-Cel) As Second-Line (2L) Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in Switzerland
|
Deger, K.
|
|
|
26 |
12S |
p. S152-S153
|
artikel
|
| 409 |
EE456 Cost-Effectiveness of the Development Assistance for Health in Sub-Saharan Africa for HIV, Malaria and Tuberculosis (1995-2018)
|
Sidiropoulos, S.
|
|
|
26 |
12S |
p. S139
|
artikel
|
| 410 |
EE563 Cost-Effectiveness of the PPARγ Modulator N-Acetyl-Ged-0507-34-Levo (NAC-GED 5%) Versus Benzoyl Peroxide-Adapalene for Moderate to Severe Acne
|
Matos, T.
|
|
|
26 |
12S |
p. S161
|
artikel
|
| 411 |
EE154 Cost-Effectiveness of Transcatheter Aortic Valve Intervention (TAVI) as Compared with Surgical Aortic Valve Intervention (SAVR) in Swedish Low Risk Aortic Stenosis Patients: Evidence Using Swedeheart Registry Data (2018-2020)
|
Nilsson, K.
|
|
|
26 |
12S |
p. S80
|
artikel
|
| 412 |
EE708 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Aclidinium/Formoterol (ACL/FOR) in Patients with COPD in the United Kingdom
|
Shah, D.
|
|
|
26 |
12S |
p. S190-S191
|
artikel
|
| 413 |
EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective
|
Kendall, R.
|
|
|
26 |
12S |
p. S191
|
artikel
|
| 414 |
EE643 Cost-Effectiveness of Universal Asymptomatic Preoperative SARS-CoV-2 PCR Screening: A Cost-Utility Analysis
|
Uno, S.
|
|
|
26 |
12S |
p. S177
|
artikel
|
| 415 |
EE746 Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
|
Zhang, X.S.
|
|
|
26 |
12S |
p. S198
|
artikel
|
| 416 |
EE592 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Filipino Adults Aged ≥50 Years
|
Santiaguel, J.
|
|
|
26 |
12S |
p. S167
|
artikel
|
| 417 |
EE440 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Indian Adults Aged ≥60 Years
|
Kulkarni, N.
|
|
|
26 |
12S |
p. S136
|
artikel
|
| 418 |
EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years
|
Averin, A.
|
|
|
26 |
12S |
p. S77
|
artikel
|
| 419 |
EE638 Cost-Effectiveness of Vasopressin Alone or in Combination With SOC in the Treatment of Sepsis and Septic Shock Patients
|
Walter, E.
|
|
|
26 |
12S |
p. S176
|
artikel
|
| 420 |
EE272 Cost-Effectiveness of Voclosporin in Combination with Mycophenolate Mofetil for Active Lupus Nephritis in Sweden
|
Gittfried, A.
|
|
|
26 |
12S |
p. S103-S104
|
artikel
|
| 421 |
EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective
|
Shastri, K.
|
|
|
26 |
12S |
p. S74
|
artikel
|
| 422 |
EE508 Cost Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small Cell Lung Cancer in Italy
|
Marcellusi, A.
|
|
|
26 |
12S |
p. S149
|
artikel
|
| 423 |
EE118 Cost Incurred Post-Kidney Transplant: A Systematic Review
|
Rabie, H.
|
|
|
26 |
12S |
p. S73
|
artikel
|
| 424 |
EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
|
Chanan-Khan, A.
|
|
|
26 |
12S |
p. S182
|
artikel
|
| 425 |
EE222 Cost Minimization Analysis of Damoctocog Alfa Pegol in the Treatment of Severe Hemophilia A Patients in Mexico
|
Monroy Cruz, B.
|
|
|
26 |
12S |
p. S93-S94
|
artikel
|
| 426 |
EE636 Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Jordan
|
Naser, A.
|
|
|
26 |
12S |
p. S175
|
artikel
|
| 427 |
EE628 Cost of Basal Insulin Therapy in France: An Observational Longitudinal Study
|
Emery, C.
|
|
|
26 |
12S |
p. S174
|
artikel
|
| 428 |
EE735 Cost of Chimeric Antigen Receptor (CAR) T-Cell Therapy Related Toxicities
|
Patel, N.
|
|
|
26 |
12S |
p. S196
|
artikel
|
| 429 |
EE171 Cost Offset and Budget Impact of Skytrofa for the Treatment of Pediatric Growth Hormone Deficiency: A US Payer’s Perspective
|
Smith, A.R.
|
|
|
26 |
12S |
p. S83
|
artikel
|
| 430 |
EE388 Cost of Illness for Advanced Hepatocellular Carcinoma (aHCC) in Ontario, Canada
|
Seung, S.J.
|
|
|
26 |
12S |
p. S125
|
artikel
|
| 431 |
EE713 Cost-of-Illness of Generalized Pustular Psoriasis in Italy
|
Armeni, P.
|
|
|
26 |
12S |
p. S191-S192
|
artikel
|
| 432 |
EE200 Cost of Illness of Spinal Muscular Atrophy in Turkey
|
Unver, O.
|
|
|
26 |
12S |
p. S89-S90
|
artikel
|
| 433 |
EE47 Cost of Illness Study of Migraine in Bulgarian Patients
|
Dacheva, A.
|
|
|
26 |
12S |
p. S59
|
artikel
|
| 434 |
EE495 Cost of Spinal Muscular Atrophy(SMA) Management in Turkiye
|
Öztürk, F.
|
|
|
26 |
12S |
p. S146-S147
|
artikel
|
| 435 |
EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective
|
Jabase, L.
|
|
|
26 |
12S |
p. S124-S125
|
artikel
|
| 436 |
EE357 Cost per Responder Analysis Comparing Adagrasib and Sotorasib in Patients With KRAS G12C-Mutated Previously Treated Non-Small Cell Lung Cancer (NSCLC)
|
Berardi, A.
|
|
|
26 |
12S |
p. S119-S120
|
artikel
|
| 437 |
EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective
|
Bithal, N.
|
|
|
26 |
12S |
p. S147
|
artikel
|
| 438 |
EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
|
Torres, T.
|
|
|
26 |
12S |
p. S130
|
artikel
|
| 439 |
EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden
|
Mørup, M.
|
|
|
26 |
12S |
p. S117
|
artikel
|
| 440 |
EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-12/23 and IL-23 Inhibitors in the Treatment of Psoriatic Arthritis in Sweden
|
Lyris, N.
|
|
|
26 |
12S |
p. S178
|
artikel
|
| 441 |
EE740 Costs and Clinical Outcomes of Colorectal Cancer Surgeries: Results From the Emilia-Romagna Surgical Colorectal Audit (ESCA)
|
Roncadori, A.
|
|
|
26 |
12S |
p. S197
|
artikel
|
| 442 |
EE182 Costs and Health Impact of Wastewater Surveillance to Guide Respiratory Syncytial Virus Prophylaxis in Canada, Compared to Clinical Surveillance
|
Thampi, N.
|
|
|
26 |
12S |
p. S85-S86
|
artikel
|
| 443 |
EE455 Cost Saving Potential of Rapid Microbiological Methods: Case Form Bulgaria
|
Raycheva, R.
|
|
|
26 |
12S |
p. S139
|
artikel
|
| 444 |
EE741 Costs of Breast Surgery Reconstruction and Mastectomy in France between 2019 and 2021
|
Da Deppo, L.
|
|
|
26 |
12S |
p. S197
|
artikel
|
| 445 |
EE100 Costs of Home Mechanical Ventilation and Oxygen Therapy in Russia: Real-World Data
|
Krysanova, V.
|
|
|
26 |
12S |
p. S69-S70
|
artikel
|
| 446 |
EE54 Costs of Proton Radiotherapy and Photon Radiotherapy for Non-Small Cell Lung Cancer in the Netherlands Using a Time-Driven Activity-Based Costing Approach
|
Sugden, B.
|
|
|
26 |
12S |
p. S60
|
artikel
|
| 447 |
EE576 Costs Saving Generated by Anti-TNF Biosimilars Market Penetration in France: An Analysis Based on French Health Insurance Open Data
|
Denis, H.
|
|
|
26 |
12S |
p. S163-S164
|
artikel
|
| 448 |
EE228 Cost to Society and Financial Toxicity Related to Personalized Oncology Treatment in Bulgaria
|
Dimitrova, M.
|
|
|
26 |
12S |
p. S95
|
artikel
|
| 449 |
EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy
|
Bellone, M.
|
|
|
26 |
12S |
p. S65
|
artikel
|
| 450 |
EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider?
|
Mohseninejad, L.
|
|
|
26 |
12S |
p. S150-S151
|
artikel
|
| 451 |
EE722 Cost-Utility Analysis for Haemate-P in the Treatment of Von Willebrand Disease
|
Linden, S.
|
|
|
26 |
12S |
p. S193
|
artikel
|
| 452 |
EE437 Cost-Utility Analysis of Acupotomy with Nerve Block Therapy from Lumbosacral Radiculopathy Patients in Korea
|
Jang, S.
|
|
|
26 |
12S |
p. S135
|
artikel
|
| 453 |
EE341 Cost-Utility Analysis of a Multi-Center, Parallel Group Randomized Controlled Trial of an Adapted Parenting Intervention (EPICC-ID) to Reduce Challenging Behavior in Pre-Schoolers with Moderate to Severe Intellectual Disability
|
Panca, M.
|
|
|
26 |
12S |
p. S117
|
artikel
|
| 454 |
EE418 Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Treating Iron Deficiency Anemia in Norwegian Patients With Inflammatory Bowel Disease
|
Detlie, T.E.
|
|
|
26 |
12S |
p. S131
|
artikel
|
| 455 |
EE743 Cost Utility Analysis of Influenza Vaccine Among People Aged 50 Years and Older Living with Comorbidities in Egypt
|
Eldissoky, A.
|
|
|
26 |
12S |
p. S197-S198
|
artikel
|
| 456 |
EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China
|
He, X.
|
|
|
26 |
12S |
p. S63
|
artikel
|
| 457 |
EE23 Cost Utility Analysis of Once-Weekly Semaglutide and Dulaglutide for Patients With Type 2 Diabetes in Saudi Arabia
|
Hassan, M.
|
|
|
26 |
12S |
p. S54
|
artikel
|
| 458 |
EE303 Cost-Utility Analysis of Roflumilast Cream for Plaque Psoriasis, Including Intertriginous, From the Canadian Societal Perspective
|
Garrison, K.
|
|
|
26 |
12S |
p. S109
|
artikel
|
| 459 |
EE19 Cost Utility Analysis of the Flash Glucose Monitoring System in the Management of People With Type 2 Diabetes Mellitus on Basal Insulin Therapy—An Italian Healthcare System Perspective
|
Poon, Y.
|
|
|
26 |
12S |
p. S53
|
artikel
|
| 460 |
EE308 Cost-Utility Analysis of Universal Neonatal Screening for Critical Congenital Heart Disease Based on Pulse Oximetry in Spain
|
Imaz-Iglesia, I.
|
|
|
26 |
12S |
p. S110
|
artikel
|
| 461 |
EE747 Cost-Utility Analysis of 15-Valent Pneumococcal Conjugate Vaccine in the Immunization of Adults Over 65 Years of Age in the Czech Republic
|
Volfova, G.
|
|
|
26 |
12S |
p. S198
|
artikel
|
| 462 |
EE83 Cost-Utility and Budget Impact Analyses of Cervical Cancer Screening Using Self-Collected Sample Kit for HPV DNA Testing in Thailand
|
Kositamongkol, C.
|
|
|
26 |
12S |
p. S66
|
artikel
|
| 463 |
EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis
|
Leelahavarong, P.
|
|
|
26 |
12S |
p. S132-S133
|
artikel
|
| 464 |
EE343 Cost-Utility and Cost-Effectiveness of Rapid Recovery After Joint Replacement: The Payer's Perspective
|
Salvi, I.
|
|
|
26 |
12S |
p. S117
|
artikel
|
| 465 |
EE313 Cost-Utility of Apixaban for Secondary Stroke Prevention in Brazil
|
Diegoli, H.
|
|
|
26 |
12S |
p. S111
|
artikel
|
| 466 |
EE598 Cost-Utility of Influenza Vaccination for the Brazilian Elderly Population With a High Dose Quadrivalent Vaccine in the Public Healthcare Sector
|
Watanabe, S.F.
|
|
|
26 |
12S |
p. S168
|
artikel
|
| 467 |
EE181 COVID-19 Related Work Absenteeism and Its Associated Lost Productivity Cost in Germany: A Population-Based Study
|
Yang, J.
|
|
|
26 |
12S |
p. S85
|
artikel
|
| 468 |
EE429 Current Parallel Trade Practice in the Pharmaceutical Industry Focusing on European Single Market, Utilizing a Cost-Saving Analysis in the Allergen Immunotherapy Market of Germany
|
Madkour, M.
|
|
|
26 |
12S |
p. S133
|
artikel
|
| 469 |
EE94 Current State of Health Economic Models in Hereditary Angioedema
|
Tachdjian, R.
|
|
|
26 |
12S |
p. S68-S69
|
artikel
|
| 470 |
EE548 Data Availability and Modelling Approaches in Health Economic Evaluation of Cystic Fibrosis: A Systematic Literature Review
|
Jangid, S.
|
|
|
26 |
12S |
p. S158
|
artikel
|
| 471 |
EE597 Data on Human Population Mobility in Individual-Based Models of Infectious Disease Transmission: A Systematic Review
|
Żerda, I.
|
|
|
26 |
12S |
p. S168
|
artikel
|
| 472 |
EE144 Decision Modifiers Under Uncertainty: Comparison of Deterministic and Probabilistic Methods in Disease Severity Classification by NICE
|
Poole, C.
|
|
|
26 |
12S |
p. S78
|
artikel
|
| 473 |
EE26 Deprescribing of Proton Pump Inhibitors in Elderly Patients: A Cost-Effectiveness Analysis
|
Xie, M.
|
|
|
26 |
12S |
p. S54
|
artikel
|
| 474 |
EE397 Determinants of Higher Cost and Inpatient Hospitalization Among Patients with AL Amyloidosis
|
D'Souza, A.
|
|
|
26 |
12S |
p. S127
|
artikel
|
| 475 |
EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)
|
Davies, N.
|
|
|
26 |
12S |
p. S73-S74
|
artikel
|
| 476 |
EE546 Development of a Drug Price Index for Approved Cystic Fibrosis Treatments
|
Seo, D.
|
|
|
26 |
12S |
p. S157
|
artikel
|
| 477 |
EE607 Development of an Online Database of Published Usable Mapping Algorithms Used to Estimate EQ-5D Utilities
|
Khan, I.
|
|
|
26 |
12S |
p. S170
|
artikel
|
| 478 |
EE469 Diabetic Retinopathy in Algeria: Costs Estimation and Medical-Economic Value of Automated Methods AI-Based in Early Screening
|
Mansouri, K.
|
|
|
26 |
12S |
p. S141-S142
|
artikel
|
| 479 |
EE45 Differing Approaches to the Health Economic Investigation of the Informal Care of People Living With Multiple Sclerosis: A Systematic Review and Meta-Analysis
|
Adal, T.
|
|
|
26 |
12S |
p. S58
|
artikel
|
| 480 |
EE365 Discrepancies Between Actual Costs and Reimbursement Tariffs for Breast Cancer Radiotherapy in Indonesia: A Hospital-Based Retrospective Study
|
Suryanegara, F.D.A.
|
|
|
26 |
12S |
p. S121
|
artikel
|
| 481 |
EE733 Distributional Cost-Effectiveness Analysis: A Case Study on Its Potential Prospects in HTA
|
Soboil, J.
|
|
|
26 |
12S |
p. S196
|
artikel
|
| 482 |
EE568 Does the Introduction of an Infliximab Biosimilar Always Result in Savings for Hospitals? A Descriptive Study Using Real-World Data
|
Krstic, M.
|
|
|
26 |
12S |
p. S162
|
artikel
|
| 483 |
EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)
|
Felizzi, F.
|
|
|
26 |
12S |
p. S151
|
artikel
|
| 484 |
EE510 Downstaging Pancreatic Cancer is Cost-Effective: Can We Achieve a Cost-Effective Early Diagnosis?
|
Zamora Talaya, B.
|
|
|
26 |
12S |
p. S149-S150
|
artikel
|
| 485 |
EE307 Drive-the-Doctor Paradigm for Acute Ischemic Stroke with Large Vessel Occlusion: A Cost-Effectiveness Analysis
|
Nguyen, C.
|
|
|
26 |
12S |
p. S110
|
artikel
|
| 486 |
EE577 Early Initiation of Guselkumab Increases Duration of Complete Remission (Psoriasis Area and Severity Index 100) in Patients With Moderate-to-Severe Psoriasis
|
Moreau, R.
|
|
|
26 |
12S |
p. S164
|
artikel
|
| 487 |
EE729 Early Intervention With Biosimilars Compared With Leflunomide in Established Rheumatoid Arthritis: A Cost-Effectiveness Analysis in Hong Kong
|
Peng, K.
|
|
|
26 |
12S |
p. S195
|
artikel
|
| 488 |
EE515 Economical Impact of Dose Reduction Treatment for Ribociclib, Palbociclib and Abemaciclib in Colombia
|
Arcos, J.
|
|
|
26 |
12S |
p. S150
|
artikel
|
| 489 |
EE492 Economic Analysis and Outcome Research on the Effectiveness of the Return to Work Program on Occupational Injury Cases for Workers with Disabilities
|
Kurnianto, A.
|
|
|
26 |
12S |
p. S146
|
artikel
|
| 490 |
EE403 Economic Analysis of Dupilumab Use in Patients With Chronic Rhinosinusitis With Nasal Polyps in Colombia
|
Upegui, A.
|
|
|
26 |
12S |
p. S128
|
artikel
|
| 491 |
EE110 Economic Analysis of Sugammadex for Neuromuscular Block Reversal for Laparoscopic Surgery from a Single Hospital System in China
|
Chen, L.
|
|
|
26 |
12S |
p. S72
|
artikel
|
| 492 |
EE575 Economic Analysis of the Costs Associated With Reusable Flexible Ureteroscopes – Implications for the Utilization of Single-Use Digital Flexible Ureteroscopes
|
Kelly, T.
|
|
|
26 |
12S |
p. S163
|
artikel
|
| 493 |
EE234 Economic Analysis of the Pronto Study
|
Seung, S.J.
|
|
|
26 |
12S |
p. S96
|
artikel
|
| 494 |
EE696 Economic and Clinical Burden Associated with Respiratory Syncytial Virus (RSV) and Expected Impact of Universal Immunization with Nirsevimab Among All Infants in Their First Rsv Season Against Standard of Care in Italy
|
Bini, C.
|
|
|
26 |
12S |
p. S188
|
artikel
|
| 495 |
EE263 Economic and Healthcare Burden of Blood Transfusions in Transfusion-Dependent Beta-Thalassemia in Thailand and Brazil
|
Glassberg, M.
|
|
|
26 |
12S |
p. S102
|
artikel
|
| 496 |
EE413 Economic and Humanistic Burden of Chronic Spontaneous Urticaria: A Systematic Literature Review
|
Tavi, J.
|
|
|
26 |
12S |
p. S130
|
artikel
|
| 497 |
EE407 Economic Assessment in Resource-Constrained Systems – a Case Study Using an Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema
|
Li, T.
|
|
|
26 |
12S |
p. S129
|
artikel
|
| 498 |
EE703 Economic Burden and Changing Treatment Landscape in Stargardt Disease: A Literature and Database Review
|
Knott, C.
|
|
|
26 |
12S |
p. S189
|
artikel
|
| 499 |
EE395 Economic Burden and Cost Drivers of Dystrophic Epidermolysis Bullosa: A Systematic Literature Review
|
Bodke, A.
|
|
|
26 |
12S |
p. S126-S127
|
artikel
|
| 500 |
EE179 Economic Burden and Health-Related Quality of Life Among Older People With Dementia Living at Home and Their Informal Caregivers in the Milan Metropolitan Area
|
Manfredi, S.
|
|
|
26 |
12S |
p. S85
|
artikel
|
| 501 |
EE161 Economic Burden Associated with Stroke: A Comparative Analysis of Post-Stroke Care Costs
|
Slavchev, G.
|
|
|
26 |
12S |
p. S81
|
artikel
|
| 502 |
EE36 Economic Burden of Adults Hospitalized with Respiratory Syncytial Virus Infection in Spain, 2016–2019
|
Sato, R.
|
|
|
26 |
12S |
p. S56
|
artikel
|
| 503 |
EE330 Economic Burden of Biologic Therapy for Chinese Patients with Crohn's Disease
|
Sheng, Y.
|
|
|
26 |
12S |
p. S114-S115
|
artikel
|
| 504 |
EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019
|
Patel, D.A.
|
|
|
26 |
12S |
p. S159
|
artikel
|
| 505 |
EE185 Economic Burden of Chlamydia Trachomatis: A Targeted Literature Review and Gap Analysis
|
Patel, R.
|
|
|
26 |
12S |
p. S86
|
artikel
|
| 506 |
EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye
|
Kurnaz, M.
|
|
|
26 |
12S |
p. S163
|
artikel
|
| 507 |
EE557 Economic Burden of Cystic Fibrosis in Five Key European Countries: A Systematic Review
|
Verma, R.
|
|
|
26 |
12S |
p. S160
|
artikel
|
| 508 |
EE256 Economic Burden of Geographic Atrophy: A Systematic Review and Meta-Analysis
|
Aggarwal, P.
|
|
|
26 |
12S |
p. S100
|
artikel
|
| 509 |
EE261 Economic Burden of Hemophilic Arthropathy in Patients with Hemophilia
|
Byun, J.Y.
|
|
|
26 |
12S |
p. S101
|
artikel
|
| 510 |
EE31 Economic Burden of Hospitalized Respiratory Syncytial Virus Infection Among Children in Spain, 2016–2019
|
Law, A.
|
|
|
26 |
12S |
p. S55
|
artikel
|
| 511 |
EE155 Economic Burden of Obstructive Hypertrophic Cardiomyopathy in France
|
Charron, P.
|
|
|
26 |
12S |
p. S80
|
artikel
|
| 512 |
EE98 Economic Burden of Patients with Paroxysmal Nocturnal Hemoglobinuria in China
|
Dou, L.
|
|
|
26 |
12S |
p. S69
|
artikel
|
| 513 |
EE699 Economic Burden of Propionic Acidemia by Age Stratum in the United States
|
Banerjee, G.
|
|
|
26 |
12S |
p. S188-S189
|
artikel
|
| 514 |
EE102 Economic Burden of Short-Acting Beta-2 Agonist Overuse Among Asthma Patients in Turkiye: A Cost Analysis with Respect to Updated Recommendations of the Global Initiative for Asthma
|
Yorgancıoğlu, A.
|
|
|
26 |
12S |
p. S70
|
artikel
|
| 515 |
EE112 Economic Burden of SLE in Nordic Countries - a Systematic Literature Review (SLR)
|
Sharma, M.
|
|
|
26 |
12S |
p. S72
|
artikel
|
| 516 |
EE18 Economic Burden of Type 2 Diabetes in Peru: A Cost-of-Illness Study Valuing Cost Differences Associated With the Level of Glycemic Control
|
Seinfeld, J.
|
|
|
26 |
12S |
p. S53
|
artikel
|
| 517 |
EE534 Economic Burden of Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphoid Leukemia
|
Paoletti, M.
|
|
|
26 |
12S |
p. S154-S155
|
artikel
|
| 518 |
EE398 Economic Burden of Wilson's Disease: A Systematic Review
|
Garg, J.
|
|
|
26 |
12S |
p. S127
|
artikel
|
| 519 |
EE475 Economic Burden on Diabetes and Cardiovascular Disease: Real World Data and Empirical Analysis in Algeria
|
Tebaibia, A.
|
|
|
26 |
12S |
p. S142
|
artikel
|
| 520 |
EE482 Economic Cost of Implementation of a Frailty Care Bundle to Reduce Risk of Hospital Associated Decline Among Older Patients
|
Murphy, A.
|
|
|
26 |
12S |
p. S144
|
artikel
|
| 521 |
EE250 Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review
|
Jindal, S.
|
|
|
26 |
12S |
p. S99
|
artikel
|
| 522 |
EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico
|
Romero, R.
|
|
|
26 |
12S |
p. S187
|
artikel
|
| 523 |
EE609 Economic Evaluation and Return-on-Investment (ROI) of Fostering Physical Activity Policies (Simulation With Two Different Tools)
|
Efthymiou, I.
|
|
|
26 |
12S |
p. S170
|
artikel
|
| 524 |
EE445 Economic Evaluation of Alternative Measles-Mumps-Rubella Childhood Vaccination Schedules in Denmark
|
Nymark, L.
|
|
|
26 |
12S |
p. S137
|
artikel
|
| 525 |
EE371 Economic Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors Compared with Standard Chemotherapy in Thailand
|
Luksameesate, P.
|
|
|
26 |
12S |
p. S122
|
artikel
|
| 526 |
EE684 Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review
|
Garg, J.
|
|
|
26 |
12S |
p. S185
|
artikel
|
| 527 |
EE751 Economic Evaluation of Hepatitis B Vaccination Programme in Finland
|
Nieminen, T.
|
|
|
26 |
12S |
p. S199
|
artikel
|
| 528 |
EE466 Economic Evaluation of Improving Medication Adherences for Secondary Cardiovascular Disease Prevention: A Threshold Analysis
|
Cho, J.Y.
|
|
|
26 |
12S |
p. S141
|
artikel
|
| 529 |
EE285 Economic Evaluation of Knee Arthroscopic Surgery: A Comparison of Ambulatory and In-Patient Knee Arthroscopic Surgery in Thailand
|
Luksameesate, P.
|
|
|
26 |
12S |
p. S105-S106
|
artikel
|
| 530 |
EE379 Economic Evaluation of Nubeqal for the Treatment of Adult Patients With Non-Metastatic Castration Resistant Prostate Cancer in the Mexican Context
|
Monroy Cruz, B.
|
|
|
26 |
12S |
p. S123
|
artikel
|
| 531 |
EE396 Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review
|
Ghoshal, D.
|
|
|
26 |
12S |
p. S127
|
artikel
|
| 532 |
EE611 Economic Evaluation of Person-Centred Care Using a Digital Platform and Structure Telephone Support for People with Chronic Heart Failure and/or Chronic Obstructive Pulmonary Disease
|
Harvey, B.
|
|
|
26 |
12S |
p. S170-S171
|
artikel
|
| 533 |
EE463 Economic Evaluation of Single Pill Combination Clopidogrel: Aspirin Versus Free Combination Clopidogrel Plus Aspirin for Prevention of Cardiovascular Events After Acute Coronary Syndrome in China
|
Wu, Y.
|
|
|
26 |
12S |
p. S140-S141
|
artikel
|
| 534 |
EE194 Economic Evaluation of Tofacitinib for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis in Greece
|
Tzanetakos, C.
|
|
|
26 |
12S |
p. S88
|
artikel
|
| 535 |
EE436 Economic Evaluation of Transcatheter Versus Surgical Aortic Valve Replacement in Low- and Intermediate-Risk Patients with Severe Aortic Stenosis in China
|
Peng, J.
|
|
|
26 |
12S |
p. S135
|
artikel
|
| 536 |
EE521 Economic Evaluation of Trastuzumab Deruxtecan for HER2+ Advanced Gastric Cancer Patients
|
Mudumba, R.
|
|
|
26 |
12S |
p. S151-S152
|
artikel
|
| 537 |
EE226 Economic Evaluation of Trastuzumab in HER2-Positive Early Breast Cancer in Indonesia: A Cost-Effectiveness Analysis
|
Khoirunnisa, S.
|
|
|
26 |
12S |
p. S94
|
artikel
|
| 538 |
EE235 Economic Evaluations of Medical Devices Used in the Treatment of Breast Cancer: A Systematic Review
|
Madan, T.
|
|
|
26 |
12S |
p. S96
|
artikel
|
| 539 |
EE567 Economic Evaluations of Pharmacological Interventions for Lupus Population – a Targeted Literature Review
|
Bisen, R.
|
|
|
26 |
12S |
p. S162
|
artikel
|
| 540 |
EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France
|
Leblond, V.
|
|
|
26 |
12S |
p. S185
|
artikel
|
| 541 |
EE338 Economic Impact of Herpes Zoster and Postherpetic Neuralgia on Healthcare Resource Use in Sweden
|
Mårdberg, K.
|
|
|
26 |
12S |
p. S116
|
artikel
|
| 542 |
EE637 Economic Impact of Managing Invasive Mold Disease With Isavuconazole Compared With Liposomal Amphotericin B in Spain
|
Moya, M.C.
|
|
|
26 |
12S |
p. S175-S176
|
artikel
|
| 543 |
EE726 Economics Costs Associated with Hyperkalemia in Argentina
|
Tabares, M.
|
|
|
26 |
12S |
p. S194
|
artikel
|
| 544 |
EE415 Effect of Vitamin C Use on Cost of Common Cold in Turkiye
|
Erkut, Y.
|
|
|
26 |
12S |
p. S131
|
artikel
|
| 545 |
EE135 Efficiency Management of Immunization Programs in Peru, in the Context of the COVID-19 Pandemic: The Fully Liquid Acellular Hexavalent Vaccine
|
Mendoza, M.A.
|
|
|
26 |
12S |
p. S76
|
artikel
|
| 546 |
EE247 Emicizumab is Cost-Saving for Finnish Hemophilia A Patients with Factor VIII Inhibitors
|
Viita, A.M.
|
|
|
26 |
12S |
p. S98
|
artikel
|
| 547 |
EE76 End-of-Life Cost and Characteristics of Acute Myeloid Leukemia Decedents: A National Study From 2011-2020
|
Han, H.
|
|
|
26 |
12S |
p. S64-S65
|
artikel
|
| 548 |
EE58 Endometrial Cancer Care in Colombia: A Cost-of-Illness Study Based on Administrative Claims Databases
|
Buitrago, G.
|
|
|
26 |
12S |
p. S60
|
artikel
|
| 549 |
EE287 Epidemiologic and Economic Impact of COVID-19 Vaccination Among at-Risk Individuals and Individuals Aged ≥60 Years in Germany
|
Joshi, K.
|
|
|
26 |
12S |
p. S106
|
artikel
|
| 550 |
EE441 Estimating Changes in Lifetime Tax Revenue and Transfer Payments Associated with the Pediatric Immunization Program in Belgium
|
Kotsopoulos, N.
|
|
|
26 |
12S |
p. S136
|
artikel
|
| 551 |
EE578 Estimating Economic Impact of Fenofibrate Among Patients with Diabetic Retinopathy in China
|
Ahn, J.
|
|
|
26 |
12S |
p. S164
|
artikel
|
| 552 |
EE107 Estimating EQ-5D Utilities From the Facial Vitiligo Area Scoring Index (F-VASI) in Vitiligo Patients Using a Mapping Algorithm Applied to 2 Pooled Randomized Controlled Trials
|
Begum, R.
|
|
|
26 |
12S |
p. S71
|
artikel
|
| 553 |
EE425 Estimating HCP Labor Time and Cost Saving with the Use of Rapid Rituximab Infusions Versus Standard Rituximab Infusions for the Treatment of Adults with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma in Induction Phase
|
Finocchiaro, D.
|
|
|
26 |
12S |
p. S133
|
artikel
|
| 554 |
EE304 Estimating Health Related Quality of Life Effects in Vitiligo: Mapping EQ-5D-5L Utilities from Vitiligo Specific Scales, Re-Pigmentation Measures Using Data from the HI-Light Trial
|
Begum, R.
|
|
|
26 |
12S |
p. S109
|
artikel
|
| 555 |
EE659 Estimating the Economic Consequences of Migraine in Sweden: A Fiscal Model Using the Government Perspective of Costs
|
Martins, R.
|
|
|
26 |
12S |
p. S180
|
artikel
|
| 556 |
EE731 Estimating the Economic Impact of Enabling the Digital Transfer of Patients’ Prescription Information in the English National Health Service
|
Elliott, R.
|
|
|
26 |
12S |
p. S195
|
artikel
|
| 557 |
EE374 Estimating the Impact of Tumors of the Oesophageal and Gastro-Oesophageal Junction on Work, Leisure and Household Activity Times: Evidence from a Patient Survey in Switzerland
|
Stoffel, S.
|
|
|
26 |
12S |
p. S123
|
artikel
|
| 558 |
EE472 Estimation of the Burden of Chronic Kidney Disease in the Argentine Health System
|
Jorgensen, N.
|
|
|
26 |
12S |
p. S142
|
artikel
|
| 559 |
EE293 Estimation of the Cost of the National Immunization Program for Children and Adolescents in Greece
|
Gountas, I.
|
|
|
26 |
12S |
p. S107
|
artikel
|
| 560 |
EE223 Estimation of the T-Cell Engagers (Bi-Specific Monoclonal Antibodies and Chimeric Antigen Receptor [CAR T-CELL]) Therapy Administration Pathways From French Hospitals and National Health Insurance Perspective and Financial Impact
|
Le Dissez, C.
|
|
|
26 |
12S |
p. S94
|
artikel
|
| 561 |
EE215 Estimation of 10-Year Healthcare Costs of Patients Diagnosed With Myeloproliferative Neoplasms in Denmark
|
Stenling, A.
|
|
|
26 |
12S |
p. S92
|
artikel
|
| 562 |
EE193 Evaluating Clinical Benefits of Vertebral Body Stenting in Treating Osteoporotic Vertebral Compression Fracture: A Physician Survey
|
Shi, Q.
|
|
|
26 |
12S |
p. S88
|
artikel
|
| 563 |
EE450 Evaluating Price Trends in Supplements from 2018 to 2022 in Turkiye
|
Kilic, A.G.
|
|
|
26 |
12S |
p. S138
|
artikel
|
| 564 |
EE431 Evaluating the Budget Impact of NOVOCART Inject Plus (Ninject) for Symptomatic Knee Cartilage Defects in the NHS
|
Mandalia, V.
|
|
|
26 |
12S |
p. S134
|
artikel
|
| 565 |
EE174 Evaluating the Budget Impact of the Co-Existence of Oral and Injectable Forms of Semaglutide in the Saudi Public Healthcare System
|
Alluhidan, M.
|
|
|
26 |
12S |
p. S84
|
artikel
|
| 566 |
EE545 Evaluating the Clinical Burden of Disease and Costs of ANCA-Associated Vasculitis in Spain: Main Findings from the EUVAS Based Registry.
|
Bordignon Draibe, J.
|
|
|
26 |
12S |
p. S157
|
artikel
|
| 567 |
EE614 Evaluating the Cost-Effectiveness of CYP2C19 Genetic Testing in Patients Who Have Experienced an Ischaemic Stroke or Transient Ischaemic Attack in England and Wales
|
Carroll, J.
|
|
|
26 |
12S |
p. S171
|
artikel
|
| 568 |
EE65 Evaluating the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Strategy in Oncology and Implications for Policy: A Literature Review
|
Wilsdon, T.
|
|
|
26 |
12S |
p. S62
|
artikel
|
| 569 |
EE346 Evaluating the Economic Burden of Osteoporosis in the United States: Insights from a MEPS-Based Analysis
|
Balkhi, B.
|
|
|
26 |
12S |
p. S118
|
artikel
|
| 570 |
EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysis
|
Muluneh, B.
|
|
|
26 |
12S |
p. S188
|
artikel
|
| 571 |
EE332 Evaluation of Hospital Pandemic Control Strategies of a Chinese Tertiary Care Hospital During the Late Phase of COVID-19 Pandemic
|
Wang, D.
|
|
|
26 |
12S |
p. S115
|
artikel
|
| 572 |
EE665 Evaluation of Resource Use and Costs of Pertuzumab and Trastuzumab Formulations in HER2- Positive Breast Cancer
|
Meirelles, I.
|
|
|
26 |
12S |
p. S181
|
artikel
|
| 573 |
EE52 Evaluation of the Economic Impact of Initial Diagnostic Modality Selection for Patients Suspected of Having Colorectal Cancer Liver Metastases or Hepatocellular Carcinoma in the UK
|
Corbin, A.
|
|
|
26 |
12S |
p. S59-S60
|
artikel
|
| 574 |
EE248 Evolution in Price Levels of Orphan Medicinal Products (OMP): Looking Back at the Past Decade
|
Patel, B.
|
|
|
26 |
12S |
p. S98-S99
|
artikel
|
| 575 |
EE602 Examination of Changes Experienced in Prices of Goods and Services That Affect Manufacturing Costs in Health Industry for Slovenia
|
Erkut, Y.
|
|
|
26 |
12S |
p. S169
|
artikel
|
| 576 |
EE728 Examining Hospital-Onset Urinary Tract Infection (HO-UTI) in Male Patients – Modeling the Economic Impact of Utilizing External Male Wicking Catheters (EMWCS)
|
Kelly, T.
|
|
|
26 |
12S |
p. S194-S195
|
artikel
|
| 577 |
EE647 Excess Healthcare Resource Use Among Subgroups With Anxiety and Depressive Symptoms in Hungary
|
Ferenczik, A.
|
|
|
26 |
12S |
p. S178
|
artikel
|
| 578 |
EE6 Expected Value of Perfect Implementation of Icosapent Ethyl (Vazkepa) in Sweden
|
Eklund, M.
|
|
|
26 |
12S |
p. S50-S51
|
artikel
|
| 579 |
EE639 Explorative Cost-Effectiveness Analysis of a Rapid ID/AST Solution for Patients with Bloodstream Infection
|
Boughazi, H.E.
|
|
|
26 |
12S |
p. S176
|
artikel
|
| 580 |
EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population
|
Batchelder, L.
|
|
|
26 |
12S |
p. S137
|
artikel
|
| 581 |
EE399 Exploring the Economic Consequences of Caring for Patients With Rare Diseases: A Systematic Literature Review
|
Crossley, O.
|
|
|
26 |
12S |
p. S127
|
artikel
|
| 582 |
EE477 Exploring the Perceived Value of Fixed-Dose Combinations in Type 2 Diabetes Mellitus in the EU4 and the UK
|
Cruz Arrioja, J.C.
|
|
|
26 |
12S |
p. S143
|
artikel
|
| 583 |
EE225 Exploring the Value of Country-Specific Cost-Effectiveness Models in Early Stages of Drug Development
|
Ronquest, N.
|
|
|
26 |
12S |
p. S94
|
artikel
|
| 584 |
EE715 Faricimab Vs. Standard of Care in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Cost-Utility Analysis in Italy
|
Ghetti, G.
|
|
|
26 |
12S |
p. S192
|
artikel
|
| 585 |
EE721 Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Pregnancy, Inflammatory Bowel Disease, Heart Failure and Bariatric Surgery Under the Payer’s Perspective of the Supplementary System in Brazil
|
Clemente, V.
|
|
|
26 |
12S |
p. S193
|
artikel
|
| 586 |
EE314 Ferric Carboxymaltose in the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Private Health Care System: Cost-Effectiveness Analysis and Budget Impact in Brazil
|
Campagnaro, M.
|
|
|
26 |
12S |
p. S111
|
artikel
|
| 587 |
EE334 Five-Year Budget Impact of Community-Based HIV Testing Strategies for Oral Pre-Exposure Prophylaxis Scale-up in Western Kenya: A Modeling Analysis
|
Cox, S.
|
|
|
26 |
12S |
p. S115
|
artikel
|
| 588 |
EE30 Framework Concepts for Economic Evaluation of New Antibiotics
|
Yang, W.
|
|
|
26 |
12S |
p. S55
|
artikel
|
| 589 |
EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors
|
Soini, E.
|
|
|
26 |
12S |
p. S120
|
artikel
|
| 590 |
EE131 Genetic-Guided Pharmacotherapy for Cardiovascular Disease: A Systematic and Critical Review of Economic Evaluations
|
Lim, K.K.
|
|
|
26 |
12S |
p. S75-S76
|
artikel
|
| 591 |
EE530 Global Clinical, Economic, Health-Related Quality of Life Burden, and Treatment Outcomes in Follicular Lymphoma: A Systematic Review
|
Shah, B.
|
|
|
26 |
12S |
p. S153-S154
|
artikel
|
| 592 |
EE381 Health Benefits and Cost-Effectiveness Analysis of Early Breast Cancer Diagnosis in Bulgaria
|
Slavchev, G.
|
|
|
26 |
12S |
p. S124
|
artikel
|
| 593 |
EE526 Health Benefits and Cost-Effectiveness Analysis of Early Cervical Cancer Diagnosis in Bulgaria
|
Slavchev, G.
|
|
|
26 |
12S |
p. S153
|
artikel
|
| 594 |
EE565 Healthcare Consumption and Costs of Hemophilia B in France
|
Lilliu, H.
|
|
|
26 |
12S |
p. S161
|
artikel
|
| 595 |
EE268 Healthcare Costs and All-Cause Mortality Following a Hyperkalemia Event and Reduction of RAASi Therapy in Sweden
|
Svensson, M.K.
|
|
|
26 |
12S |
p. S103
|
artikel
|
| 596 |
EE328 Healthcare Costs in Patients With Hepatic Encephalopathy Receiving Rifaximin-α Treatment in the IMPRESS-II Study
|
Buxton, A.
|
|
|
26 |
12S |
p. S114
|
artikel
|
| 597 |
EE160 Healthcare Expenditure for Treatment of Hypertension and Hypertensive Complications in Japan: A Claims Data Analysis
|
Tanaka, Y.
|
|
|
26 |
12S |
p. S81
|
artikel
|
| 598 |
EE297 Healthcare Resources Utilization Among Sectors in Saudi Arabia
|
Binsalman, O.
|
|
|
26 |
12S |
p. S108
|
artikel
|
| 599 |
EE84 Healthcare Resource Use and Cost in Metastatic Castration Resistant Prostate Cancer (mCRPC) in Finland
|
Rannikko, A.
|
|
|
26 |
12S |
p. S66-S67
|
artikel
|
| 600 |
EE674 Healthcare Resource Use and Costs Associated with Endometrial Cancer Treatment in the Private Setting in Brazil
|
Padula, A.C.
|
|
|
26 |
12S |
p. S183
|
artikel
|
| 601 |
EE142 Healthcare Resource Use and Costs Associated with Herpes Zoster/Post-Herpetic Neuralgia Episodes in Italy: A Retrospective Observational Study
|
Zarkadoulas, E.
|
|
|
26 |
12S |
p. S78
|
artikel
|
| 602 |
EE325 Healthcare Resource Use and Costs Associated with Obesity and Obesity-Related Complications in Saudi Arabia
|
Al-Omar, H.
|
|
|
26 |
12S |
p. S113
|
artikel
|
| 603 |
EE166 Healthcare Resource Use and Economic Burden of Stroke Among People with Type 2 Diabetes: A Real-World Evidence Study in France
|
Fauchier, L.
|
|
|
26 |
12S |
p. S82
|
artikel
|
| 604 |
EE717 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France
|
Baldwin, J.
|
|
|
26 |
12S |
p. S192
|
artikel
|
| 605 |
EE109 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in France
|
Baldwin, J.
|
|
|
26 |
12S |
p. S71
|
artikel
|
| 606 |
EE44 Health Care Resource Utilization and Cost in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada
|
Baribeau, V.
|
|
|
26 |
12S |
p. S58
|
artikel
|
| 607 |
EE244 Healthcare Resource Utilization and Costs in Patients with Alagille Syndrome Using Population-Based Healthcare Data from South Korea
|
Kim, S.
|
|
|
26 |
12S |
p. S98
|
artikel
|
| 608 |
EE258 Healthcare Resource Utilization and Economic Burden of Hidradenitis Suppurativa in German Patients with Hidradenitis Suppurativa
|
Bechara, F.G.
|
|
|
26 |
12S |
p. S101
|
artikel
|
| 609 |
EE137 Healthcare Resource Utilization and Estimated Costs in Adult Pneumococcal Disease in Peru: Results from a Panel of Experts
|
Figueroa, J.
|
|
|
26 |
12S |
p. S76-S77
|
artikel
|
| 610 |
EE493 Healthcare Resource Utilization Associated with Major Depressive Disorder with Insomnia Symptoms: A Retrospective Cohort Study in Hungary
|
Szekeres, G.
|
|
|
26 |
12S |
p. S146
|
artikel
|
| 611 |
EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database
|
Borate, U.
|
|
|
26 |
12S |
p. S67
|
artikel
|
| 612 |
EE533 Healthcare Resource Utilization (HCRU) and Related Direct Healthcare Costs for Patients with Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Cohort Study in a Clinical Practice Setting in Italy
|
Kearney, M.
|
|
|
26 |
12S |
p. S154
|
artikel
|
| 613 |
EE48 Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Employment Changes for Early, Middle and Late-Stage People with Amyotrophic Lateral Sclerosis (pALS) in Italy: Results from a Real-World Survey
|
Stenson, K.
|
|
|
26 |
12S |
p. S59
|
artikel
|
| 614 |
EE552 Healthcare Resource Utilization in Alpha-Mannosidosis: Results from an International Caregiver Survey
|
Dorling, P.
|
|
|
26 |
12S |
p. S158-S159
|
artikel
|
| 615 |
EE489 Healthcare Utilization and Costs Among Treatment-Experienced Medicaid Beneficiaries Utilizing Single-Treatment Versus Multi-Treatment Regimens for HIV
|
Chen, M.
|
|
|
26 |
12S |
p. S145-S146
|
artikel
|
| 616 |
EE129 Health-Economic Analysis of Digestive Stents in France Based on the French Social Insurance Healthcare Database
|
de Launay, J.
|
|
|
26 |
12S |
p. S75
|
artikel
|
| 617 |
EE427 Health Economic Decision Models Used in the Cost-Effectiveness Analyses of Innovative Products Submitted to the French National Authority for Health (HAS)
|
Sion, M.
|
|
|
26 |
12S |
p. S133
|
artikel
|
| 618 |
EE422 Health Economic Modelling of Current Population Health Management Interventions for CKD in the UK Using a Population-Level Markov Model
|
Agathangelou, G.
|
|
|
26 |
12S |
p. S132
|
artikel
|
| 619 |
EE657 Health Resource Utilization by Disease Stage for People with Amyotrophic Lateral Sclerosis (pALS) in the French National Health Data System (SNDS)
|
Stenson, K.
|
|
|
26 |
12S |
p. S180
|
artikel
|
| 620 |
EE85 Health System Costs and Resources for Stage-Specific Breast Cancer: A Population-Based Approach (Updated)
|
Mittmann, N.
|
|
|
26 |
12S |
p. S67
|
artikel
|
| 621 |
EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients
|
Verma, S.
|
|
|
26 |
12S |
p. S155
|
artikel
|
| 622 |
EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)
|
Renaud, S.
|
|
|
26 |
12S |
p. S151
|
artikel
|
| 623 |
EE176 Hospitalization Trends for All Intestinal Infectious Diseases Since Introduction of Rotavirus Gastroenteritis (RVGE) Vaccine in Ireland
|
Murphy, A.
|
|
|
26 |
12S |
p. S84
|
artikel
|
| 624 |
EE537 How Good Are Cost-Effectiveness Model Predictions When Compared to Longer Follow-up Data? An Example of Nivolumab Studies in the First-Line Gastro-Oesophageal Setting
|
Young, R.
|
|
|
26 |
12S |
p. S155
|
artikel
|
| 625 |
EE190 How Many Patients Diagnosed with Mild Cognitive Impairment Are Willing to Pay for a PET Scan to Receive the Treatment for Alzheimer′S Disease in Japan?
|
Ha, C.
|
|
|
26 |
12S |
p. S87
|
artikel
|
| 626 |
EE239 How to Consider Caregiver Health-Related Quality of Life in a Cost-Effectiveness Analysis? An Illustration with Dupilumab for the Treatment of Severe Atopic Dermatitis in Infants in France
|
Sutour, L.
|
|
|
26 |
12S |
p. S97
|
artikel
|
| 627 |
EE645 How Wrong Can It Be? The Impact of Using Inappropriate Adult-Specific Value Set for EQ-5D-Y in Cost-Effectiveness Estimates
|
Chuang, L.H.
|
|
|
26 |
12S |
p. S177
|
artikel
|
| 628 |
EE702 Humanistic and Economic Burden of Methylmalonic Acidemia—A Systematic Literature Review
|
Babarczy, B.
|
|
|
26 |
12S |
p. S189
|
artikel
|
| 629 |
EE22 Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR
|
Brown, L.
|
|
|
26 |
12S |
p. S53-S54
|
artikel
|
| 630 |
EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods
|
Lister, J.
|
|
|
26 |
12S |
p. S174-S175
|
artikel
|
| 631 |
EE147 "I'll Live Less, You'll Live Better, Let's Make It Count": A Qualitative Exploration of Drivers & Barriers for Sacrificing Remaining Life Expectancy to Restore Relatives to Full Health in Time Trade Off Exercises
|
Wratten, S.
|
|
|
26 |
12S |
p. S78
|
artikel
|
| 632 |
EE501 Impact of Eptinezumab on Healthcare Resource Utilization in Patients with Migraine in the United States: A Retrospective Cohort Claims Database Study
|
Rieckmann, A.
|
|
|
26 |
12S |
p. S148
|
artikel
|
| 633 |
EE591 Impact of Flu Vaccine Shortage on the National Health Service (NHS) in England and Wales
|
Amin, F.
|
|
|
26 |
12S |
p. S167
|
artikel
|
| 634 |
EE503 Impact of Managing Multiple Sclerosis Patients in a Private Health Insurance Company in Brazil
|
Alves Junior, J.M.
|
|
|
26 |
12S |
p. S148
|
artikel
|
| 635 |
EE320 Impact of NASH Disease Model Adjustment to New Literature Findings: Assessing Cost-Effectiveness of Actual and Theoretical Treatments
|
Pochopien, M.
|
|
|
26 |
12S |
p. S112-S113
|
artikel
|
| 636 |
EE130 Impact of Phacoemulsification Equipment in Surgical Throughput, Under the Perspective of a Greek Hospital
|
Papadopoulos, M.
|
|
|
26 |
12S |
p. S75
|
artikel
|
| 637 |
EE706 Impact of Valoctocogene Roxaparvovec on the Economic Burden of Adults with Severe Hemophilia A Managed with Prophylaxis in the United States
|
Wang, T.
|
|
|
26 |
12S |
p. S190
|
artikel
|
| 638 |
EE622 Improved Glycemic Outcomes and Associated Cost Savings with an Advanced Hybrid Closed Loop System for People with Type 1 Diabetes with Suboptimal Glycemic Control in Europe
|
Ozdemir Saltik, A.Z.
|
|
|
26 |
12S |
p. S172-S173
|
artikel
|
| 639 |
EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness
|
Alves Junior, J.M.
|
|
|
26 |
12S |
p. S119
|
artikel
|
| 640 |
EE620 Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients
|
Butzner, M.
|
|
|
26 |
12S |
p. S172
|
artikel
|
| 641 |
EE651 Incremental Cost per Remission in Patients With Rheumatoid Arthritis Who Had Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Colombia
|
Jauregui, E.
|
|
|
26 |
12S |
p. S178-S179
|
artikel
|
| 642 |
EE414 Incremental Costs of Abrocitinib Compared to Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Denmark
|
Sciera, L.
|
|
|
26 |
12S |
p. S130-S131
|
artikel
|
| 643 |
EE650 Incremental Costs of Tofacitinib Compared to Adalimumab and Ixekizumab for the Treatment of Active Ankylosing Spondylitis in Denmark
|
Mølbach, T.
|
|
|
26 |
12S |
p. S178
|
artikel
|
| 644 |
EE262 Indirect Cost Burden for Individuals Living with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Europe
|
Lilly, L.
|
|
|
26 |
12S |
p. S101-S102
|
artikel
|
| 645 |
EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe
|
Lilly, L.
|
|
|
26 |
12S |
p. S72
|
artikel
|
| 646 |
EE384 Indirect Cost of HPV-Attributable Cancer in the United Kingdom
|
Engelbrecht, K.
|
|
|
26 |
12S |
p. S124
|
artikel
|
| 647 |
EE245 Indirect Cost of Spinal Muscular Atrophy (SMA) in Singapore
|
Lim, Z.Z.
|
|
|
26 |
12S |
p. S98
|
artikel
|
| 648 |
EE571 Indirect Costs and Out-of-Pocket Expenses of Chronic Kidney Disease on Dialysis in Bogota, Colombia
|
Gonzalez, C.
|
|
|
26 |
12S |
p. S162-S163
|
artikel
|
| 649 |
EE724 Inside CKD: Projecting the Population Level Economic Burden of Chronic Kidney Disease According to Urine Albumin-to-Creatinine Ratio (uACR) Categories
|
Garcia Sanchez, J.J.
|
|
|
26 |
12S |
p. S194
|
artikel
|
| 650 |
EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer
|
Wing, S.
|
|
|
26 |
12S |
p. S62-S63
|
artikel
|
| 651 |
EE460 Intraarterial Thrombectomy for Acute Ischemic Stroke: Cost-Effective or Dominant across All Age Groups in Brazil
|
Magalhães, P.
|
|
|
26 |
12S |
p. S140
|
artikel
|
| 652 |
EE92 Introduction to the Duchenne Muscular Dystrophy Burden-of-Illness Study Expanded (US AND SPAIN)
|
Castro, D.
|
|
|
26 |
12S |
p. S68
|
artikel
|
| 653 |
EE744 Invasive Meningococcal Disease Economic Burden: A Comprehensive Analysis
|
Langevin, E.
|
|
|
26 |
12S |
p. S198
|
artikel
|
| 654 |
EE471 Investigating the Impact of Pseudo-Random Numbers Generator on a Probabilistic Sensitive Analysis (PSA) Results
|
Dziedzic, J.
|
|
|
26 |
12S |
p. S142
|
artikel
|
| 655 |
EE523 Is Dismissing Intervention Development Costs a Fallacy? a Case Study of a Digital Health Intervention E-MAT
|
Murphy, A.
|
|
|
26 |
12S |
p. S152
|
artikel
|
| 656 |
EE246 Is It Possible to Reduce the Costs of Care for Pediatric Patients With Hemophilia A and Inhibitors in Trinidad & Tobago?
|
Munoz Bedoya, A.
|
|
|
26 |
12S |
p. S98
|
artikel
|
| 657 |
EE584 Is Point-of-Care Testing in Emergency Departments Cost-Effective? A Systematic Literature Review
|
Andreasen, J.
|
|
|
26 |
12S |
p. S165
|
artikel
|
| 658 |
EE754 Is the Paradigm Shifting? The REvalMED Pilot Program and Subsequent Integration of Economic Evaluations to Influence Pricing and Reimbursement Discussions in Spain
|
Sosa, J.
|
|
|
26 |
12S |
p. S200
|
artikel
|
| 659 |
EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review
|
Veijer, C.
|
|
|
26 |
12S |
p. S86
|
artikel
|
| 660 |
EE550 Lifetime Cost of Orphan Therapies in Paediatric Indications in Europe
|
Wex, J.
|
|
|
26 |
12S |
p. S158
|
artikel
|
| 661 |
EE459 Lifetime Healthcare and Long-Term Care Use of Heart Failure Patients in the Netherlands
|
Mokri, H.
|
|
|
26 |
12S |
p. S139-S140
|
artikel
|
| 662 |
EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions
|
Gay Molina, J.
|
|
|
26 |
12S |
p. S67
|
artikel
|
| 663 |
EE300 Looking Sharp! Applying Cutting-Edge Shapley Additive Explanation (SHAP) Approaches to Cost-Effectiveness Modelling in Contrast to One-Way Sensitivity Analysis
|
Perni, S.
|
|
|
26 |
12S |
p. S108
|
artikel
|
| 664 |
EE219 Lorlatinib as a First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Greece
|
Gourzoulidis, G.
|
|
|
26 |
12S |
p. S93
|
artikel
|
| 665 |
EE39 Loss of Productivity, Use of Healthcare Resources and Cost Associated with Insomnia
|
Bellido, M.C.
|
|
|
26 |
12S |
p. S57
|
artikel
|
| 666 |
EE670 Management Costs of Grade 3/4 Adverse Events Associated with Emerging and Existing Systemic Therapies for Metastatic Colorectal Cancer with at Least Two Prior Lines of Therapy in Italy, Portugal, Spain, and the United States
|
Paly, V.
|
|
|
26 |
12S |
p. S182-S183
|
artikel
|
| 667 |
EE635 Medical Cost Trends for Diseases Associated with Bedridden Rural Residents in Japan
|
Shoji, A.
|
|
|
26 |
12S |
p. S175
|
artikel
|
| 668 |
EE37 Method Matters: Cost-Minimization Versus Cost-Effectiveness Frameworks in Assessing Opioid Use Disorder Treatments
|
Rittenhouse, B.
|
|
|
26 |
12S |
p. S56
|
artikel
|
| 669 |
EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022
|
Tehard, B.
|
|
|
26 |
12S |
p. S169
|
artikel
|
| 670 |
EE529 Methodology for the Monetization of Vial Remnants in the Aseptic Unit
|
Gonzalez Durio, J.
|
|
|
26 |
12S |
p. S153
|
artikel
|
| 671 |
EE451 Methods to Measure the Environmental Impacts of Health Technologies and to Include Them in Economic Evaluations: A Scoping Literature Review
|
Ardito, V.
|
|
|
26 |
12S |
p. S138
|
artikel
|
| 672 |
EE3 Micro-Costing Analysis for the Treatment of Atrial Fibrillation: An Economic Evaluation
|
Maglionico, G.
|
|
|
26 |
12S |
p. S50
|
artikel
|
| 673 |
EE317 Microsimulation Model in Obesity: A Feasibility Study Using Object-Oriented C++ Code
|
Foos, V.
|
|
|
26 |
12S |
p. S112
|
artikel
|
| 674 |
EE231 Model-Based Assessment of the Costs and Benefits of Directly Mailing Self-Sampling HPV Kits to Non-Participants in Cervical Screening in the Czech Republic
|
Ngo, O.
|
|
|
26 |
12S |
p. S95
|
artikel
|
| 675 |
EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping
|
Batteson, R.
|
|
|
26 |
12S |
p. S122
|
artikel
|
| 676 |
EE730 Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics in Eosinophilic-Associated Diseases
|
Jia, X.
|
|
|
26 |
12S |
p. S195
|
artikel
|
| 677 |
EE707 Modelling the Cost Effectiveness and Budget Impact of Uterine Botulinum Toxin Injections in Severe Dysmenorrhoea: A France Perspective
|
Kouame, K.J.
|
|
|
26 |
12S |
p. S190
|
artikel
|
| 678 |
EE758 Modelling Visual Acuity Distributions to Inform a Simplified Cost Effectiveness Analysis
|
Hirst, A.
|
|
|
26 |
12S |
p. S200
|
artikel
|
| 679 |
EE278 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United Kingdom
|
Lopez, A.
|
|
|
26 |
12S |
p. S104
|
artikel
|
| 680 |
EE279 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia in the United Kingdom
|
Udeze, C.
|
|
|
26 |
12S |
p. S104-S105
|
artikel
|
| 681 |
EE312 Multi-Comparator ICERS in Cost-Effectiveness Analysis to Account for Changes in Clinical Practice after the Introduction of a New Technology
|
Weston, G.
|
|
|
26 |
12S |
p. S111
|
artikel
|
| 682 |
EE484 Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes
|
Chowdhury, E.
|
|
|
26 |
12S |
p. S144
|
artikel
|
| 683 |
EE486 Municipality Costs Due to COVID-19 Infections in Denmark: A Cost-of-Illness Study
|
Mølbach, T.
|
|
|
26 |
12S |
p. S145
|
artikel
|
| 684 |
EE580 New Anti-CGRP in France: Estimated Financial Impact of Eptinezumab in Hospitals, a Prospective Stake
|
Cartolano, P.
|
|
|
26 |
12S |
p. S164-S165
|
artikel
|
| 685 |
EE169 Novel Post-Processing Methods for Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Heat Map and Density-Based Clustering
|
Dziedzic, J.
|
|
|
26 |
12S |
p. S83
|
artikel
|
| 686 |
EE682 Number Needed to Treat (NNT) Comparing Axicabtagene Ciloleucel and Best Supportive Care for Third Line Diffuse Large B-Cell Lymphoma in Brazil
|
Asano, E.
|
|
|
26 |
12S |
p. S185
|
artikel
|
| 687 |
EE478 Obesity-Related Outcomes and Cost Impact of Weight Loss in Saudi Arabian Privately Insured Adults
|
Al-Omar, H.
|
|
|
26 |
12S |
p. S143
|
artikel
|
| 688 |
EE654 Occupational Impact of Tardive Dyskinesia: A Cross-Sectional, International Survey Assessing the Perceptions and Experiences of Patients With TD and Physicians Who Treat TD
|
Ribalov, R.
|
|
|
26 |
12S |
p. S179
|
artikel
|
| 689 |
EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations
|
Hellem Schjesvold, F.
|
|
|
26 |
12S |
p. S64
|
artikel
|
| 690 |
EE623 Open Data Available in France: A Great Asset to Study Real-Life Trends for Disease Burden - An Example With Bariatric Surgery Procedures
|
Gonzalez, J.
|
|
|
26 |
12S |
p. S173
|
artikel
|
| 691 |
EE610 Opportunities to Improve the Cost Effectiveness of the Care Pathway in Acute Ischemic Stroke: A Decision Tree Analysis
|
Tiwari, A.
|
|
|
26 |
12S |
p. S170
|
artikel
|
| 692 |
EE7 Optimizing Aortic Stenosis Management: Evaluating the Clinical and Economic Impact of Transcatheter and Surgical Valve Replacement in Taiwan
|
Fu, YH(
|
|
|
26 |
12S |
p. S51
|
artikel
|
| 693 |
EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age
|
Keary, I.
|
|
|
26 |
12S |
p. S125
|
artikel
|
| 694 |
EE494 Optimizing Treatment of Schizophrenia: Pharmacoeconomic Consequences and Potential for Patient Switching to Long-Acting Injectables
|
Zaniolo, O.
|
|
|
26 |
12S |
p. S146
|
artikel
|
| 695 |
EE224 Out-of-Pocket Health Expenditures of Leukemia and Lymphoma Patients in Portugal
|
Dimitrovova, K.
|
|
|
26 |
12S |
p. S94
|
artikel
|
| 696 |
EE655 Patients Level Cost of Treating Adverse Events in Alzheimer’s Disease for US-FDA Approved Treatments
|
Sanogo, V.
|
|
|
26 |
12S |
p. S179-S180
|
artikel
|
| 697 |
EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain
|
Campos Domínguez, M.
|
|
|
26 |
12S |
p. S129
|
artikel
|
| 698 |
EE134 Pharmacoeconomic Evaluation of National Immunization Program Realisation in Algeria
|
Laichour, A.
|
|
|
26 |
12S |
p. S76
|
artikel
|
| 699 |
EE133 Potential Budget Impact of Negative Pressure Wound Therapy (NPWT) Versus Conventional Wound Treatment (CWT) in Diabetic Foot Ulcers (DFU), Surgical Abdominal Wounds with Healing Impairment (SAWHI), and Trauma Wounds for Mexico
|
Campos, D.
|
|
|
26 |
12S |
p. S76
|
artikel
|
| 700 |
EE281 Predicted UK Health Care Associated Cost-Savings and Health-Related Quality of Life Benefits of Introducing a Digital Leakage Notification System for People Living with a Stoma
|
Cawson, M.
|
|
|
26 |
12S |
p. S105
|
artikel
|
| 701 |
EE270 Predicting Persistent Severe Acute Kidney Injury (AKI) Using the Urinary C-C Motif Chemokine Ligand 14 Biomarker (CCL14). Cost-Utility Analysis in Spain and the UK
|
Martins, R.
|
|
|
26 |
12S |
p. S103
|
artikel
|
| 702 |
EE600 Prediction of Price Dynamics of Medicine in the Netherlands
|
van der Schans, S.
|
|
|
26 |
12S |
p. S168-S169
|
artikel
|
| 703 |
EE507 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer Unselected for DDR Mutations
|
Niyazov, A.
|
|
|
26 |
12S |
p. S149
|
artikel
|
| 704 |
EE355 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With HRR Mutations
|
Niyazov, A.
|
|
|
26 |
12S |
p. S119
|
artikel
|
| 705 |
EE213 Presenting Expected Net Loss Curves to Better Communicate Decision Uncertainty in Cost Effectiveness Analysis
|
Yi, Y.
|
|
|
26 |
12S |
p. S92
|
artikel
|
| 706 |
EE298 Process and Results of the Third Update of the Dutch Guideline for Economic Evaluations in Healthcare: Evolution Instead of Revolution
|
El Alili, M.
|
|
|
26 |
12S |
p. S108
|
artikel
|
| 707 |
EE191 Projecting Costs of Care Burden of Depression Between 2023 and 2032 in Hong Kong: A Time-Inhomogeneous Cohort Markov Model Using Real-World Evidence
|
Chan, V.
|
|
|
26 |
12S |
p. S87-S88
|
artikel
|
| 708 |
EE453 Projecting the Economic Benefits of the Elective Recovery Plan in England
|
Pijper, A.
|
|
|
26 |
12S |
p. S138
|
artikel
|
| 709 |
EE432 Propel® Technology – A Budget Impact Analysis in the Italian Context
|
Borghetti, F.
|
|
|
26 |
12S |
p. S134
|
artikel
|
| 710 |
EE162 Provider Budget Impact Model: Direct Transfer to Angiography Suite (DTAS) Without Stopping for CT Imaging for Patients With Acute Stroke in a German Setting
|
Vanden Baviere, H.
|
|
|
26 |
12S |
p. S81
|
artikel
|
| 711 |
EE216 Provision and Public Expenditure of Radiotherapy Services in Greece (2013-2020)
|
Vozikis, A.
|
|
|
26 |
12S |
p. S92
|
artikel
|
| 712 |
EE294 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccination Among 50 Years Old or Older in Austria
|
Nishimwe, M.L.
|
|
|
26 |
12S |
p. S107
|
artikel
|
| 713 |
EE439 Public Health Impact of the Pediatric Immunization Program in the Netherlands
|
Cook, C.
|
|
|
26 |
12S |
p. S135-S136
|
artikel
|
| 714 |
EE669 Quality of Life and Economic Burden of Advanced Non-Small Cell Lung Cancer in Medium and Small Markets (MED&SM): A Systematic Literature Review
|
Ahn, M.J.
|
|
|
26 |
12S |
p. S182
|
artikel
|
| 715 |
EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia
|
Ceballos González, M.
|
|
|
26 |
12S |
p. S88-S89
|
artikel
|
| 716 |
EE116 Quantifying the Future Impact of Chronic Kidney Disease Screening Programs in Belgium
|
Vadia, R.
|
|
|
26 |
12S |
p. S73
|
artikel
|
| 717 |
EE59 Real-Life Costs of Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated by CAR T-Cells in France Between 2017 and 2020 (EpiCART Study)
|
Borget, I.
|
|
|
26 |
12S |
p. S60-S61
|
artikel
|
| 718 |
EE70 Real-World Comparison of Healthcare Resource Utilization and Costs Between Patients with Chronic Lymphocytic Leukemia Treated with First-Line Ibrutinib or Acalabrutinib
|
Rogers, K.A.
|
|
|
26 |
12S |
p. S63
|
artikel
|
| 719 |
EE93 Real-World Cost-Effectiveness of Asfotase Alfa for Treatment of Patients with HPP in England
|
Dawson, H.
|
|
|
26 |
12S |
p. S68
|
artikel
|
| 720 |
EE378 Real-World Data Establishing HCRU and Costs for the Treatment of Patients With Intermediate- to High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Utilizing Medicare Claims Data
|
Eccleston, A.
|
|
|
26 |
12S |
p. S123
|
artikel
|
| 721 |
EE660 Real-World Economic Burden and Healthcare Resource Utilization (HCRU) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the United States
|
Chari, A.
|
|
|
26 |
12S |
p. S180
|
artikel
|
| 722 |
EE196 Real World Evidence on the Burden of Disease for Patients and Their Nearest Relatives - the Case of Duchenne Muscular Dystrophy
|
Rudolfsen, J.H.
|
|
|
26 |
12S |
p. S89
|
artikel
|
| 723 |
EE756 Real World Evidence (RWE) Evaluation of Cost Savings through Continuous Vital Sign Monitoring in the Medical-Surgical Ward: A National Health Service (NHS) Experience
|
Khan, S.N.
|
|
|
26 |
12S |
p. S200
|
artikel
|
| 724 |
EE257 Real-World, Longitudinal, Retrospective Study of Healthcare Resource Utilization of Patients With Atopic Dermatitis Under the Public Health Insurance Plan of Quebec, Canada
|
Desjardins, O.
|
|
|
26 |
12S |
p. S100-S101
|
artikel
|
| 725 |
EE114 Reductions in Travel Time and CO2 Emissions Arising From Patient Transportation to Hospitals in Ireland for Treatment With Intravenous Iron: An Analysis Comparing Ferric Derisomaltose With Ferric Carboxymaltose
|
Ahmed, W.
|
|
|
26 |
12S |
p. S72-S73
|
artikel
|
| 726 |
EE61 Relationship between Health-Related Quality of Life and Productivity Loss and Indirect Costs of Leukemia and Lymphoma Patients and Caregivers: Estimates from a Cross-Sectional Study from Portugal
|
Dimitrovova, K.
|
|
|
26 |
12S |
p. S61
|
artikel
|
| 727 |
EE96 Resource Consumption Analysis in Patients with Hemophilia A Without Inhibitors on Prophylaxis with FVIII Before Switching to Emicizumab
|
Giacomini, E.
|
|
|
26 |
12S |
p. S69
|
artikel
|
| 728 |
EE531 Resource Optimization for Greek NHS Hospitals from the Use of Daratumumab SC for Multiple Myeloma
|
Golnas, P.
|
|
|
26 |
12S |
p. S154
|
artikel
|
| 729 |
EE716 Resource Utilisation and Healthcare Costs Among Patients with Age-Related Macular Degeneration (NAMD) in Italy: Findings from the Radiance Observational Substudy
|
Romano, M.R.
|
|
|
26 |
12S |
p. S192
|
artikel
|
| 730 |
EE634 Resource Utilization and Costs Related to Inflammatory Bowel Disease: A Longitudinal Analysis Based on Routine Data from Two German Statutory Health Insurance Providers
|
Mähs, M.
|
|
|
26 |
12S |
p. S175
|
artikel
|
| 731 |
EE51 Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations
|
Sharma, R.
|
|
|
26 |
12S |
p. S59
|
artikel
|
| 732 |
EE410 Retrospective Database Analysis of Healthcare Resource Utilization and Costs in Patients With Vitiligo in Quebec, Canada
|
Lachaine, J.
|
|
|
26 |
12S |
p. S130
|
artikel
|
| 733 |
EE704 Risdiplam for the Treatment of Spinal Muscular Atrophy: Impact on the National Healthcare Service During the First 15 Months of Commercialization in Italy
|
Ghetti, G.
|
|
|
26 |
12S |
p. S190
|
artikel
|
| 734 |
EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia
|
Cheng, J.S.
|
|
|
26 |
12S |
p. S54-S55
|
artikel
|
| 735 |
EE506 RNA Interference Therapies for hATTR Amyloidosis With Polyneuropathy: Differential Healthcare Resource Use and Direct and Indirect Cost Consequences Associated With Vutrisiran Versus Patisiran
|
Kumar, V.
|
|
|
26 |
12S |
p. S149
|
artikel
|
| 736 |
EE618 Sacubitril/Valsartan Vs Enalapril Use in Hospitalized Patients with Heart Failure in Spain
|
Parrondo García, F.J.
|
|
|
26 |
12S |
p. S172
|
artikel
|
| 737 |
EE465 Sacubitril/Valsartan Vs Enalapril Use in the Outpatient Facilities Setting in Spain
|
Parrondo García, F.J.
|
|
|
26 |
12S |
p. S141
|
artikel
|
| 738 |
EE462 Same Day Discharge after Percutaneous Transluminal Coronary Angioplasty (PTCA): Is It Cost Saving?
|
Respigo, R.
|
|
|
26 |
12S |
p. S140
|
artikel
|
| 739 |
EE204 Saving Lives through Early Access: Exploring the Impact of a Managed Access Agreement in Adjuvant EGFRm NSCLC
|
Verhoek, A.
|
|
|
26 |
12S |
p. S90
|
artikel
|
| 740 |
EE685 Screen-and-Treat Cervical Cancer Screening Strategy Using High-Risk HPV Testing: Early Evaluation for Uganda
|
Sultanov, M.
|
|
|
26 |
12S |
p. S186
|
artikel
|
| 741 |
EE599 Selection of Post-Patient Death Caregiver and Family Utilities When Estimating Spillover Effects
|
Hawkins, N.
|
|
|
26 |
12S |
p. S168
|
artikel
|
| 742 |
EE296 Should Hospitals Do Contract Research? Costs, Net Monetary Benefit, and Return on Public Sector Investments in Research at Kuopio University Hospital
|
Väätäinen, S.
|
|
|
26 |
12S |
p. S107-S108
|
artikel
|
| 743 |
EE35 Social and Economic Burden of Hepatitis C in Russia
|
Avxentyev, N.A.
|
|
|
26 |
12S |
p. S56
|
artikel
|
| 744 |
EE17 Societal Burden of Non-Alcoholic Steatohepatitis (NASH) in Denmark - Real-World Evidence from National Registries
|
Rudolfsen, J.H.
|
|
|
26 |
12S |
p. S53
|
artikel
|
| 745 |
EE641 Socioeconomic Status and Economic Burden of Pertussis in Adults: Post-Hoc Analyses of a Retrospective Database Study in England
|
Jamet, N.
|
|
|
26 |
12S |
p. S176
|
artikel
|
| 746 |
EE311 Starts with Sacubitril/Valsartan in the Inpatient Vs Outpatient Setting in Spain
|
Parrondo García, F.J.
|
|
|
26 |
12S |
p. S111
|
artikel
|
| 747 |
EE551 Study of Costs of Hereditary Angioedema in Routine Clinical Practice: Economic Impact of the Disease Burden in Spain
|
Cortes Lorenzo, I.
|
|
|
26 |
12S |
p. S158
|
artikel
|
| 748 |
EE149 Surge Capacity for Preserving Accessibility to Primary Healthcare Services during the COVID19 Pandemic in a Middle Income Country
|
Singweratham, N.
|
|
|
26 |
12S |
p. S79
|
artikel
|
| 749 |
EE719 Systematic Literature Review for Monetary Costs Data in Hemophilia
|
Bartlett, C.
|
|
|
26 |
12S |
p. S193
|
artikel
|
| 750 |
EE566 Systematic Literature Review for Utility Data in Haemophilia
|
Bartlett, C.
|
|
|
26 |
12S |
p. S161-S162
|
artikel
|
| 751 |
EE511 Systematic Review of Cost Effectiveness Assessment Reports of Immune Checkpoint Inhibitors in Early and Advanced/Metastatic Stages of Cancer in France
|
Lachaize, C.
|
|
|
26 |
12S |
p. S150
|
artikel
|
| 752 |
EE549 Systematic Review of the Cost Effectiveness of Newborn Screening for Severe Combined Immunodeficiency
|
Maher, A.
|
|
|
26 |
12S |
p. S158
|
artikel
|
| 753 |
EE648 Systematic Review of the Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy
|
Jordan, K.
|
|
|
26 |
12S |
p. S178
|
artikel
|
| 754 |
EE33 Targeted Literature Review on the Economic and Quality of Life Burden Caused by Acne
|
Proshenska, D.
|
|
|
26 |
12S |
p. S55-S56
|
artikel
|
| 755 |
EE299 The Absence of Risk Preferences in Health Economics – What Can We Learn From Transport Economics?
|
Persson, U.
|
|
|
26 |
12S |
p. S108
|
artikel
|
| 756 |
EE426 The Acceptance of Indirect Treatment Comparisons in Pharmacoeconomic Analyses by the Dutch Healthcare Institute (ZIN)
|
Pham, H.A.
|
|
|
26 |
12S |
p. S133
|
artikel
|
| 757 |
EE727 The Budgetary Impact of Introducing Expanded Haemodialysis, Enabled by Theranova (HDX), Compared to High-Flux Haemodialysis (HF-HD) in Private Sector in the Kingdom of Saudi Arabia
|
Mohamed, O.
|
|
|
26 |
12S |
p. S194
|
artikel
|
| 758 |
EE315 The Budget Impact of Including the Automated Time-Resolved Fluorescence Immunoassay As Point-of-Care Testing on Cardiac Markers in an Emergency Department in China
|
Xu, X.
|
|
|
26 |
12S |
p. S111-S112
|
artikel
|
| 759 |
EE237 The Budget Impact of Introducing Automated Hematoxylin and Eosin Staining for Cancer Diagnosis in China
|
Xu, X.
|
|
|
26 |
12S |
p. S97
|
artikel
|
| 760 |
EE588 The Budget Impact of Introducing Robotic-Assisted Surgery for Spinal Fusion Procedures in Spain
|
Álvarez-Sala, F.
|
|
|
26 |
12S |
p. S166
|
artikel
|
| 761 |
EE255 The Budget Impact of Switching From High to Low Carbon Emission Inhalers in England
|
Broadbent, E.G.
|
|
|
26 |
12S |
p. S100
|
artikel
|
| 762 |
EE559 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Honduras, El Salvador, & Dominican Republic
|
Hidalgo, J.
|
|
|
26 |
12S |
p. S160
|
artikel
|
| 763 |
EE742 The Comparative Healthcare Cost between Robotic Esophagectomy and Video-Assisted Esophagectomy for Esophageal Cancer in Japan
|
Hong, Y.E.
|
|
|
26 |
12S |
p. S197
|
artikel
|
| 764 |
EE561 The Comparative Pharmacoeconomic Analysis of Using Different Anti-VEGF Drugs for Diabetic Macular Edema Therapy in Russia
|
Klabukova, D.
|
|
|
26 |
12S |
p. S160-S161
|
artikel
|
| 765 |
EE214 The Cost-Effectiveness of Abemaciclib Combined With Endocrine Therapy (ET) for the Treatment of Persons With HR+, HER2- Node Positive, Early Breast Cancer (EBC) at High Risk of Recurrence: A Spanish Healthcare Perspective
|
Davie, A.
|
|
|
26 |
12S |
p. S92
|
artikel
|
| 766 |
EE192 The Cost-Effectiveness of a Bimekizumab Versus Secukinumab Treatment Pathway in Patients with Active Axial Spondyloarthritis in Scotland
|
Mørup, M.F.
|
|
|
26 |
12S |
p. S88
|
artikel
|
| 767 |
EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US
|
Pang, F.
|
|
|
26 |
12S |
p. S126
|
artikel
|
| 768 |
EE558 The Cost-Effectiveness of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Salmeterol/Fluticasone Plus As-Needed Salbutamol Among Asthma Patients ≥12 Years in China
|
Zhou, K.
|
|
|
26 |
12S |
p. S160
|
artikel
|
| 769 |
EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China
|
Guo, J.
|
|
|
26 |
12S |
p. S65
|
artikel
|
| 770 |
EE416 The Cost-Effectiveness of WaveWriter Alpha Spinal Cord Stimulation System in a Swedish Setting
|
Norlin, J.
|
|
|
26 |
12S |
p. S131
|
artikel
|
| 771 |
EE479 The Cost of Treating Gastroesophageal Reflux Disease: A Systematic Review
|
Hoffsten, J.
|
|
|
26 |
12S |
p. S143
|
artikel
|
| 772 |
EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)
|
Aburmilah, A.
|
|
|
26 |
12S |
p. S112
|
artikel
|
| 773 |
EE423 The Cost Savings Potential Associated with the Use of Nefecon for Adults with Primary IgA Nephropathy in the United States
|
Yaghoubi, M.
|
|
|
26 |
12S |
p. S132
|
artikel
|
| 774 |
EE642 The Costs of Oral Antiviral Delivery in UK Clinical Practice: Expert Opinion Survey
|
Butfield, R.
|
|
|
26 |
12S |
p. S176-S177
|
artikel
|
| 775 |
EE409 The Costs of Unaddressed Hearing Loss as a Basis for Cost-Effectiveness Analyses
|
Schwarz, C.
|
|
|
26 |
12S |
p. S129-S130
|
artikel
|
| 776 |
EE663 The Disease and Economic Burden of Hepatocellular Carcinoma in Australia
|
Gao, L.
|
|
|
26 |
12S |
p. S181
|
artikel
|
| 777 |
EE624 The Economic Burden of Macrovascular Complications of Diabetes in Algeria
|
Mansouri, K.
|
|
|
26 |
12S |
p. S173
|
artikel
|
| 778 |
EE348 The Economic Burden of Multiple Sclerosis in an Italian Cohort of Patients: Analysis of Disease Cost and Its Components
|
Ponzio, M.
|
|
|
26 |
12S |
p. S118
|
artikel
|
| 779 |
EE630 The Economic Burden of Obesity in 4 Selected South-Eastern European Countries: Healthcare Resource Use and Costs Associated with Obesity-Related Comorbidities
|
Athanasakis, K.
|
|
|
26 |
12S |
p. S174
|
artikel
|
| 780 |
EE539 The Economic Burden of Systemic Drug Therapy Administration Route in Treating HER2-Positive Breast Cancer for Patients, Healthcare Professionals, and Healthcare System: A Systematic Literature Review
|
Landeiro, L.C.G.
|
|
|
26 |
12S |
p. S156
|
artikel
|
| 781 |
EE391 The Economic Burden of Varicella Among Children in France: A Societal Perspective
|
Samant, S.
|
|
|
26 |
12S |
p. S126
|
artikel
|
| 782 |
EE404 The Economic Burden That Respiratory Syncytial Virus (RSV) Imposes on Irish Hospitals
|
Patterson, K.
|
|
|
26 |
12S |
p. S128
|
artikel
|
| 783 |
EE236 The Economic Impact of Third Line Chronic Phase Chronic Myeloid Leukemia Treatment in Greece From a National Payer Perspective
|
Tychala, C.
|
|
|
26 |
12S |
p. S96
|
artikel
|
| 784 |
EE252 The Economic Implication of Sinus Rapid Relief Pathway in Italy: Awake Surgery Vs General Anesthesia to Guarantee Quick Access to Patients Who Needs Sinus Surgery
|
Tito, F.
|
|
|
26 |
12S |
p. S99
|
artikel
|
| 785 |
EE710 The Environmental, Healthcare, and Societal Impact of Asthma Pathway in the UK: A Cost-of-Illness Study
|
Orlovic, M.
|
|
|
26 |
12S |
p. S191
|
artikel
|
| 786 |
EE468 The Full Circle: Systematic Evaluation, Replication and Validation of Structural Health Economic Modelling Approaches: Lessons Learned in the Field of Obesity
|
Schwander, B.
|
|
|
26 |
12S |
p. S141
|
artikel
|
| 787 |
EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome
|
Bitchell, L.
|
|
|
26 |
12S |
p. S190
|
artikel
|
| 788 |
EE5 The Health Return on Investment (ROI) Assessor: Evaluating Novel Cardiovascular Disease (CVD) Prevention Approaches in Estonia
|
Hernandez-Villafuerte, K.
|
|
|
26 |
12S |
p. S50
|
artikel
|
| 789 |
EE640 The Impact of Blue-Light Emitting Device on the Loss of Productivity From COVID-19 in North Carolina
|
Caterino, M.
|
|
|
26 |
12S |
p. S176
|
artikel
|
| 790 |
EE251 The Impact of Cesarean Birth Complications on Maternal and Infant Health in the World and Turkiye
|
Erkut, Y.
|
|
|
26 |
12S |
p. S99
|
artikel
|
| 791 |
EE761 The Impact of Differences in Patient Demographics on Assessment of Long-Term Cost-Effectiveness in Cohort Level Economic Models
|
Edmonds, T.
|
|
|
26 |
12S |
p. S201
|
artikel
|
| 792 |
EE544 The Impact of Pulmonary Arterial Hypertension in the Brazilian Public Healthcare System: A Microcosting Approach Based on Expert's Opinion
|
Duva, A.
|
|
|
26 |
12S |
p. S157
|
artikel
|
| 793 |
EE205 The Impact of the COVID-19 Pandemic on Physician Visits Among Patients Diagnosed with Breast Cancer and Heart Failure in the United States
|
Hsu, C.Y.
|
|
|
26 |
12S |
p. S90
|
artikel
|
| 794 |
EE683 The Impact of Tumor Treating Fields (TTFields) Therapy Usage on Cost-Effectiveness: An Analysis of the Incremental Cost-Effectiveness Ratio (ICER)
|
Nino de Rivera Guzman, J.
|
|
|
26 |
12S |
p. S185
|
artikel
|
| 795 |
EE349 The Impact of Using Real-World Data on the Cost-Effectiveness of Fremanezumab for Migraine Prevention in a UK Healthcare Perspective Analysis
|
Sacco, S.
|
|
|
26 |
12S |
p. S118
|
artikel
|
| 796 |
EE152 The Implicit Devaluation of Health Benefits Over Time in NICE Decision-Making Criteria: Assessing NICE’s Static Willingness to Pay Threshold in the Context of Inflation.
|
Percival, C.
|
|
|
26 |
12S |
p. S79
|
artikel
|
| 797 |
EE527 The Indirect Costs and Burden of Vaccine Preventable Cancers Mortality in Middle East and North Africa (MENA) Countries
|
Bencina, G.
|
|
|
26 |
12S |
p. S153
|
artikel
|
| 798 |
EE280 The Lean Assessment Process (LAP) Methodology: An Iterative and Multi-Disciplinary Method for Identifying Clinical Needs, Assessing Technology Acceptance, a Precursor for Early Economic Evaluation and Adoption Strategies
|
Bajre, M.
|
|
|
26 |
12S |
p. S105
|
artikel
|
| 799 |
EE139 The Need for Economic Systems Modelling to Assess the True Value of Healthcare Innovations: An Application to Influenza Vaccinations
|
Romanelli, R.
|
|
|
26 |
12S |
p. S77
|
artikel
|
| 800 |
EE629 The Obesity Burden and Impact of Weight Loss on Saudi Public Payers Using Value of Weight Loss Simulation Model
|
Alqhatani, S.
|
|
|
26 |
12S |
p. S174
|
artikel
|
| 801 |
EE392 The Potential Impact of Delandistrogene Moxeparvovec on Work Productivity on Individuals With Duchenne Muscular Dystrophy in the United States (US)
|
Innis, B.
|
|
|
26 |
12S |
p. S126
|
artikel
|
| 802 |
EE627 The Potential Value of Identifying Type 2 Diabetes Subgroups in the CPRD Cohort for Guiding Intensive Treatment: A HTx Study Comparing Novel Data-Driven Clustering to Traditional Risk-Driven Subgroups
|
Li, X.
|
|
|
26 |
12S |
p. S173-S174
|
artikel
|
| 803 |
EE661 The Quality of Economic Evaluations of Breast Cancer for Diagnostics, Screening, and Therapeutics in the Middle East: A Targeted Literature Review
|
Dasari, A.
|
|
|
26 |
12S |
p. S180-S181
|
artikel
|
| 804 |
EE259 The Societal Cost of Age-Related Macular Degeneration and Diabetic Macular Edema: An Estimation Using a Pragmatic Literature Review
|
Gerves-Pinquie, C.
|
|
|
26 |
12S |
p. S101
|
artikel
|
| 805 |
EE547 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the United States
|
Bean, K.
|
|
|
26 |
12S |
p. S157-S158
|
artikel
|
| 806 |
EE157 The Societal Impact of Inclisiran Using Population Health Approaches Across 15 Countries
|
Ostwald, D.A.
|
|
|
26 |
12S |
p. S80
|
artikel
|
| 807 |
EE136 The Socio-Economic Value of Adult Immunization: Results from a Comprehensive Literature Review of Four Immunization Programs in Ten Countries
|
El Banhawi, H.
|
|
|
26 |
12S |
p. S76
|
artikel
|
| 808 |
EE113 The Use of Ferric Carboxymaltose for Pregnant and Postpartum Women in Brazil: Estimation of Target Poputation and Budget Impact Analysis from the Public Health Care System Perspective
|
Campagnaro, M.
|
|
|
26 |
12S |
p. S72
|
artikel
|
| 809 |
EE367 The Use of Genomic Tests for Early Breast Cancer in Finland Is Likely to be Cost-Effective at Common WTP Threshold
|
Marocco, C.
|
|
|
26 |
12S |
p. S121
|
artikel
|
| 810 |
EE608 The Use of Vignette Studies to Estimate Health-State Preference in Sweden and Norway
|
Bottazzi, L.
|
|
|
26 |
12S |
p. S170
|
artikel
|
| 811 |
EE585 Threshold Price Analysis of Micro-Hole Zone Technology Catheters Compared to Standard Hydrophilic-Coated Catheters in Long-Term Intermittent Catheter Users in the UK
|
Cawson, M.
|
|
|
26 |
12S |
p. S165
|
artikel
|
| 812 |
EE678 Time and Cost Savings from Adopting an Alternative Dosing Schedule with Pembrolizumab for Patients with Advanced Melanoma in Greece
|
Draganigos, A.
|
|
|
26 |
12S |
p. S184
|
artikel
|
| 813 |
EE625 Time in Range As Alternative to HBA1C Change in the IQVIA Core Diabetes Model
|
Martins, L.
|
|
|
26 |
12S |
p. S173
|
artikel
|
| 814 |
EE606 Tools for the Critical Appraisal of Health Economic Analyses: A Scoping Review
|
Dalmas Gräf, D.
|
|
|
26 |
12S |
p. S170
|
artikel
|
| 815 |
EE664 Total Direct Costs of Ovarian Cancer in Colombia: A National Cohort Study Based on Administrative Claims Databases
|
Buitrago, G.
|
|
|
26 |
12S |
p. S181
|
artikel
|
| 816 |
EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France
|
Kirion, J.
|
|
|
26 |
12S |
p. S79
|
artikel
|
| 817 |
EE449 Uncertainty Around HRQoL Values Is Under-Reported: Are We Misleading Decision Makers?
|
Devlin, N.
|
|
|
26 |
12S |
p. S137-S138
|
artikel
|
| 818 |
EE394 Understanding Reasons of Negative Reimbursement Decisions for Orphan Drugs in the Spanish National Health System (APRIL 2019-MAY 2023)
|
Gil, A.
|
|
|
26 |
12S |
p. S126
|
artikel
|
| 819 |
EE212 Understanding Service Use for Melanoma in the UK National Health Service: An Expert Elicitation Exercise Using a New Method for Eliciting Proportions
|
Hainsworth, R.
|
|
|
26 |
12S |
p. S91-S92
|
artikel
|
| 820 |
EE583 Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review
|
Gautam, R.
|
|
|
26 |
12S |
p. S165
|
artikel
|
| 821 |
EE412 Unraveling the Disease Burden of Generalized Pustular Psoriasis: A Comparative Analysis of Flares with Psoriasis Vulgaris in Taiwan
|
Tseng, C.Y.
|
|
|
26 |
12S |
p. S130
|
artikel
|
| 822 |
EE319 Update to the Macrovascular Submodels of the IQVIA Core Diabetes Model
|
Martins, L.
|
|
|
26 |
12S |
p. S112
|
artikel
|
| 823 |
EE150 Usage of Social Return on Investment Modelling in the Analysis of Healthcare Interventions: A Review of Current Utilization
|
Harrop, D.
|
|
|
26 |
12S |
p. S79
|
artikel
|
| 824 |
EE589 Use of Copulas for Correlated Sampling of Cost and Utility Parameters During Probabilistic Sensitivity Analysis for Cost-Effectiveness Analyses
|
Lim, S.
|
|
|
26 |
12S |
p. S166
|
artikel
|
| 825 |
EE339 Use of Dalbavancin in the Treatment of Pediatric Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis
|
Rios, M.
|
|
|
26 |
12S |
p. S116
|
artikel
|
| 826 |
EE187 Use of Resources and Economic Cost of People Living with HIV in the Brazilian Supplementary Health System
|
Tanaka, S.
|
|
|
26 |
12S |
p. S87
|
artikel
|
| 827 |
EE430 Use of Single-Arm Trials in Health Technology Assessment Reviews of Axicabtagene Ciloleucel
|
Zhang, E.
|
|
|
26 |
12S |
p. S133-S134
|
artikel
|
| 828 |
EE153 Using a Cumulative Low-Density Lipoprotein Cholesterol Modelling Approach to Estimate the Reduction of Risk of Atherosclerotic Cardiovascular Events from a Primary Prevention Program
|
Clayson, M.
|
|
|
26 |
12S |
p. S79-S80
|
artikel
|
| 829 |
EE760 Using Discrete Choice Experiment to Elicit Treatment Preferences for Acute Allergic Reactions in Sweden: The Case of Patients with Swallowing Problems
|
Löfvendahl, S.
|
|
|
26 |
12S |
p. S200-S201
|
artikel
|
| 830 |
EE13 Using Sensor-Based Glucose Monitors Dominates Self-Monitoring of Blood Glucose for Adults with Type 1 Diabetes in the Danish Healthcare Setting
|
Sørensen, A.
|
|
|
26 |
12S |
p. S52
|
artikel
|
| 831 |
EE351 Using Social Return on Investment to Capture the Broader Impact of Medicines: Advanced Parkinson's Disease Example
|
Mikolaizak, S.
|
|
|
26 |
12S |
p. S118
|
artikel
|
| 832 |
EE243 Utilization of Healthcare Resources and Costs of Hemolytic Disease of Fetus and Newborn (HDFN) in Israel
|
Fallach, N.
|
|
|
26 |
12S |
p. S97-S98
|
artikel
|
| 833 |
EE306 Utilizing Real World Evidence for Cost-Effectiveness Analysis of the Disease Management Program for Chronic Heart Failure Herzmobil Tirol
|
Jahn, B.
|
|
|
26 |
12S |
p. S109-S110
|
artikel
|
| 834 |
EE43 Utilizing Real-World Evidence to Estimate Treatment Costs Among Norwegian Patients with Myasthenia Gravis Treated with Intravenous Immunoglobulin (IVIG)
|
Bugge, C.
|
|
|
26 |
12S |
p. S58
|
artikel
|
| 835 |
EE354 Value for Money: Evaluating the Economic Benefit of a Hypothetical Disease Modifying Therapy for Alzheimer's Disease From Canadian Payer and Societal Perspectives
|
Maity, T.
|
|
|
26 |
12S |
p. S119
|
artikel
|
| 836 |
EE302 Value of End-of-Life Health Gains
|
Bobinac, A.
|
|
|
26 |
12S |
p. S109
|
artikel
|
| 837 |
EE283 Value of Information Analyses for Advanced Cell Therapies: A Systematic Review
|
Heaps, A.
|
|
|
26 |
12S |
p. S105
|
artikel
|
| 838 |
EE646 Waiting Times and Cost-Effectiveness: An Early Case Study in Cognitive Behavioral Therapy for Anxiety
|
Naylor, R.
|
|
|
26 |
12S |
p. S177-S178
|
artikel
|
| 839 |
EE227 Waldenstrom's Macroglobulinemia: An Overview of Treatment Patterns, Resource Use, and Costs From the Brazilian Private Healthcare Perspective
|
Macedo, M.
|
|
|
26 |
12S |
p. S95
|
artikel
|
| 840 |
EE562 What Is More Valuable Than Optimal Resource Use? The Development of Interactive Tool Visualizing the Costs and Time Consumption Related to Diabetic Macular Edema’s Intravitreal Treatments in Finland
|
Teittinen, P.
|
|
|
26 |
12S |
p. S161
|
artikel
|
| 841 |
EE50 What Is the Economic Impact of an Early Adoption of High Efficacy Treatments in Multiple Sclerosis? A Cost-Consequence Analysis From a Societal Perspective in the Portuguese Setting
|
Gonçalves, N.
|
|
|
26 |
12S |
p. S59
|
artikel
|
| 842 |
EE454 What Is the Goal of Value-Based Pricing, and to Whom Is Value Created?
|
Vassoler, H.
|
|
|
26 |
12S |
p. S138-S139
|
artikel
|
| 843 |
EE759 Willingness-To-Pay for a QALY: A New Approach to Estimate Cost-Effectiveness Threshold Applied to France
|
Tehard, B.
|
|
|
26 |
12S |
p. S200
|
artikel
|
| 844 |
EE295 Willingness to Pay for COVID-19 Vaccines in Hungary
|
Beretzky, Z.
|
|
|
26 |
12S |
p. S107
|
artikel
|
| 845 |
EE447 Working With Probabilistic Models for Cost-Effectiveness Analysis: Computational Tools Integrating Exact Methods vs Simulation-Based Approaches
|
Figueiredo, D.
|
|
|
26 |
12S |
p. S137
|
artikel
|
| 846 |
EE368 Would Initiating Colorectal Cancer Screening from Age of 45 Be Cost-Effective in Germany? An Individual-Level Simulation Analysis
|
Lwin, M.
|
|
|
26 |
12S |
p. S121-S122
|
artikel
|
| 847 |
EPH86 Access to a First Disease-Modifying Therapy Leads to a Disproportionate Increase in the Patient Population Diagnosed with a Rare Disease
|
Tschumi, B.
|
|
|
26 |
12S |
p. S218
|
artikel
|
| 848 |
EPH166 Access Trends to Cardiac Implantable Electronic Devices in the Brazilian Public Healthcare System: A Twelve-Year Real World Data Analysis
|
Marcolino, M.
|
|
|
26 |
12S |
p. S234
|
artikel
|
| 849 |
EPH208 Adoption of Precision Health (PH) and Precision Medicine (PM) Approaches in Addressing Population Health Needs in Europe
|
Sablek, A.
|
|
|
26 |
12S |
p. S241
|
artikel
|
| 850 |
EPH75 Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)
|
Almutairi, R.
|
|
|
26 |
12S |
p. S216
|
artikel
|
| 851 |
EPH221 Age, Sex, and Comorbidity Differences Between Patients with Mild and Severe Aortic Stenosis in German Cardiology Practices
|
Kostev, K.
|
|
|
26 |
12S |
p. S243
|
artikel
|
| 852 |
EPH263 Algorithmic Public Health? The Path Towards AI-Assisted Health Promotion
|
Navrátil, M.
|
|
|
26 |
12S |
p. S251
|
artikel
|
| 853 |
EPH123 A Machine Augmented Systematic Literature Review: Prevalence of Coinfections in COVID-19 Patients During Early and Late Pandemic Periods
|
Patel, D.
|
|
|
26 |
12S |
p. S226
|
artikel
|
| 854 |
EPH21 An Assessment of Validated Algorithms for Identifying Multiple Sclerosis Cases, Subtypes, and Relapses in Real-World Databases: A Systematic Review
|
Albalawi, O.
|
|
|
26 |
12S |
p. S206
|
artikel
|
| 855 |
EPH59 An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy
|
Butzner, M.
|
|
|
26 |
12S |
p. S213
|
artikel
|
| 856 |
EPH77 An Incidence- and Survival-Based Epidemiological Model for the Prevalence of Duchenne Muscular Dystrophy in Nine Countries
|
Lorenz, C.
|
|
|
26 |
12S |
p. S216
|
artikel
|
| 857 |
EPH197 An Integrated Modelling Methodology for Estimating Global, Regional, and Country-Specific Incidence and Prevalence of Tay-Sachs Disease at the Subtype Level
|
Buffel, C.
|
|
|
26 |
12S |
p. S239
|
artikel
|
| 858 |
EPH144 Annual Health Insurance Treatment Cost of Female Infertility, Unspecified Based on Routinely Collected Financing Data Between 2010-2019
|
Pónusz-Kovács, D.
|
|
|
26 |
12S |
p. S230
|
artikel
|
| 859 |
EPH198 Annual Health Insurence Treatment Cost of Polycystic Ovary Sindrome Based on Routinely Collected Financing Data Between 2010-2019
|
Pónusz-Kovács, D.
|
|
|
26 |
12S |
p. S239
|
artikel
|
| 860 |
EPH267 A Quinquennial Review of the WHO’s Global Call for Action to Eliminate Cervical Cancer - an Indian Perspective
|
Santpurkar, N.
|
|
|
26 |
12S |
p. S252
|
artikel
|
| 861 |
EPH111 A Real-World Study of the Relationship between Lipoprotein(A) [Lp(A)] Concentrations and Atherosclerotic Cardiovascular Disease (ASCVD) Prognosis, Healthcare Resource Utilization and Medical Costs in Chinese Patients
|
Jian, Y.
|
|
|
26 |
12S |
p. S223
|
artikel
|
| 862 |
EPH181 Are Social Networks Harming Our Teens? Assessing the Plausibility of a Link between Social Network Use and Depression Using a Microsimulation Model
|
Leleu, H.
|
|
|
26 |
12S |
p. S236
|
artikel
|
| 863 |
EPH162 A Retrospective Analysis of the Public Health Product Tax in Hungary, 2011-2022
|
Csákvári, T.
|
|
|
26 |
12S |
p. S233-S234
|
artikel
|
| 864 |
EPH139 A Retrospective Cohort Study of Pediatric Patients Undergoing Percutaneous Vascular Procedures
|
Melis, G.
|
|
|
26 |
12S |
p. S229
|
artikel
|
| 865 |
EPH78 A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs
|
Gold, A.
|
|
|
26 |
12S |
p. S216-S217
|
artikel
|
| 866 |
EPH51 Artificial Intelligence (AI) Tools for Outbreak Detection and Response: A Transnational Platform for Surveillance, Monitoring and Decision Support
|
Génin, M.
|
|
|
26 |
12S |
p. S211-S212
|
artikel
|
| 867 |
EPH26 Assessing Cancer Related Premature Mortality and Productivity Loss in Lung, Melanoma, and Breast Cancers in European Regions: Temporal Trends in 2010-2019
|
Brandtmuller, A.
|
|
|
26 |
12S |
p. S207
|
artikel
|
| 868 |
EPH165 Assessing Public Health Models in France: A Systematic Review
|
Moreau, R.
|
|
|
26 |
12S |
p. S234
|
artikel
|
| 869 |
EPH101 Assessing the Relative Benefits Associated With Developing Vaccines for Nipah Virus Infection and Rift Valley Fever From Local, National, and Global Perspectives
|
Gani, R.
|
|
|
26 |
12S |
p. S221
|
artikel
|
| 870 |
EPH113 Assessment of the Quality of Life in Patients With Acute Ischemic Stroke Diagnosed With Brainomix Artificial Intelligence-Based System, Under Different Therapeutic Approaches (Standard Treatment, Thrombolysis, Thrombectomy)
|
Kovács, B.
|
|
|
26 |
12S |
p. S224
|
artikel
|
| 871 |
EPH125 A Systematic Literature Review and Meta-Analysis on the Disease Burden of Chikungunya
|
Tiozzo, G.
|
|
|
26 |
12S |
p. S226
|
artikel
|
| 872 |
EPH252 A Systematic Review of the Global Burden of Endometriosis
|
Gordois, A.
|
|
|
26 |
12S |
p. S249
|
artikel
|
| 873 |
EPH28 Burden of Chronic Lymphocytic Leukemia in the United States: A Review of Literature
|
Bisen, R.
|
|
|
26 |
12S |
p. S207
|
artikel
|
| 874 |
EPH155 Burden of Clinical Syndromes Associated with Pneumococcal Disease in Peru: A 2019 Perspective
|
Mezones-Holguin, E.
|
|
|
26 |
12S |
p. S232
|
artikel
|
| 875 |
EPH37 Burden of Disease and Cost of Illness of Age Related Macular Degeneration and Diabetic Macular Edema in Portugal
|
Gouveia, M.
|
|
|
26 |
12S |
p. S209
|
artikel
|
| 876 |
EPH4 Burden of Disease and Cost of Permanent Productivity Loss of Cardiovascular Disease (CVD) in South America (SA)
|
Bandeira, T.F.G.D.S.
|
|
|
26 |
12S |
p. S203
|
artikel
|
| 877 |
EPH84 Burden of Respiratory Syncytial Virus in Children ≤ 2 Years of Age in Germany: Retrospective Analysis of Health Claims Data from 2014-2019
|
Beese, C.
|
|
|
26 |
12S |
p. S218
|
artikel
|
| 878 |
EPH14 Burden of Respiratory Syncytial Virus Infection in Germany: A Systematic Review
|
Poshtiban, A.
|
|
|
26 |
12S |
p. S205
|
artikel
|
| 879 |
EPH178 Burden of the Disease and Management in COVID-19 Hospitalized Patients in MSO and Home Care in France: COVID-Hosp Study (2020-2022)
|
Pozzar, M.
|
|
|
26 |
12S |
p. S236
|
artikel
|
| 880 |
EPH32 Canadian Pustular Psoriasis Study (CAPPS): Examining Disease Burden, Treatments, and Healthcare Resource Utilization for Generalized Pustular Psoriasis Flares
|
Milan, R.
|
|
|
26 |
12S |
p. S208
|
artikel
|
| 881 |
EPH41 Cardiovascular and Renal Replacement Risks in Patients with Sub-Optimally Treated Anemia of Non-Dialysis-Dependent Chronic Kidney Disease
|
Shaheen, F.
|
|
|
26 |
12S |
p. S210
|
artikel
|
| 882 |
EPH254 Changes in Asthma-Related Healthcare Resource Use in Asthma Patients in the United States During the COVID-19 Pandemic
|
Packnett, E.
|
|
|
26 |
12S |
p. S250
|
artikel
|
| 883 |
EPH24 Changes in Prescribing of Systemic Cancer Therapies in England: A Nationwide Analysis of Community and Hospital Medicines Utilisation
|
Selle Arocha, L.
|
|
|
26 |
12S |
p. S207
|
artikel
|
| 884 |
EPH70 Claims Data Analysis of Health Care Resource Use and Costs of Respiratory Syncytial Virus Prevention in Infants in Germany
|
Kliemt, R.
|
|
|
26 |
12S |
p. S215
|
artikel
|
| 885 |
EPH95 Claims Data Analysis of the Prevalence and Healthcare Resource Utilization of Chronic Kidney Disease-Associated Pruritus in German Hemodialysis Patients
|
Stremel, T.
|
|
|
26 |
12S |
p. S220
|
artikel
|
| 886 |
EPH85 Clinical Burden of GM2 Gangliosidoses in the United States (US): A Retrospective Observational Cohort Study Using Electronic Health Records (EHR)
|
Rodriguez, M.B.
|
|
|
26 |
12S |
p. S218
|
artikel
|
| 887 |
EPH190 Clinical Characteristics and Treatment Patterns of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Mexico
|
Flores- Caballero, M.A.
|
|
|
26 |
12S |
p. S238
|
artikel
|
| 888 |
EPH81 Clinical Characteristics and Treatment Patterns of Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)
|
Flores- Caballero, M.A.
|
|
|
26 |
12S |
p. S217
|
artikel
|
| 889 |
EPH114 Clinical Characteristics, Average Cost Per Visit, and Major Adverse Cardiovascular Events in Patients with Diagnosed Chronic Kidney Disease Combined with Cardiovascular Disease: A Study from a Large Healthcare Database in China
|
Wang, M.
|
|
|
26 |
12S |
p. S224
|
artikel
|
| 890 |
EPH250 Clinical Characteristics of Generalized Pustular Psoriasis Flares in the Real-World Setting
|
Lavasani, L.
|
|
|
26 |
12S |
p. S249
|
artikel
|
| 891 |
EPH153 Clinical Characterization and Healthcare Resource Utilization in Adrenoleukodystrophy: A Nationwide Retrospective Cohort Using Swedish National Registries
|
Chowdhury, M.
|
|
|
26 |
12S |
p. S232
|
artikel
|
| 892 |
EPH223 Clinical, Economic, and Humanistic Burden of Atherosclerotic Cardiovascular Disease (ASCVD) and Familial Hypercholesterolemia (FH) in Latin America: A Scoping Review (SR)
|
Natani, H.
|
|
|
26 |
12S |
p. S244
|
artikel
|
| 893 |
EPH227 Clinical, Economic, and Patient-Reported Impact of Obesity in Selected European Countries: A Systematic Review
|
Artime, E.
|
|
|
26 |
12S |
p. S245
|
artikel
|
| 894 |
EPH171 Clinical, Economic, and Patient-Reported Impact of Obesity in the Asia-Pacific Region: A Systematic Review
|
Artime, E.
|
|
|
26 |
12S |
p. S235
|
artikel
|
| 895 |
EPH176 Comorbidities Among Individuals at Risk to Develop Severe Form of COVID-19 in Case of Sars-Cov-2 Infection
|
Guyot, E.
|
|
|
26 |
12S |
p. S235
|
artikel
|
| 896 |
EPH94 Comparative Analysis of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Nationwide US Medicare Perspective
|
Gerstley, H.
|
|
|
26 |
12S |
p. S220
|
artikel
|
| 897 |
EPH121 Contraindicated Remdesivir Use Among Individuals Hospitalized Due to COVID-19: According to the Danish Treatment Guidelines
|
Hoe, J.
|
|
|
26 |
12S |
p. S225
|
artikel
|
| 898 |
EPH202 Current Policy, Clinical and Economic Environment of Eye Care and Vision Health in Bulgaria
|
Ivanova, L.
|
|
|
26 |
12S |
p. S240
|
artikel
|
| 899 |
EPH163 Dental Preventive Examinations and Caries Prevalence in Children Aged 8-14 Years
|
Bebesi, D.
|
|
|
26 |
12S |
p. S234
|
artikel
|
| 900 |
EPH138 Descriptive Analysis of Communication About Cancer Prevention and Screening on the Social Network Twitter
|
Cavallucci, M.
|
|
|
26 |
12S |
p. S229
|
artikel
|
| 901 |
EPH157 Developing an Analysis to Determine the Value of Time When Delaying the Who's Seasonal Influenza Vaccine Strain Selection Recommendation
|
Reynard, C.
|
|
|
26 |
12S |
p. S233
|
artikel
|
| 902 |
EPH23 Diagnosis Patterns in Breast Cancer Women in Brazil: Inequities Among Public and Private Settings in São Paulo State
|
Julian, G.
|
|
|
26 |
12S |
p. S207
|
artikel
|
| 903 |
EPH217 Discriminant Validity of EQ-5D-Y-3L Between Children-Reported Health-Related Quality of Life and Parent-Reported Developmental Disabilities
|
Wong, E.
|
|
|
26 |
12S |
p. S243
|
artikel
|
| 904 |
EPH119 Disease Burden and Cost-of-Illness of Hepatocellular Carcinoma in Portugal: A Model-Based Analysis Considering the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm System
|
Martins, P.
|
|
|
26 |
12S |
p. S225
|
artikel
|
| 905 |
EPH69 Disease Burden of Patients With Antibiotic-Resistant Bacteria (Extended-Spectrum Beta-Lactamase or Carbapenem-Resistant Enterobacteriaceae) in Korea
|
Gil, H.Y.
|
|
|
26 |
12S |
p. S215
|
artikel
|
| 906 |
EPH148 Disease Burden of Sickle Cell Disease in Saudi Arabia
|
Bouguerra, H.
|
|
|
26 |
12S |
p. S231
|
artikel
|
| 907 |
EPH130 Drug Utilization Patterns of Guanfacine Hydrochloride Indicated for Attention Deficit Hyperactivity Disorder in European Countries
|
von Bredow, D.
|
|
|
26 |
12S |
p. S227
|
artikel
|
| 908 |
EPH83 Ecological Study of the Incidence and Prevalence of Cancer Associated with Social Determinants of Health
|
Richards, M.
|
|
|
26 |
12S |
p. S218
|
artikel
|
| 909 |
EPH268 Effectiveness of Pneumococcal Vaccination in Older Adults in a Real-World Setting: A Systematic Review and Meta-Analysis of Observational Studies Using Test-Negative Designs
|
Wolf, A.
|
|
|
26 |
12S |
p. S252
|
artikel
|
| 910 |
EPH105 Effects of Abortion Debate on Fertility Intentions of Women of Childbearing Age
|
Wang, J.
|
|
|
26 |
12S |
p. S222
|
artikel
|
| 911 |
EPH249 Effects of Adolescent MenACWY and MenC Vaccination in Germany: A Modelling Study
|
Gruhn, S.
|
|
|
26 |
12S |
p. S248-S249
|
artikel
|
| 912 |
EPH118 Elevated Amputation Rates in Painful Diabetic Polyneuropathy: Insights from a Real-World Large Payer Data Set
|
Siegel, E.
|
|
|
26 |
12S |
p. S225
|
artikel
|
| 913 |
EPH89 Epidemiological Disease Burden of Female Infertility, N.O.S, Based on Routinely Collected Health Insurance Claims Data Between 2010-2019
|
Pónusz-Kovács, D.
|
|
|
26 |
12S |
p. S219
|
artikel
|
| 914 |
EPH146 Epidemiological Insights in Cutaneous Lupus Erythematosus: A Systematic Literature Review
|
Rai, P.
|
|
|
26 |
12S |
p. S230
|
artikel
|
| 915 |
EPH67 Epidemiology and Economic Burden of Tick-Borne Encephalitis Hospitalizations in Mainland France: 2014-2021 Analysis of the PMSI Database
|
Benhamou, J.
|
|
|
26 |
12S |
p. S214
|
artikel
|
| 916 |
EPH39 Epidemiology and Patient Characteristics of Pemphigus Vulgaris in Italy Based on Administrative Database
|
De Ruyck, F.
|
|
|
26 |
12S |
p. S209
|
artikel
|
| 917 |
EPH204 Epidemiology and Patient Characteristics of Pemphigus Vulgaris in UK: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)
|
Blein, C.
|
|
|
26 |
12S |
p. S240
|
artikel
|
| 918 |
EPH253 Epidemiology Disease Burden of Polycistic Ovary Syndrome Based on Routinely Collected Health Insurence Claims Data Between 2010-2019
|
Pónusz-Kovács, D.
|
|
|
26 |
12S |
p. S249
|
artikel
|
| 919 |
EPH240 Epidemiology, Economic Burden, and Humanistic Burden in Multiple Sclerosis Spasticity (MSS): A Systematic Literature Review (SLR)
|
Drachenberg, C.
|
|
|
26 |
12S |
p. S247
|
artikel
|
| 920 |
EPH161 Epidemiology Landscape and Impact of Obesity: Multi-Country Results from the Impact-O Study
|
Artime, E.
|
|
|
26 |
12S |
p. S233
|
artikel
|
| 921 |
EPH201 Epidemiology of Actinic Keratosis in France: A General Population Survey (REAKT STUDY)
|
Dréno, B.
|
|
|
26 |
12S |
p. S240
|
artikel
|
| 922 |
EPH132 Epidemiology of Breast and Cervical Cancer in Women of the Colombian Caribbean Region During 2018-2021
|
Alcocer, A.E.
|
|
|
26 |
12S |
p. S227-S228
|
artikel
|
| 923 |
EPH170 Epidemiology of Stroke in Bulgaria
|
Vutova, Y.
|
|
|
26 |
12S |
p. S235
|
artikel
|
| 924 |
EPH79 Epidemiology of Systemic Mastocytosis (SM) and Indolent Systemic Mastocytosis (ISM) in Germany
|
Herold, M.
|
|
|
26 |
12S |
p. S217
|
artikel
|
| 925 |
EPH61 Epidemiology of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis
|
Witte, J.
|
|
|
26 |
12S |
p. S214
|
artikel
|
| 926 |
EPH269 Estimating the Burden of Vaccine-Preventable Infectious Diseases Caused by Herpesviruses Beyond Herpes Zoster in Europe: What's Going on in Spain and Germany?
|
Serip, S.
|
|
|
26 |
12S |
p. S252-S253
|
artikel
|
| 927 |
EPH214 Estimating the Burden of Vaccine-Preventable Insect-Borne Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?
|
Martínez-Pérez, Ó
|
|
|
26 |
12S |
p. S242
|
artikel
|
| 928 |
EPH103 Estimating the Burden of Vaccine-Preventable Respiratory Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?
|
Cuervo, J.
|
|
|
26 |
12S |
p. S222
|
artikel
|
| 929 |
EPH226 Estimating the Future Prevalence, Costs, and Clinical Impact of Overweight and Obesity Classes I, II, and III in the UK
|
Grasic, K.
|
|
|
26 |
12S |
p. S244
|
artikel
|
| 930 |
EPH29 Estimating the Incidence and Characteristics of Female Patients in Norway With Early Breast Cancer Who Are at High Risk of Disease Recurrence
|
Walid, F.
|
|
|
26 |
12S |
p. S208
|
artikel
|
| 931 |
EPH12 Estimating the Prevalence of Hepatitis Delta in the UK: A Migration Model Approach Applied in Practice
|
Talbot-Watt, N.
|
|
|
26 |
12S |
p. S204
|
artikel
|
| 932 |
EPH7 Estimating the Projected Impact of Weight Loss on Obesity Prevalence and Healthcare Costs in a UK Population
|
Grasic, K.
|
|
|
26 |
12S |
p. S203
|
artikel
|
| 933 |
EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France
|
Nuttens, C.
|
|
|
26 |
12S |
p. S246
|
artikel
|
| 934 |
EPH159 Evaluation of Invasive Pneumococcal Disease and Pneumococcal Vaccination Coverage in a Hospital of Spain
|
Marin Caba, E.
|
|
|
26 |
12S |
p. S233
|
artikel
|
| 935 |
EPH128 Evaluation of the Effects of the COVID-19 Pandemic on Depression Among the Under 20-Year-Old Population in Japan, the US, and Germany Before and During the COVID-19 Pandemic: A Retrospective Observational Study Using Real-World Data
|
Takeno, S.
|
|
|
26 |
12S |
p. S227
|
artikel
|
| 936 |
EPH40 Evolving Impact of the COVID-19 Pandemic in Chronic Dialysis Recipients According to Wave Sub-Periods
|
Leye, E.
|
|
|
26 |
12S |
p. S209-S210
|
artikel
|
| 937 |
EPH169 Examination of the Quality of Life of Patients Underwent Ischemic Stroke and Treated With Intravenous Thrombolytic and Mechanical Thrombectomy Recanalization Intervention
|
Kovács, B.
|
|
|
26 |
12S |
p. S234-S235
|
artikel
|
| 938 |
EPH120 Explaining the Differences in Social Distancing Behavior in the EU During the COVID-19 Pandemic
|
Brådvik, G.
|
|
|
26 |
12S |
p. S225
|
artikel
|
| 939 |
EPH16 Exploring the Effects of the COVID-19 Pandemic on Pneumococcal Disease in France: A Comprehensive Analysis of Public Health Impact and Economic Burden
|
Carette, J.
|
|
|
26 |
12S |
p. S205
|
artikel
|
| 940 |
EPH45 Exploring the Pandemic's Impact: An Examination of Adolescent and Adult Vaccination Rates in Different Countries During COVID-19
|
Masseria, C.
|
|
|
26 |
12S |
p. S210
|
artikel
|
| 941 |
EPH38 Exploring the Relationship Between Hemochromatosis and Fracture Risk: A Population-Based Matched Cohort Study Stratified on Ferritin Levels
|
Martinez-De la Torre, A.
|
|
|
26 |
12S |
p. S209
|
artikel
|
| 942 |
EPH182 Factors Associated with Augmentation Agent Use in Patients with Treatment-Resistant Depression
|
Wing, V.
|
|
|
26 |
12S |
p. S236-S237
|
artikel
|
| 943 |
EPH189 Factors Associated with Biosimilar Prescription for Anti-Cancer Biologics Among 58,915 Patients in Europe
|
Alymova, S.
|
|
|
26 |
12S |
p. S237-S238
|
artikel
|
| 944 |
EPH199 Factors Associated With Hospitalization for E-Cigarette/Vaping Associated Lung Injury (EVALI) in the United States
|
Blanchette, C.M.
|
|
|
26 |
12S |
p. S239
|
artikel
|
| 945 |
EPH142 Fibrodysplasia Ossificans Progressiva (FOP): Prevalence Estimate By Hospitalization Data
|
Wahler, S.
|
|
|
26 |
12S |
p. S229-S230
|
artikel
|
| 946 |
EPH126 Gender-Affirming Hormone Therapy and Psychological Distress Among Transgender and Nonbinary People: Differences by Source of Hormones
|
Pandey, A.
|
|
|
26 |
12S |
p. S226-S227
|
artikel
|
| 947 |
EPH122 Global Burden of Disease Study on Chikungunya: Estimating Dalys and Cost Burden
|
de Roo, A.
|
|
|
26 |
12S |
p. S226
|
artikel
|
| 948 |
EPH143 Health Behavior and Quality of Life in Women With Endometriosis
|
Szántóri, P.
|
|
|
26 |
12S |
p. S230
|
artikel
|
| 949 |
EPH137 Healthcare Resource Consumption and Direct Costs of Patients Newly Diagnosed with Acute Myeloid Leukemia from a Large Italian Administrative Database
|
Dell'Anno, I.
|
|
|
26 |
12S |
p. S228-S229
|
artikel
|
| 950 |
EPH255 Healthcare Resource Consumption of Patients with Cardiovascular Events after Exacerbations of Chronic Obstructive Pulmonary Disease in Italy: Results from the EXACOS-CV Study
|
Calabria, S.
|
|
|
26 |
12S |
p. S250
|
artikel
|
| 951 |
EPH200 Healthcare Resource Consumption of Patients with Chronic Obstructive Pulmonary Disease Treated with Triple and Dual Therapy and Experiencing an Acute Exacerbation
|
Calabria, S.
|
|
|
26 |
12S |
p. S239
|
artikel
|
| 952 |
EPH257 Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data
|
Calabria, S.
|
|
|
26 |
12S |
p. S250
|
artikel
|
| 953 |
EPH185 Healthcare Resource Utilization and Cost Burden Assessment of Patients with Myasthenia Gravis in Denmark, Finland, and Sweden
|
Vissing, J.
|
|
|
26 |
12S |
p. S237
|
artikel
|
| 954 |
EPH256 Healthcare Resource Utilization and Related Cost Among Patients Hospitalized for Prurigo Nodularis: A Retrospective Cohort Study Using Italian Health Claims Data
|
Giacomini, E.
|
|
|
26 |
12S |
p. S250
|
artikel
|
| 955 |
EPH274 Health-Related Quality of Life in a Large Cohort of Adult Patients With Sickle Cell Disease in France (The DREPAtient Study)
|
Yaya, I.
|
|
|
26 |
12S |
p. S253-S254
|
artikel
|
| 956 |
EPH213 Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) Related Cancers Elimination Impact on Treatment Patterns (HELP-France) in France
|
Bencina, G.
|
|
|
26 |
12S |
p. S242
|
artikel
|
| 957 |
EPH229 Hospitalization Patterns and Costs of Primary Biliary Cholangitis (PBC) in Germany
|
Wahler, S.
|
|
|
26 |
12S |
p. S245
|
artikel
|
| 958 |
EPH88 Human Papillomavirus (HPV) Vaccination Coverage Among French Adolescents: Papillon Study
|
Guyot, E.
|
|
|
26 |
12S |
p. S219
|
artikel
|
| 959 |
EPH104 Human Papilloma Virus (HPV) Vaccination: Financial Impact and Recommendations
|
Walter, E.
|
|
|
26 |
12S |
p. S222
|
artikel
|
| 960 |
EPH179 Ibuprofen, Other Nsaids, & COVID-19: A Narrative Review
|
Laughey, W.
|
|
|
26 |
12S |
p. S236
|
artikel
|
| 961 |
EPH10 ICD-10 Surrogates of the Modified Frailty Index Predict Hospital Referrals in Outpatients Followed in German General Practices
|
Kostev, K.
|
|
|
26 |
12S |
p. S204
|
artikel
|
| 962 |
EPH150 Impact CKD: The Growing Burden of CKD in Spain
|
Rao, N.
|
|
|
26 |
12S |
p. S231
|
artikel
|
| 963 |
EPH25 Impact of Cancer Deaths on Years of Life and Productivity Losses in Japan in 2019
|
Aguiar-Ibáñez, R.
|
|
|
26 |
12S |
p. S207
|
artikel
|
| 964 |
EPH50 Impact of Dispensed Medication on Mean Age of Death: A Brazilian Public Health System Study
|
Bigoni, A.
|
|
|
26 |
12S |
p. S211
|
artikel
|
| 965 |
EPH62 Impact of Ethnicities on the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes: Results of a Systematic Review and Meta-Analysis
|
Pitre, S.
|
|
|
26 |
12S |
p. S214
|
artikel
|
| 966 |
EPH158 Impact of Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) Related Cancers Elimination on Treatment Patterns in the United Kingdom (HELP-UK)
|
Bencina, G.
|
|
|
26 |
12S |
p. S233
|
artikel
|
| 967 |
EPH30 Impact of Paternal Treatment on Birth Outcomes Among Individuals with Autoimmune Rheumatic Diseases
|
Shao, Y.H.
|
|
|
26 |
12S |
p. S208
|
artikel
|
| 968 |
EPH270 Impacts of Different SARS-CoV-2 Variants on Hospital Usage and Performance in the United Arab Emirates: A Comparison Among Alpha, Delta, and Omicron
|
Dai-Woodys, L.L.
|
|
|
26 |
12S |
p. S253
|
artikel
|
| 969 |
EPH237 Incidence and Risk Factors for Psychiatric Disorders Across Different Health Insurance Systems in Japan
|
Iwasaki, K.
|
|
|
26 |
12S |
p. S246-S247
|
artikel
|
| 970 |
EPH18 Incidence of Postpartum Mental and Behavioral Disorders in Japan
|
Iwasaki, K.
|
|
|
26 |
12S |
p. S205-S206
|
artikel
|
| 971 |
EPH209 Incidence Rates for an Extensive List of Adverse Events of Special Interest in the Pre-COVID-19 and Active COVID-19 Eras: A Comprehensive Source for Representative Historical Background Rates in the US General Population
|
Wang, C.
|
|
|
26 |
12S |
p. S241
|
artikel
|
| 972 |
EPH239 Incremental Cost Burden of Major Depressive Disorder in Patients with Rheumatoid Arthritis in Korea
|
Haeun, L.
|
|
|
26 |
12S |
p. S247
|
artikel
|
| 973 |
EPH215 Informal Caregiving and Illicit Drug Use in England and Wales
|
Dai-Woodys, L.L.
|
|
|
26 |
12S |
p. S242-S243
|
artikel
|
| 974 |
EPH205 Inside CKD: Predicting the Clinical and Economic Burden of Chronic Kidney Disease in Belgium
|
Vadia, R.
|
|
|
26 |
12S |
p. S240-S241
|
artikel
|
| 975 |
EPH8 Insulin Analogs in Type 1 Diabetes Treatment: An Incorporation Process Study in Brazilian Unified Health System (SUS)
|
Costa, L.
|
|
|
26 |
12S |
p. S203-S204
|
artikel
|
| 976 |
EPH106 Intercultural Approach and Knowledge of Migrant Health Policy in Healthcare Teams and Migrants in Chile
|
Cabieses, B.
|
|
|
26 |
12S |
p. S222
|
artikel
|
| 977 |
EPH191 Iron Deficiency Anemia Is Associated with Colorectal and Stomach Cancer Diagnoses in Germany
|
Kostev, K.
|
|
|
26 |
12S |
p. S238
|
artikel
|
| 978 |
EPH272 It Is Known Since 1922 at 2B Level of Evidence, Yet Not Used: Attitude Towards Intraosseous Medication
|
Csiszár, R.
|
|
|
26 |
12S |
p. S253
|
artikel
|
| 979 |
EPH218 Knowledge of Contraception and Sexually Transmitted Diseases Regarding the Quality of Education and Parent-Child Relationship Among Secondary School Students
|
Karácsony, I.
|
|
|
26 |
12S |
p. S243
|
artikel
|
| 980 |
EPH34 Knowledge on HPV and Vaccination Among Undergraduates in Vojvodina
|
Lénárt, Z.
|
|
|
26 |
12S |
p. S209
|
artikel
|
| 981 |
EPH241 Labor-Market Affiliation Among Danish Migraine Patients Discontinuing Triptan Treatment—A Register-Based Study
|
Ashina, M.
|
|
|
26 |
12S |
p. S247
|
artikel
|
| 982 |
EPH131 Landscape Analysis of Alzheimer's Disease-Specific Caregiver Outcome Assessments
|
Doma, R.
|
|
|
26 |
12S |
p. S227
|
artikel
|
| 983 |
EPH246 Landscape of Diffuse Large B-Cell Lymphoma (DLBCL) in Brazilian Public Healthcare System (SUS)
|
Fahham, L.
|
|
|
26 |
12S |
p. S248
|
artikel
|
| 984 |
EPH244 Late-Stage Cancer Diagnosis and Systemic Therapy in England Since 2018
|
Selle Arocha, L.
|
|
|
26 |
12S |
p. S248
|
artikel
|
| 985 |
EPH53 Leave or Stay? Influencing Factors of Intention to Leave or Stay in Healthcare Profession After Coronavirus Pandemic Among Frontline Nurses
|
Bogdán, P.
|
|
|
26 |
12S |
p. S212
|
artikel
|
| 986 |
EPH22 Mean Time on Triptan Treatment Among Danish Migraine Patients Before Discontinuing Treatment—A Register-Based Study
|
Ashina, M.
|
|
|
26 |
12S |
p. S206
|
artikel
|
| 987 |
EPH266 Mechanisms of HPV Vaccine Knowledge Levels Under Restricted Supply of Nine-Valent Vaccine in China Mainland
|
Wang, J.
|
|
|
26 |
12S |
p. S252
|
artikel
|
| 988 |
EPH19 Mental Health Disparities for Young Adults with Arrest Histories in the United States
|
Baser, O.
|
|
|
26 |
12S |
p. S206
|
artikel
|
| 989 |
EPH154 Modeled Head-to-Head Comparison of Nirsevimab and Rsvpref Maternal Vaccine in the US
|
Kieffer, A.
|
|
|
26 |
12S |
p. S232
|
artikel
|
| 990 |
EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories
|
Nucit, A.
|
|
|
26 |
12S |
p. S211
|
artikel
|
| 991 |
EPH156 Modelling Herpes Zosters Burden and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine Among Adults Aged ≥50 Years Old in Seven Countries in Central and South America
|
Han, R.
|
|
|
26 |
12S |
p. S232-S233
|
artikel
|
| 992 |
EPH73 Modelling the Wider Socio-Economic Costs of Problematic Opioid Use in Germany
|
Keel, G.
|
|
|
26 |
12S |
p. S216
|
artikel
|
| 993 |
EPH20 Muscular Dystrophy-Related Hospitalizations and Outpatient Procedures in the Brazilian Public Healthcare System: A Real World Data Analysis
|
Lara, L.
|
|
|
26 |
12S |
p. S206
|
artikel
|
| 994 |
EPH9 Non-Alcoholic Fatty Liver Disease Awareness in the United States: National Health and Nutrition Examination Survey Data 1999-2020
|
Chhatwal, J.
|
|
|
26 |
12S |
p. S204
|
artikel
|
| 995 |
EPH63 Obesity Related Complications: Can America Be Europe's Canary in the Coal Mine?
|
Brady, B.
|
|
|
26 |
12S |
p. S214
|
artikel
|
| 996 |
EPH243 Overview of Lung Cancer Screening Studies in France and Bordering Countries
|
Groenez, A.
|
|
|
26 |
12S |
p. S247-S248
|
artikel
|
| 997 |
EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis
|
Witte, J.
|
|
|
26 |
12S |
p. S224
|
artikel
|
| 998 |
EPH72 Polysubstance Use of Psychoactive Stimulants, Suicidal Behavior, and Mental Health Disability Among Women of Reproductive Age
|
Kim, S.
|
|
|
26 |
12S |
p. S215
|
artikel
|
| 999 |
EPH33 Postpartum Hemorrhage: A Look into Colombia's Health System
|
Casas-Ramirez, D.
|
|
|
26 |
12S |
p. S208-S209
|
artikel
|
| 1000 |
EPH102 Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) Among Canadian Infants
|
Goyette, A.
|
|
|
26 |
12S |
p. S221-S222
|
artikel
|
Tijdschrift beschrijving